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The goal of this PhD is to investigate imaging markers of pre-clinical and clinical Alzheimer's disease, 
mild cognitive impairment, and vascular dementia with a particular focus on the integration of 
electronic health records. Currently, many of these imaging markers and diagnostic techniques have 
been validated in research cohorts but not clinical cohorts. This thesis examines the applicability of 
these tools in a clinical cohort, and aims to validate their accuracy in such a cohort.  
To accomplish this I performed four different studies: 
Study 1. The integration of electronic health records and automated MRI analysis techniques to 
determine the relationship between mini mental state exam scores (MMSE) and hippocampal volume, 
this will also involve the linkage of electronic health records with imaging data which has not been done 
previously. 
Study 2. The application of multivariate image analysis techniques to MRI of dementia patients in clinical 
practice, to see if current research techniques are applicable to a wider population based cohort. 
Study 3. Examining the rate of underdiagnosis of Alzheimer's disease in mixed dementia patients who 
are clinically diagnosed with vascular dementia, using white matter hyperintensity analysis techniques 
to ensure those who are diagnosed with vascular dementia are not excluded from helpful treatments 
currently aimed at Alzheimer's Disease patients only.  
Study 4. The creation of a randomised clinical trial of the application of automated hippocampal 
volumetry measures for dementia patients in clinical practice, with a goal to increase clinical 
radiologist's confidence when making a diagnosis. 
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The results of these studies suggest that while the use of these tools in a clinical setting needs more 
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1 INTRODUCTION TO THE USE OF IMAGING IN DEMENTIA AND INTEGRATION 
OF ELECTRONIC HEALTH RECORDS FOR RESEARCH PURPOSES 
1.1 INTRODUCTION TO DEMENTIA:  
1.1.1 Alzheimer’s Disease 
1.1.1.1 Epidemiology 
It is currently estimated that 40 million people worldwide have some form of dementia, and that 
number is predicted to double every 20 years until 2050 (Prince et al., 2013). This figure mainly includes 
those aged older than 60 years, with only less than 1 per 4000 cases under the age of 50 years. AD is the 
most common form of dementia, with an estimated 60-70% of dementia cases attributed to the disease 
(Jindal, Bhatt, Sk, & Singh Malik, 2014; Philip Scheltens et al., 2016).  
Approximately only 10% of AD patients are diagnosed as early-onset (younger than age 65) (Cacace, 
Sleegers, & Van Broeckhoven, 2016; Vieira et al., 2013). Unlike late-onset dementia, which is regarded 
as a complex disease with varied etiology, early-onset AD is almost entirely genetically determined. It 
has been proposed the heritability of the disease ranges between 92% and 100% (Wingo, Lah, Levey, & 
Cutler, 2012). Research has found that mutations in three main genes, amyloid precursor protein (APP) 
and presenilins 1 and 2 (PSEN1 and PSEN2) are part of the autosomal dominant causes of early-onset AD 
(Cacace et al., 2016). Approximately 10% of early-onset cases are due to autosomal dominant gene 
mutations, while the other cases are due to autosomal-recessive causes (Wingo et al., 2012). 
Late-onset dementia is a much more complicated disease, with an etiology that remains relatively 
unclear. When looking at the genetics of late-onset dementia, it is clear the Apolipoprotein E (APOE) 
gene has the greatest influence on disease development. Those with the APOE4 variant of the gene have 
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a lifetime risk for AD greater than 50%. Those with one APOE4 variant and one APOE3 variant have a 20-
30% lifetime risk, compared for 11% for men and 14% for women regardless of APOE genotype (Genin et 
al., 2011), meaning there is a dose-dependent effect of genotype (Corder et al., 1993). 
1.1.1.2 Neuropathology 
AD is a gradual, irreversible, neurodegenerative disease characterised by extracellular β-amyloid (Aβ) 
plaques, neurofibrillary tangles (NFT), and subsequent systematic atrophy throughout the brain (Braak & 
Braak, 1991; Hampel, Frank, et al., 2010). Typical clinical manifestation is presented as memory 
impairment and executive dysfunction severe enough to impede daily activities (G. McKhann et al., 
1984; Philip Scheltens et al., 2016). Other times, patients can exhibit uncommon manifestations such as 
language, visual, executive problems before, and more distinctly, than memory deficits (Alladi et al., 
2007; Philip Scheltens et al., 2016). These presentations with prominent cognitive impairment in other 
domains besides memory, like prominent apraxia, language problems or executive dysfunction may 
occur and are more common in early-onset AD (Koedam et al., 2010; Mendez, 2017). Early-onset AD 
also has greater neocortical pathology, particularly in the parietal cortex, greater tau compared with 
amyloid burden, and less hippocampal atrophy (Mendez, 2017). 
1.1.2 Current diagnostic criteria of Alzheimer’s Disease 
According to the National Institute of Neurological Disorders and Stroke (NINCDS) and Alzheimer 
Disease and Related Disorders (ADRDA), histological evidence from post mortem examination is the only 
way to prove the underlying pathology and root of the clinical symptoms is actually AD, and therefore 
give a diagnosis of definite AD (Dubois et al., 2007; G. McKhann et al., 1984). However, disease onset is 
decades before death and between 10 and 15 years before symptom manifestation (Sperling et al., 
2011), once significant brain changes have already occurred. In order to treat patients, and research for 
cures and interventions, much earlier diagnoses are needed. Because of this, and the occasionally lack of 
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consistent neuropathology, there is doubt that the current ‘gold standard’ of post mortem confirmation 
is actually useful (Philip Scheltens & Rockwood, 2011).  
The original criteria for the clinical diagnosis of AD was first established by the NINCDS and ADRDA in 
1984 (G. McKhann et al., 1984). These guidelines have since been revised to incorporate the advances in 
the scientific community that now allow us to visualise more of the pathophysiological processes 
occurring in AD and the new conceptualizations of the clinical spectrum of AD that includes Mild 
Cognitive Impairment (MCI) and the preclinical stages of the disease (Albert et al., 2011; Jack Jr. et al., 
2011; G. M. McKhann et al., 2011; Sperling et al., 2011). The original model did not account for cognitive 
impairment that did not meet the threshold for an AD diagnosis, and did not recognize the slow 
development of AD pathology over time. Additionally, one of the most important observations since the 
original criteria is that the pathology of AD is not always consistent with the presentation of the disease. 
In some cases, neuropathology such as Aβ plaques can be present in the absence of any cognitive 
impairment (Knopman et al., 2003), while others can exhibit unconventional symptomology (Alladi et al., 
2007).  
Clinical diagnosis must include a detailed history from the patient and their carers, neuropsychological 
testing, and analysis of the progression of symptoms (G. M. McKhann et al., 2011; Philip Scheltens et al., 
2016).  The core clinical criteria for diagnosis provides adequate diagnostic accuracy in a majority of 
patients (G. M. McKhann et al., 2011).  
These new guidelines take use of biomarkers into consideration, and their ability to detect pathology in 
the absence of the traditional AD symptomology.  
1.1.2.1 The Preclinical Stage of Alzheimer’s Disease 
Perhaps one of the most important changes to the diagnostic criteria has been the identification of a 
prodromal/preclinical AD stage. Those diagnosed as preclinical AD are defined as having evidence of AD 
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pathology based on any number of biomarkers, in the absence of any cognitive decline or other AD 
symptomology (Dubois, Hampel, et al., 2016). This distinction is essential for progression of AD research, 
and it estimated that early interventions delaying clinical onset by one year could reduce the prevalence 
of AD by 9 million cases by 2050 (Brookmeyer, Johnson, Ziegler-Graham, & Arrighi, 2007). One of the 
greatest challenges in defining preclinical AD is there is yet to be a definite profile of AD pathology that 
leads to the development of AD in the future. A specific combination of biomarkers that are mostly likely 
to predict AD would aid in selecting appropriate populations for clinical trials and pre-clinical therapeutic 
intervention. Additionally, current therapeutic interventions that have not been successful may be more 
likely to be effective if applied earlier in the disease time course (Sperling et al., 2011). A working 
hypothetical model of the biomarkers observed in AD has been proposed, but the model is not universal 
to all preclinical AD patients (Figure 1-1) (Jack Jr et al., 2010).  
Figure 1-1 – Dynamic biomarkers of the Alzheimer's pathological cascade. Aβ is identified by CSF Aβ42 or PET amyloid imaging. 
Tau-mediated neuronal injury and dysfunction is identified by CSF tau or fluorodeoxyglucose-PET. Brain structure is measured by 




1.2 BIOMARKERS IN ALZHEIMER’S DISEASE AND DEMENTIA 
Biological markers, or biomarkers, are biological characteristics that can be measured objectively and 
used as an indicator normal or pathological processes in the body (Biomarkers Definitions Working 
Group., 2001). A biomarker can be any substance, structure, or process that can be measured within the 
body or its products, and can predict the incidence or outcome of a given disease or disorder (World 
Health Organization & International Programme on Chemical Safety, 2001). Ideally, a biomarker is 
reproducible, widely available and directly reflects disease processes (Biomarkers Definitions Working 
Group., 2001).  
Biomarkers can be categorised by their use, including diagnostic biomarkers, staging/prognostic 
biomarkers, and biomarkers used to monitor clinical response to medical or therapeutic interventions. 
Diagnostic biomarkers are used to identify those with a disease or abnormal condition, whereas 
staging/prognostic biomarkers determine disease stage and severity, and can predict further cognitive 
decline or improvement. Lastly, biomarkers can be used to measure biological responses to an 
intervention, making them useful in clinical trial settings (Biomarkers Definitions Working Group., 2001). 
In dementia specifically, biomarkers can be used to distinguish aspects of underlying pathology, predict 
cognitive decline and conversion between disease states (such as MCI to AD), and monitor response to 
treatment (Ahmed et al., 2014). When looking at AD, biomarkers can further be broken down into the 
pathologies the reflect.  
1.2.1 Biomarkers of Alzheimer’s Disease Pathology 
There are two groups of well validated biomarkers currently used in AD research and diagnostics, ones 
that measure Aβ accumulation and ones that measure neuronal degeneration or injury, which can be 
measured by tau proteins (Jack Jr. et al., 2011). However, AD is characterized as a disease with an 
extremely complex etiology, and there are many other biochemical processes at play. Oxidative stress 
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and inflammation markers may give insight to a variety of pathways that are disrupted in AD, and could 
provide additional information on AD pathology. They are yet to be well-validated, and are not currently 
used in research cohorts or as a diagnostic tool and therefore will not be discussed here (Albert et al., 
2011).  
Recently, a new classification system, the “A/T/N” system, has been proposed by Jack and colleagues 
(Clifford R. Jack et al., 2016). Here, seven major AD biomarkers (further described in detail in subsequent 
sections) are divided into three categories: “A” or Aβ biomarkers (such as CSF Aβ-42 or Aβ Positron 
Emission Tomography (PET) imaging), “T” or Tau biomarkers (such as CSF phosphorylated tau or Tau PET 
imaging), and “N” or biomarkers of neurodegeneration and neuronal injury (such as [18F]-
fluorodeoxyglucose PET, structural MRI, or CSF total tau).  
This new system allows for a more comprehensive view of AD pathology, and potentially insight into the 
temporal order of development in patients. Additionally, it provides the opportunity to identify patients 
that may not have a typical presentation of AD.  
1.2.1.1 Aβ deposition 
Accumulation of abnormally folded Aβ in systematic distribution in the brain is a hallmark of AD (Braak 
& Braak, 1991). There is strong genetic, pathological, and biochemical evidence that abnormalities in the 
production of and removal of Aβ in the brain leads to this aggregation of misfolded proteins, creating 
plaques (Villemagne & Chételat, 2016). This was originally thought to be the primary event in the 
cascade that leads to further neurofibrillary degradation, widespread atrophy and ultimately dementia 
(Karran, Mercken, & Strooper, 2011; Masters, Cappai, Barnham, & Villemagne, 2006). However, more 
recent studies suggest that this may very well occur in parallel to other pathological events but may not 
be sufficient on its own to cause AD (Chételat, 2013; Pimplikar, Nixon, Robakis, Shen, & Tsai, 2010). 
Numerous studies have found Aβ in cognitively normal individuals, suggesting these individuals may go 
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on to develop symptoms later on. Undoubtedly, Aβ plaques play an important role in AD and 
abnormalities with Aβ may become apparent in patients 10-20 years before any kind of symptom onset 
(Jack Jr. et al., 2011). Because of this large lag in symptom onset, Aβ biomarkers are essential in defining 
at-risk/preclinical AD patients. 
1.2.1.2 Neuronal injury  
The secondary hallmark of AD as described by Braak and Braak are neurofibrillary changes in the brain 
(Braak & Braak, 1991). Similarly to Aβ plaques, NFT contain aggregates of hyperphosphorylated tau 
proteins and are distributed in a systematic way throughout the brain (Kaj Blennow, de Leon, & 
Zetterberg, 2006). In addition to tau markers, AD causes a wide variety of larger scale functional and 
structural changes within the brain which are also assumed to reflect wide-scale neuronal damage and 
dysfunction. These include volume loss in the hippocampus and medial temporal lobe as measured by 
automated volumetry techniques or visual inspection, global brain atrophy, and reduced metabolism or 
perfusion (Albert et al., 2011).  
1.2.2 Cerebrospinal fluid Biomarkers 
Cerebrospinal fluid (CSF) analysis allows for measurement of concentrations of both Aβ and tau. The 
characteristic CSF profile for AD patients is low Aβ-42 and high total tau (t-tau) and phosphorylated tau 
(p-tau) (Hampel, Blennow, et al., 2010). In the context of CSF, t-tau is a marker of the intensity of 
neurodegeneration, while p-tau is indicative of neurofibrillary pathology specifically (Philip Scheltens et 
al., 2016). Core CSF biomarker measurements appear to have high diagnostic accuracy (Kaj Blennow et 
al., 2007; de Leon et al., 2007; Hansson et al., 2007; Mattsson et al., 2009, 2011) and high sensitivity and 
specificity of 85-90% when trying to identify prodromal AD in the MCI stage (Shaw et al., 2009; Pieter 
Jelle Visser et al., 2009). CSF markers are important in clinical diagnostic decision making because of 
their negative predictive value; normal levels of all three markers almost completely excludes AD (Philip 
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Scheltens et al., 2016). Unfortunately, the variability of cut-off points, and lack of standardisation in 
methods used to collect and analyse CSF samples hinders the ability to create normative data for 
balanced use and interpretation in clinical practice (Ahmed et al., 2014; Hort, Bartos, Pirttilä, & 
Scheltens, 2010).   
1.2.2.1 Cerebrospinal Fluid Biomarkers of Aβ-42 
The aggregates of Aβ in the brain that are a result of dysfunction in the production and clearance of the 
Aβ protein are reflected in measures of Aβ-42 in CSF. This is because slower Aβ removal from the brain 
is likely to lead to Aβ deposition and therefore lower CSF concentrations (Bateman et al., 2006; 
Mawuenyega et al., 2010). On average, Aβ-42 concentrations are reduced to approximately 50% of 
control concentrations (Kaj Blennow et al., 2006). Studies have found correlations between Aβ-42 in CSF 
and amyloid plaque load both ante-mortem (Tapiola et al., 2009) and post-mortem (Strozyk, Blennow, 
White, & Launer, 2003), signifying that CSF Aβ-42 measures are indicative of brain pathology.  
1.2.2.2 Cerebrospinal Fluid Biomarkers of Tau Proteins 
Because t-tau is an indicator of overall neurodegeneration and neuronal injury, reflecting the size of 
tissue damage, it is not specific to AD (Hesse et al., 2001; Ost et al., 2006). In AD CSF t-tau levels increase 
approximately 300% from control concentrations (Kaj Blennow et al., 2006). Studies have found t-tau 
levels to be associated with rapid decline from MCI to AD (Blom et al., 2009), and potentially indicative 
of quicker cognitive decline and a high mortality rate in AD patients (Sämgård et al., 2010; Wallin, 
Hansson, Blennow, Londos, & Minthon, 2009), indicating they are an important biomarker for AD 
diagnosis.  
Conversely, p-tau appears to be more indicative of AD as it reflects both the phosphorylation of tau and 
formation of neurofibrillary tangles within neurons (Kaj Blennow, Hampel, Weiner, & Zetterberg, 2010). 
Unlike t-tau that is exhibited in numerous neurodegenerative disease, other brain damage, and healthy 
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ageing, p-tau is more specific to AD (K. Blennow et al., 1995; Sjögren et al., 2001). Studies that have 
obtained CSF samples during life and at autopsy have found that p-tau levels correlate well with 
neurofibrillary tangles and rate of hippocampal atrophy (Buerger et al., 2006; Hampel et al., 2005; 
Tapiola et al., 2009). Furthermore, tau phosphorylated at a specific binding site (p-tau 181) is linked with 
faster progression to AD from MCI (Blom et al., 2009) and particularly swift decline once AD is diagnosed 
(Sämgård et al., 2010). p-tau is also capable of distinguishing AD from other forms of dementia, such as 
dementia with Lewy bodies (DLB) (Hampel et al., 2004), making it very important for differential 
diagnoses in the clinic.  
1.2.3 Neuroimaging Biomarkers in Alzheimer’s Disease and Dementia 
Imaging is often used to rule out other brain abnormalities when making a diagnosis of dementia (R. 
Duara et al., 2008; G. M. McKhann et al., 2011), but there is also use in diagnosing MCI or identifying the 
preclinical stage of AD (Albert et al., 2011; Sperling et al., 2011). Aside from ruling out non-
neurodegenerative conditions, imaging is used to measure the extent and pattern of brain atrophy 
(Barkhof, 2011). Brain atrophy is a neuropathological feature of dementia, and shows similar patterns in 
most patients with AD and MCI (Braak & Braak, 1991). These patterns can inform clinicians and 
researchers about type of dementia (in addition to AD, such as vascular dementia (VaD), frontotemporal 
lobar dementia (FTLB), DLB, dementia associated with Parkinson’s and other movement disorders, and 
alcohol induced dementia) and stage of dementia (Barkhof, 2011; Qizilbash et al., 2002). Brain imaging 
techniques, measuring both structural and functional changes, can help make a diagnosis in a timelier 
manner, allowing patients to receive the care they need earlier on. Right now, unstructured reporting by 
a radiologist is the most common method of image analysis used in clinics, however some clinics do use 
structured rating scales (L.-O. Wahlund et al., 2016). The most frequently used structural imaging 
techniques are computed tomography (CT) and Magnetic Resonance Imaging (MRI). While MRI does 
show better soft tissue contrast, CT is also used in a clinical setting due to cost, or reasons that prevent 
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the patient from being eligible for an MRI scan such as a pacemaker or claustrophobia (Barkhof, 2011). 
MRI is most often the preferred method of structural imaging, and is often the best for visualisation of 
vascular changes that may indicate VaD (Harper, Barkhof, Scheltens, Schott, & Fox, 2014; Philip 
Scheltens et al., 2016). If structural imaging does not provide additional information about disease 
progression, functional imaging may give insights to changes in brain activity that are indicative of 
changes in neuronal health and furthermore dementia.  
1.2.3.1 Structural Imaging Biomarkers – Magnetic Resonance Imaging and Computerised Tomography  
The majority of patients with AD or MCI show a standard pattern of atrophy throughout the medial 
temporal lobe (MTL), specifically in the entorhinal cortex (ERC) and hippocampus (HC) (Braak & Braak, 
1991). These patterns of atrophy are associated with the declarative memory deficits that are part of 
the core clinical criteria of AD and MCI (McDonald et al., 2012; Sarazin et al., 2010).  This is measured 
using structural imaging techniques such as MRI and CT. Currently, while hippocampal and MTL atrophy 
are observed in a majority of AD and MCI patients, it is not sufficient to diagnose the disease on its own 
(G. M. McKhann et al., 2011; Schröder & Pantel, 2016).  This is due partially because of the 
methodological differences in atrophy measurements, but also because of the pathological 
susceptibilities of the hippocampal tissues from other disorders outside of AD (Schröder & Pantel, 2016). 
Lastly, because of the heterogeneity of AD, there is a variety of presentations in patients and not all 
experience hippocampal atrophy to the same extent (Daniel Ferreira, Verhagen, et al., 2017).   
1.2.3.1.1 Visual Rating scales  
Visual rating scales (VRS) are one of the most commonly used tools to support dementia diagnosis. 
Based on several studies, VRS are a reliable tool for deciding degree of atrophy (Hyun Cho, Kwon, & Seo, 
2009; Philip Scheltens, Launer, Barkhof, Weinstein, & van Gool, 1995; Urs et al., 2009; L. O. Wahlund et 
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al., 2001; L.-O. Wahlund, Julin, Johansson, & Scheltens, 2000; L.-O. Wahlund, Junlin, Lindqvist, & 
Scheltens, 1999; Westman, Cavallin, Muehlboeck, et al., 2011b).  
Scheltens and colleagues created a well-known MTL scale that uses coronal MRI or CT images. Scheltens 
rating scale gives a medial temporal lobe atrophy (MTA) score of 0-4 based on width of the choroid 
fissure, width of the temporal horn, and height of the HC (Ph Scheltens et al., 1992). This method has 
been shown to accurately predict progression from MCI to dementia in subjects diagnosed with 
prodromal AD (Charles DeCarli et al., 2007).More scales have been created based on Scheltens scale, 
providing reliable measures of individual MTA structures such as the HC, ERC, and perirhinal cortex 
(PRC) (R. Duara et al., 2008; Urs et al., 2009; Wattjes et al., 2009).  
One problem with the MTA scale is that it is not specific to AD. MTA occurs in a number of other types of 
dementia as well, especially FTLD (Barkhof, 2011). To address this, Galton et al. proposed a more specific 
rating scale that focuses on more detailed scoring of the temporal pole and lateral temporal lobe 
(Galton et al., 2001). While MTA is a characteristic finding in those with amnesic type presentations, 
especially AD patients with the APOE4 allele (Pereira et al., 2014a), it may be milder in those who are 
presenile, non-amnestic typed dementia patients.  
The Global Cortical Atrophy Scale (GCA) is used to visually assess cortical atrophy, taking into 
consideration not only degree of atrophy but also degree of lobar and regional atrophy (Pasquier et al., 
1996; L.-O. Wahlund et al., 2016). This is also vital for patients with atypical AD with atrophy that is 
focused in the frontal and posterior areas, instead of the temporal areas normally seen in AD (Daniel 
Ferreira, Verhagen, et al., 2017).  
The posterior/parietal atrophy rating scale looks at three different planes for right and left brain 
separately. If there are multiple scores on different orientations, the highest score is used. These scores 
focus on the posterior cingulate, precuneus, and superior parietal regions (Barkhof, 2011; Koedam et al., 
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2011; Lehmann et al., 2012). While not as popular as the GCA, it may also be useful in younger patients 
with atypical AD. 
In addition to atrophy, a variety of VRS are also used to assess white matter changes associated with 
ageing and dementia.  They are mainly designed to be used with MRI or CT scans, however some can be 
used with both. A simple, commonly used scale is the Fazekas scale (Fazekas, Chawluk, Alavi, Hurtig, & 
Zimmerman, 1987), which gives a score from zero to three. Other scales are more complicated, such as 
the Age-Related White Matter Changes scale (L. O. Wahlund et al., 2001), the Scheltens White Matter 
Changes scale (Philip Scheltens et al., 1998), and Manolio’s scale which scores based on a template 
(Barkhof, 2011; Manolio et al., 1994). 
It is important to note that atrophy is also a function of normal ageing (Barkhof, 2011), and therefore 
normal scores on a VRS are affected by age (Barkhof, 2011; R. M. Duara et al., 2013; Pereira et al., 
2014a). VRS are subject to individual rater variation, which may introduce some biases into each 
evaluation. Another limitation of some of the VRS is they are based on assessments of a single slice, 
which limits the perspective of the entire brain pathology.  
1.2.3.1.2 Manual and Automated Volumetric Biomarkers 
Quantitative imaging techniques often give a more detailed assessment, and wider perspective, than a 
VRS. There are a variety of quantitative methods that can give substantial information about changes in 
the brain, provided both the image type and image quality are suitable for the desired technique 
(Barkhof, 2011). 
Hippocampal volume is the most frequently measured variable aside from whole brain volume in 
patients with AD, and it has been found to have substantial predictive accuracy of diagnosis of the 
disease without any other additional variables (Barkhof, 2011; Westman, Simmons, Zhang, et al., 2011). 
A common approach to region of interest (ROI) analysis is manual outlining by a human. While this is a 
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frequently used approach, it can be variable. It is important to have clear anatomical boundaries and 
using high resolution T1 weighted images, with voxel sizes around 1x1x1 mm3, can provide such 
boundaries. Manual hippocampal delineation also depends on the exact protocol used and software 
utilised to do the segmentation, in addition to individual rater variation (Barkhof, 2011). The European 
Alzheimer's Disease Consortium and Alzheimer's Disease Neuroimaging Initiative (EADC-ADNI) 
Harmonized Protocol (HarP) is one of the largest initiatives to standardise manual hippocampal 
delineation protocols. The initiative surveyed a variety of manual segmentation protocols, finalised 
selected landmarks and agreed on a suitable language for segmentation directions (Boccardi et al., 2011; 
Duchesne et al., 2015). The HarP has demonstrated significantly increased agreement amongst raters (G. 
B. Frisoni et al., 2015). Even with the high validity, one of the biggest disadvantages to manual 
segmentation is the time consuming nature, which makes it impractical for clinical use (Westman, 
Simmons, Zhang, et al., 2011). 
A second option for ROI analysis is an automated method done with segmentation software, such as 
FREESURFER (Figure 1-2) (Bruce Fischl, 2012) or LEAP (Wolz et al., 2010). These outline brain regions and 
calculate individual volumes, but often significantly depend on image quality. Additionally, they often 
require large amounts of computing power and some human interaction.  
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Figure 1-2 - Representations of Regions of Interest (ROIs) as segmented in FREESURFER. (A) Regional subcortical volumes. (B) 
Regional cortical thickness measures. From Westman et. al 2012 (Westman, Muehlboeck, & Simmons, 2012). 
 
Segmentation based analysis aim to distinguish grey matter (GM), white matter (WM) and CSF voxels in 
the brain based on their image intensity, and location in a given space such as a template. Voxels are 
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assigned an intensity describing the probability it belongs in each group (GM, WM, or CSF) (Barkhof, 
2011).   
Registration based and deformation based analysis are used to determine the rate of cerebral atrophy in 
a patient over time, by aligning scans taken at two separate time points. Registration based methods do 
not need a large amount of computing power, and deformation based method are only moderately 
more computing intensive, both need to have comparable scan acquisitions (scanner, coil, pulse 
sequence) (Barkhof, 2011). 
In addition to the quantitative methods looking at brain atrophy, there are also new methods to 
quantify measures of white matter changes assessed by visual rating scales as well. These techniques 
use automated detection methods and vary from semi-automated programs to fully automated 
(Damangir et al., 2012; Gibson, Gao, Black, & Lobaugh, 2010; Iorio et al., 2013; Samaille et al., 2012; 
Smart, Firbank, & O’Brien, 2011; van der Lijn et al., 2012). 
1.2.3.1.3 Hippocampal Subfield Measurements 
Because hippocampal volume is one of the most well-studied biomarkers of AD and dementia, it makes 
sense to look more carefully at the details of this structure. The advances in MRI technology in the past 
decade have made it possible to visualise the subfields of the HC in vivo. In the past, the HC was looked 
at as a single entity, and its volume as a whole has been used to evaluate AD. However the HC is a 
heterogeneous structure, with various subfields containing different connectivity to the rest of the brain 
and different cellular structure. These subfields have been divided by the cytoarchitectonics of the 
hippocampus to include several cornu ammonis fields (CA1–CA4), the dentate gyrus (DG), and the 
subiculum (Aggleton, 2012; de Flores, La Joie, & Chételat, 2015). It is presumed these various sub 
regions serve different functions, and therefore experience varied vulnerability to disease and injury (de 
Flores et al., 2015; Small, Schobel, Buxton, Witter, & Barnes, 2011). While the advent of higher 
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resolution MRI allows us to better visualize anatomical landmarks to delineate subfields, it is still not 
possible to view the cytoarchitectonics at the cellular level, and therefore subfield segmentation is still 
an approximation.  
Specifically in AD, neuropathology develops at different paces in various sub regions of the HC. The HC is 
one of the primary targets of AD pathology as first described by Braak and Braak, most specifically the 
NFTs and subsequent neuronal loss (Braak & Braak, 1991). According to a variety of studies, NFTs first 
appear in CA1, followed by CA2, CA3, and finally CA4 and the DG (Braak & Braak, 1991; Braak, Braak, & 
Bohl, 1993; Fukutani et al., 2000; Lace et al., 2009; Schönheit, Zarski, & Ohm, 2004). Following this, 
neuronal loss occurs mostly in CA1 as demonstrated in histological samples (West, Coleman, Flood, & 
Troncoso, 1994), and seems to correlate with disease severity (J. L. Price et al., 2001).  
While there are clear advantages of examining the HC at the subfield level, this also poses many 
difficulties. Firstly, there is a lack of standardisation of both manual and automated subfield 
measurement, with differences across number of segmented subfields, which subfields are grouped 
together, actual subfield borders, and if segmentation is performed on the entire HC or just a portion of 
it (de Flores et al., 2015; Maruszak & Thuret, 2014). This lack of standardisation makes it difficult to 
implement these techniques in clinical practice. Additionally, subfields are usually only able to be 
segmented at high field strengths (minimally 3T and up) which are not often available clinically. As a 
result, hippocampal subfield segmentation shows significant promise in research but cannot be posed as 
a useful clinical biomarker at the current time.  
1.2.3.2 Molecular Imaging Biomarkers in Alzheimer’s Disease and Dementia 
1.2.3.2.1 FDG Positron Emission Tomography 
Glucose is integral to healthy cell function in the brain, and general brain health can be assessed by 
measuring the metabolism of glucose in the brain. This is most commonly done by using Positron 
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Emission Tomography (PET), and numerous studies have found changes in metabolic brain metabolism 
in AD using 18fluorodeoxy-glucose (FDG) (Cohen & Klunk, 2014; Karl Herholz, 2012; Johnson, Fox, 
Sperling, & Klunk, 2012). In AD, this is most commonly manifested as decreased consumption of the FDG 
in the temporoparietal and posterior cingulate cortices (Coleman, 2005; Devanand et al., 1997; Jagust, 
Reed, Mungas, Ellis, & Decarli, 2007; Salmon et al., 1994), which reflects neuronal metabolism and 
therefore neuronal health. Patients with MCI exhibit similar patterns of hypometabolism (Chetelat et al., 
2003; Chételat et al., 2005; Lisa Mosconi et al., 2006), as do cognitively healthy individuals with some 
form of one of the early-onset gene mutations (Kennedy et al., 1995; Rossor, Kennedy, & Frackowiak, 
1996). Hypometabolism as demonstrated by FDG-PET has shown to be correlated with cognitive 
function (Furst et al., 2012; Landau et al., 2011) and may be predictive of further decline (Drzezga et al., 
2003, 2005; L. Mosconi et al., 2004). Longitudinal measures of FDG-PET have shown a similar continuous 
decline in brain metabolism (Alexander, Chen, Pietrini, Rapoport, & Reiman, 2002; Karl Herholz, 2012; 
Hirono, Hashimoto, Ishii, Kazui, & Mori, 2004), further supporting the notion that is directly related to 
cognitive function.  
FDG-PET is also particularly helpful in drug development and clinical trials for AD, as it can measure 
pharmacological effects within a few weeks in smaller sample sizes (K. Herholz, Boecker, Nemeth, & 
Dunn, 2013). 
Unfortunately, FDG-PET’s high cost and current lack of regulatory approval and standardisation make it 
a suboptimal biomarker.  
1.2.3.2.2 Aβ PET ligands  
In addition to measuring Aβ decrease in CSF, Aβ deposition in the brain can be measured in-vivo using 
PET imaging. The first Aβ PET imaging study was conducted well over a decade ago (Klunk et al., 2004), 
and since a number of tracers have been developed to measure Aβ deposition in the brain. These 
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tracers bind to the amyloid proteins in the brain with high affinity. Quantitative and visual assessments 
of the patterns of ligand distribution in the brain closely represent the pattern of Aβ deposition found in 
the brain at autopsy, which includes Aβ deposition beginning in the orbitofrontal and inferior temporal 
cortices and cingulate gyrus, and later spreading to the remaining prefrontal, lateral temporal, and 
parietal cortices (Braak et al., 1993; Villemagne & Chételat, 2016). The most successfully tracer, and for 
some time the most widely used, is 11C-Pittsburgh Compound B (11C-PIB) (Villemagne et al., 2017). There 
is about 80% agreement between (11C-PIB) and CSF measures when classifying a patient as Aβ positive 
or negative (Villemagne & Chételat, 2016). As expected, PET studies have shown a vast difference in Aβ 
retention in AD patients and healthy age-matched controls using both 11C-PIB (Furst et al., 2012; Clifford 
R. Jack, Lowe, et al., 2008; Klunk et al., 2004; John C. Morris et al., 2009; J. C. Price et al., 2005; C. C. 
Rowe et al., 2007; Christopher C. Rowe et al., 2010) and other radiotracers (Barthel et al., 2011; Camus 
et al., 2012; Cselényi et al., 2012; Fleisher et al., 2011; Kudo et al., 2007; Villemagne et al., 2011). The 
pattern of Aβ deposition as visualised by PET imaging follows what is found at autopsy (Braak & Braak, 
1991).  As previously mentioned, Aβ accumulation can occur 10-20 years before symptom onset and is 
apparent in Aβ PET imaging (De Meyer et al., 2010; Mintun et al., 2006; Pike et al., 2007; Christopher C. 
Rowe et al., 2010; Sojkova et al., 2011).  As many as 25-35% of non-demented individuals over 60 years 
of age present with 11C-PIB positive scans, despite performing normally on cognitive tests (Mintun et al., 
2006; C. C. Rowe et al., 2007; Christopher C. Rowe et al., 2010). This figure fits with the findings that 
approximately 25% of non-demented adults over the age of 75 have Aβ deposition in the brain post-
mortem (Davies et al., 1988; Forman et al., 2007; J. C. Morris & Price, 2001). Additionally, the frequency 
of high retention 11C-PIB patients increases each decade as the same rate as the prevalence of non-
demented subjects with Aβ plaques at autopsy (Christopher C. Rowe et al., 2010).  
Unfortunately, the 20 minute decay half-life of the tracer limits use and makes it too costly for routine 
clinical use. Several second generation Aβ tracers have been created using fluorine-18 (18F), which has a 
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half-life of 110 minutes, making it more practical for use in both clinics and research. These include 18F-
florbetapir (Clark et al., 2011; Wong et al., 2010), 18F-florbetaben (Barthel et al., 2011; Christopher C. 
Rowe et al., 2008; Villemagne et al., 2011), 18F-flutemetamol (Nelissen et al., 2009; Vandenberghe et al., 
2010), and 18F-NAV4694 (Cselényi et al., 2012), all of which to seem to compare well with 11C-PIB studies 
showing marked differences between AD patients and age-matched controls in the relevant brain areas 
(Barthel et al., 2011; Camus et al., 2012; Cselényi et al., 2012; Fleisher et al., 2011; Furst et al., 2012; 
Clifford R. Jack, Lowe, et al., 2008; Klunk et al., 2004; Mintun et al., 2006; John C. Morris et al., 2009; 
Pike et al., 2007; J. C. Price et al., 2005; Rabinovici et al., 2007; C. C. Rowe et al., 2007; Christopher C. 
Rowe et al., 2010; Villemagne et al., 2011, 2017). 
1.2.3.2.3 TAU PET Ligands 
Similarly to Aβ, ligands have recently been developed to measure tau distribution in the brain in-vivo 
(Bischof, Endepols, van Eimeren, & Drzezga, 2017). This has been much more challenging as tau 
aggregates are usually found intraneuronally, and tau aggregates are not found as abundantly as Aβ 
plaques. There are varying forms of tau pathology in the brain, including straight filaments and paired 
helical filaments (Bischof et al., 2017), and different ligands may bind to one or both of these types of 
tau. There has been evidence that these tau PET ligands display tracer retention patterns that mirror the 
expected tau-pathology in AD (Chien et al., 2013; Hanna Cho et al., 2016; Johnson et al., 2016; Schöll et 
al., 2016; Schwarz et al., 2016). However, current tau PET tracers are not comprehensively validated, 
and need to be explored further before being used in a clinical setting.  
1.2.3.3 Single Photon Emission Computed Tomography 
Another popular functional imaging technique that measures brain activation is perfusion Single Photon 
Emission Computed Tomography (SPECT). Similarly to PET, perfusion SPECT uses gamma-emitting 
isotopes to measure regional cerebral blood flow (rCBF). There is a correlation between CBF, neuronal 
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activity, and metabolism known as neurovascular coupling. This correlation allows deductions to be 
made about brain activity without direct measurement (Vestergaard et al., 2016). Because of the 
characteristic pattern of hypometabolism in temporoparietal areas of the brain in AD, SPECT can be a 
useful technique in the differential diagnosis of the disease (Weih et al., 2010). Studies have shown 
SPECT has decent histological correlation in an number of patients at autopsy (Bonte, Weiner, Bigio, & 
White, 1997). SPECT is most often used to rule out AD rather than confirm it, as the sensitivity of SPECT 
lags far behind the sensitivity. The two most popular ligands used in SPECT perfusion are 
99mTechnetium-hexamethyl-propylenamine oxime (99mTc-HMPAO) and 99mTechnetium-L,Lethyl 
cysteinate dimer (99mTc-ECD) (Dougall, Bruggink, & Ebmeier, 2004).  
1.2.3.4 Other Imaging Methods in  Alzheimer’s Disease and Dementia 
The above list of imaging biomarkers used in dementia and AD is by no means and exhaustive one. 
There are a multitude of other techniques including Functional Magnetic Resonance Imaging (fMRI), 
Arterial Spin Labelling (ASL), Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy 
(MRS). However these are less validated and not often, if ever, used in the clinic.  More research is 
required to learn if these techniques are useful in a clinical setting.  
1.2.3.4.1 Functional Magnetic Resonance Imaging 
Aside from looking at brain activation using PET and SPECT imaging, researchers have studied the impact 
of dementia on the functional connectivity of the brain using fMRI. fMRI is based on the blood oxygen 
level-dependent (BOLD) signals. The magnetic susceptibility differs between oxygenated and 
deoxygenated blood, because of the varying levels of iron. Brain activation of a certain area will result in 
the brain sending more oxygenated blood to that area, resulting in an increase of BOLD signal. This 
intrinsic contrast allows for the measurement of brain function without the use of radioactive tracers, 
like those used in PET imaging.  
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Functional brain connectivity can be measured in two ways: spontaneously at rest and during a task. 
Spontaneous fluctuations in brain activity at rest can be measured using resting-state fMRI. Brain 
regions that are temporally correlated, or coactivated with similar timecourses, especially in low-
frequency fluctuations less than 0.1 Hz are defined as resting-state networks (RSNs) and represent 
inherent organisation of functional brain networks (Biswal, Van Kylen, & Hyde, 1997; Damoiseaux et al., 
2006). Previous studies have shown decreased functional connectivity throughout the brain at rest in 
patients with AD and MCI compared to controls (Allen et al., 2007; He et al., 2007; Yong Liu et al., 2008; 
Wang et al., 2006; Zhang et al., 2010), namely in the default mode network (DMN) (Celone et al., 2006; 
Greicius, Srivastava, Reiss, & Menon, 2004; Rombouts et al., 2009). The DMN includes the anterior and 
posterior cingulate, the lateral parietal and prefrontal areas, inferior and middle temporal gyri, 
cerebellar areas, and extends into the MTL (Damoiseaux et al., 2006; Filippini et al., 2009; Raichle et al., 
2001; S. M. Smith et al., 2009). The RSN is of particular interest because many of these areas are heavily 
involved in AD, and are some of the first areas to be affected by the disease (Mintun et al., 2006; Sheline 
et al., 2010). It is especially interesting that the pattern of Aβ deposition closely mirrors the DMN 
(Buckner et al., 2005; Sperling et al., 2009; Villemagne & Chételat, 2016). Additionally, studies have 
found that connectivity is negatively correlated with disease severity, supporting the theory of a 
connection between the two (Wu et al., 2011; Zhang et al., 2010). 
In addition to measuring the brain at rest, fMRI can be used to measure brain activation in response to 
specific stimuli or tasks. This can be particularly useful when looking at the effects of AD on episodic 
memory and related problematic areas. Reduction in episodic memory is a function of natural ageing, 
and is heavily affected in a variety of dementias making it a prime target for AD studies (Nyberg, 2017). 
Studies looking at memory in AD patients have shown altered activation in the MTL and parietal lobes, 
which is consistent with deficits seen in structural scans (Hampel, Frank, et al., 2010). Furthermore, fMRI 
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can be used to directly measure effects of treatment on various brain areas making it potentially useful 
in measurements in future clinical trials (Bokde et al., 2009; Hampel et al., 2004).  
1.2.3.4.2 MRI perfusion – Arterial Spin Labelling  
Arterial Spin Labelling (ASL) is one technique used to measure CBF changes by using arterial blood water 
as a tracer by magnetically labelling arterial blood water protons (Petcharunpaisan, Ramalho, & Castillo, 
2010).Compared to normal aged matched controls, AD patients appear to have up to 40% global 
decrease in CBF (Asllani et al., 2008). The most common areas that experience this decrease in AD are 
the precuneus, posterior cingulate, and superior parietal regions (Alsop, Detre, & Grossman, 2000). 
Additionally, it appears this occurs even in the absence of grey matter atrophy (Hu et al., 2010). Because 
of this, and evidence that cerebral hypoperfusion may contribute to AD, measurements of CBF may 
serve as a possible biomarker of AD (Wierenga, Hays, & Zlatar, 2014).  
MRI perfusion studies have shown similar results to SPECT/PET perfusion and PET metabolism studies, 
however there is less data is available to fully assess the use of MRI perfusions as a biomarker of AD 
(Albert et al., 2011).  
1.2.3.4.3 Diffusion Tensor Imaging  
While AD is primarily considered a disease of GM, there is evidence of changes in WM as well (A. A. 
Gouw et al., 2008; P. Scheltens et al., 1995; C. D. Smith, Snowdon, Wang, & Markesbery, 2000). These 
changes are thought to be a results of axonal damage and the breakdown of oligodendrocytes and 
myelin in the WM (Bartzokis, 2004; Bartzokis, Lu, & Mintz, 2007; Roher et al., 2002; C. D. Smith et al., 
2000). These WM changes can appear independent of GM lesions (Brun & Englund, 1986) and 
indications of VaD (Sjöbeck, Haglund, & Englund, 2006), and can appear in the very early stages of AD 
(Amlien & Fjell, 2014). These white matter changes can be measured using diffusion weighted imaging 
(DWI). DWI uses the diffusion of water molecules to generate contrast in magnetic resonance (MR) 
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images. More specifically, DTI measures the diffusion of water along axons in the WM. Because of the 
myelin sheaths covering the axonal fibres, water flows in a specified direction. By placing a magnetic 
gradient in several directions, various information about water flow through membranes of the fibres 
can be deducted (Barkhof, 2011). This can be used to evaluated the integrity and trajectory of the fibres 
(Nir et al., 2015). Diffusion based techniques have shown moderate clinical value in AD (Nir et al., 2015; 
Pini et al., 2016) but are less useful in cases of MCI. There are also difficulties in the reproducibility of 
DWI across clinical settings, making it an interesting area for further research but not a main imaging 
biomarker at this time (Pini et al., 2016).  
1.2.3.4.4 Magnetic Resonance Spectroscopy  
In-vivo quantitative measures of biochemical compounds in brain tissue can be measured using MRS or 
Proton MRS (1H-MRS). These metabolites can reflect the neuropathological processes occurring in AD 
and dementia (Kantarci, 2007). The most commonly measured compounds are: N-acetylaspartate 
(NAA), a measure for neuronal density and function, myo-inositol (mI), a measure for astrogliosis, and 
choline (Cho), a measure of cell membrane degradation (Soares & Law, 2009). Levels of NAA are found 
to be reduced in AD, even independent of atrophy (Chao et al., 2005; Hampel, Frank, et al., 2010). Other 
metabolites besides NAA have not been as well studied in AD and their potential as a biomarker is 
debated (Hampel, Frank, et al., 2010). 
 
1.2.4 Problems with Current Imaging Biomarkers 
Imaging biomarkers are currently only officially suggested for clinical research criteria.  Diagnoses are 
based on core clinical criteria, but imaging methods are becoming more prominent in clinical settings (G. 
M. McKhann et al., 2011).  
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There is a general difficulty in defining appropriate biomarkers because despite the advances made in 
recent decades in AD research, there is still a lack of firm links between the appearance of a specific 
biomarker and the subsequent onset of a specific clinical symptom.  Biomarkers are reflections of the 
underlying AD pathology, but it is still difficult to know exactly to what extent the biomarkers indicate 
the actual pathology, and on what time scale (Sperling et al., 2011). There is pathological evidence in 
healthy appearing individuals, and not all patients with clinical AD symptoms experience the same 
pathology. Additionally, Aβ, p-tau, and t-tau proteins are not solely specific to AD and can be found in 
other neurological conditions. Neuronal injury is also a broad spectrum biomarker, and alone cannot 
indicate AD (Jack Jr. et al., 2011). Variability between biomarker measurements between different clinics 
and laboratories also make it difficult to determine agreed universal cut-offs for positive results (Philip 
Scheltens et al., 2016).  
More work needs to be done to properly validate the current biomarkers, and especially on the 
standardisation of both protocol and outcome measures. Additionally, there is not universal access to all 
biomarkers across clinical communities, which can make it difficult to include them as standard practice. 
Moving forward, more research needs to be done comparing biomarkers, and combinations of 
biomarkers as often times multimodal biomarker studies are limited (Albert et al., 2011; Jack Jr. et al., 
2011). There also needs to be more biomarker comparison with post-mortem studies, to see how well 
biomarkers actually reflect brain pathology (Jack Jr. et al., 2011).  
Lastly, the validation work that has been done on current biomarkers may suffer some confounding 
issues. Many of these studies are done on large AD cohorts such as the Alzheimer Disease Neuroimaging 
Initiative (ADNI) and AddNeuroMed (Mueller et al., 2005; Simmons et al., 2011). These cohorts may 
suffer additional biases because they are sometimes comprised of people who volunteer that come are 
highly educated and come from wealthier socioeconomic backgrounds. They are also less likely to have 
age-related comorbidities that may also influence their cognitive decline (Sperling et al., 2011). This 
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would be best combated by using current biomarker techniques on the wider population, namely 
memory clinic samples.  
1.3 IMPORTANCE OF VALIDATING RESEARCH ON BIOMARKERS: THE USE OF ELECTRONIC HEALTH 
RECORDS 
Despite the numerous advances in imaging research techniques in dementia and AD, most are not yet 
applied to the clinic and are only used in research or clinical trial settings. There are a variety of cohort 
types, each with their own advantages and disadvantages.  
Ideally, a sample selected completely at random, would be used for all studies. A random selection from 
a source that is reflective of the general population (for example an electoral roll), will most closely 
reflect the general population and therefore have the most generalisable results and highest external 
validity (Hulley, Cummings, Browner, Grady, & Newman, 2013). It is important to remember that no 
sample is completely representative, as participation is always voluntary and in theory there could be 
fundamental differences in those willing to volunteer versus those who are not (the so-called “volunteer 
gene”) (L. J. Launer, Wind, & Deeg, 1994). Lastly, even registers are not fully representative as they do 
not include illegal immigrants or people who move often. Lastly, while population samples are ideal to 
study highly prevalent disorders and their impact on the population, it is the most complicated and 
expensive method which means it may not be appropriate when studying a rare disease, or when 
resources are minimal.  
Convenience samples are quicker, easier, and more economical than population samples. The selection 
of people is based on the ease of recruitment, and may not be reflective of the entire population. These 
samples usually share a characteristic from an epidemiological point, but are still heterogenous. 
Community-based volunteer samples are convenience samples recruited through advertisements or 
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word of mouth. The more restricted the advertising is to specific groups (for example, in a care home) 
the more biased the resulting sample will be. Volunteers tend to have a higher educational level, better 
socioeconomic status, and a particular interest in the issue being studied, in addition to the previously 
discussed potential fundamental differences in those who volunteer versus those who do not (Rosenthal 
& Rosnow, 1975). Secondly, there could be clinical (or medical help-seeking) convenience samples. 
These are samples recruited from general practitioners or more specialised clinics that usually require a 
referral to the service (such as the memory clinic used for the studies in this PhD). Lastly, samples can be 
mixed, for example a group of controls recruited from ads (community-based) and a patient population 
from a clinic. However, these mixed samples may exaggerate differences between clinical samples and 
healthy controls  (Brodaty et al., 2014). 
In the context of AD, differences in rates of decline in convenience based samples (such as ADNI) and 
population based (such as the mayo clinic) in AD may not be representative of the general population 
(Jennifer L. Whitwell et al., 2012).  On average, the mayo clinic sample (population based) was older, less 
educated, had less familial history of AD, lower MMSE, smaller hippocampal volume in controls, and less 
likely to have the APOE e4 allele (in the amnestic MCI category). These biases could be due to 
recruitment methods, where healthy subjects worried about their cognition may be more motivated to 
answer advertisements or go to a memory clinic in the first place (where the study is advertised). 
Additionally, those with higher education are more likely to seek medical help or become involved in 
observational studies.  
Similarly to the aforementioned cohorts, clinical trials may also suffer from analogous biases because 
often times participants are more affluent, have higher levels of education, and may lack other 
comorbidities that the general public suffer from. While these stratified samples are arguably very 
useful for conducting research, there must be studies examining these techniques and their 
effectiveness in the general population. 
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1.3.1 Integration of Electronic Health Records and Neuroimaging  
Both medical professionals and researchers have concluded that there is a very strong opportunity for 
studies with clinical cohorts and even population-wide research that may aid in bridging the 
translational gap between research and clinical practice through the use of sharing electronic health 
records (Jensen, Jensen, & Brunak, 2012). 
1.3.1.1 Electronic Health Record use in Research and Clinics  
Electronic health records (EHRs) are becoming a popular alternative to traditional hand written records 
in clinics and hospitals across the globe. Largely, this is due to the rapid improvements in technology and 
information storage in the last few decades. Various initiatives across the world have increased the use 
of EHRs. The HITECH act (Blumenthal, 2010) in the United states had provided $19 billion and the public-
private partnership Innovative Medicines Initiative (IMI) has put forward €2 billion in the European 
Union in order to grow and implement these technologies (Goldman, Seigneuret, & Eichler, 2015; 
Hunter, 2008). There are a variety of national strategies devoted to the development and 
implementation of interoperable health information technology systems and EHRs (Coiera, 2009; 
Morrison, Robertson, Cresswell, Crowe, & Sheikh, 2011). The main focus of these developments has 
been more comprehensive patient care, but the applicability extends far past that. 
There are many benefits to using an EHR system instead of a paper-based one. EHRs can ideally provide 
an inclusive historical overview of a patient’s history in one easily accessible place. Undoubtedly, this 
depends on the integration of GP and hospital records. Ideally, information can include, but is not 
limited to demographics, past medical and visit history, allergies, medications, and laboratory and 
radiology reports. An EHR system provides a structured template, creating a more standardised system 
with all patients having the same information. Having an electronic system facilitates sharing of 
information between medical professionals at different hospitals and clinics. Shared information allows 
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for more efficient and safe care by avoiding medical errors due to drug interactions, allergic reactions, 
and other potential issues. Additionally, implementation of EHRs have been shown to increase efficiency 
in health care delivery by avoiding the waste of resources (both supplies and manpower), such as 
redundant testing (Institute of Medicine (US) Committee on Quality of Health Care in America, 2001). 
Overall clinicians appear to prefer it and recognize the potential benefits of an electronic system 
(Menachemi, Powers, & Brooks, 2009; Mistry & Sauer, 2009). 
Conversely, there are a number of issues that arise with the use of an EHR system. Many of these issues 
stem from the initial implementation of a new system such as loss of productivity, disruption of normal 
workflow, and extra financial burden (Menachemi & Collum, 2011). These are usually temporary 
problems that result from installing and learning a new system. More longstanding problems include the 
maintenance costs associated with continued use, which are incurred with hardware replacement and 
software updates. Perhaps the biggest drawback of switching to an EHR system is the potential risk of 
privacy violations of patients.   
Beyond the arena of clinical care, EHR systems create a myriad of opportunities for research within 
clinical settings.  Firstly, EHRs help to create an enormous database of information, allowing the 
potential for researchers to gather information about disease comorbidities, effectiveness of 
medications, and more (Jensen et al., 2012). The electronic nature of the system allows more 
widespread accessibility to researchers interested in specific disorders and conditions. Additionally, the 
data is usually structured in a more unified way making it easier for researchers to acquire any relevant 
data from one single source, than paper records. A challenge of this is mining the aggregated data in 
meaningful ways despite the inherent differences in the data as free text clinical description, diagnostic 
codes, physiological data, and radiological results are all presented and stored very differently. This 
combination of data however, provides an interesting opportunity for researchers to discover potential 
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relationships with an extremely great variety of variables.  This makes EHR systems both a prime area 

















2 THE BIOMEDICAL RESEARCH CENTRE MEMORY CLINIC COHORT 
The main focus of this thesis is the translation of advanced imaging techniques from research based 
cohorts to clinical cohorts. This is a crucial step in validating analysis methods as potential biomarkers, 
which is needed in order to use these techniques in clinical practice (G. M. McKhann et al., 2011). 
Advances in scientific technologies have now allowed us to visualise more of pathology in Alzheimer’s 
Disease (AD) and dementia, which can be extremely helpful in the diagnostic process. This chapter will 
describe the memory clinic cohort that was used in the following studies aimed at the translation of 
research techniques into the clinic.  
2.1 BIOMEDICAL RESEARCH CENTRE MEMORY CLINIC COHORT 
The Biomedical Research Centre memory clinic cohort (BRCMEM) is a continuously ongoing research 
initiative run by the NIHR Maudsley Biomedical Research Centre and Dementia Unit (BRC/U), which is a 
collaborative partnership between the South London and Maudsley (SLaM) NHS Foundation Trust and 
the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. The aim of the BRC is to 
explore experimental medicine and translational research to introduce the latest research techniques 
into the mental health clinics. The group brings together researchers, clinicians, allied health 
professionals and service users across the university and NHS trust partnership to work together to 
improve care for patients.  
The BRCMEM cohort was designed based on the AddNeuroMed cohort (Lovestone et al., 2009), and 
uses the same scanning parameters described later for accurate comparability in future studies. The 
goal of this project was to follow clinical patients going through a dementia diagnosis assessment using 
one of SLaM’s memory services, and use the already available information to develop better clinical 
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imaging techniques for dementia and AD, examine new and existing biomarkers, and explore the 
feasibility of incorporating electronic health records (EHRs) for research purposes.  
As of February 16, 2017 there are 2,712 subjects in the BRCMEM cohort. For the purpose of this PhD, 
only the first 1,000 subjects were used in analyses. These participants were scanned between January 
2011 and May 2014.  
2.1.1 Demographics 
2.1.1.1 The SLaM Cohort 
SLaM covers over 1.2 million people in four major south London boroughs (Southwark, Lambeth, 
Croydon, and Lewisham). SLaM is currently structured with a variety of specialty groups including: 
Addictions, Behavioural & Developmental Psychiatry, Child & adolescent Mental Health Services, Mental 
Health of Older Adults & Dementia, Mood, Anxiety & Personality, Psychological Medicine, and Psychosis. 
SLaM also provides wider national provisions such as adult attention deficit hyperactivity disorder, adult 
personality disorder, anxiety disorders, autism assessment and behavioural genetics, brain injury (both 
outpatient and inpatient), chronic fatigue, eating disorders, female hormone clinic, mother and baby 
unit, autism, practitioner health, psychological interventions, psychosexual disorders, self-harm, and 
traumatic stress.  
2.1.1.2 The Memory Clinic Cohort 
The memory clinic cohort includes any patients that have been referred to one of the trusts participating 
memory clinics: Croydon Memory Service, Lewisham Memory Service, or Southwark and Lambeth 
Memory Service. Out of the first 1,000 participants of the memory clinic, we were able to connect 934 
with their EHRs, as described in subsequent sections. Out of the total 934 participants, 538 were female 
and 396 were male. The average age of participants at the time of their scan was 74.44 (std = 10.147), 
with a wide age range from 28-97 (Table 2-1). While the younger ages are very unusual for any kind of 
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dementia or AD, these patients were referred to one of the memory clinics by their GP and were 
therefore included in all of the studies and analyses. As described later, many of the analyses were 
broken down by diagnosis, and therefore we did not see this as a limitation. Majority of participants 
(566; 60.6%) identified as British, with the second most common ethnicity being Caribbean (106; 11.3%). 
A full breakdown of the number of participants used in each study, and reasons for exclusion are 
included in Figure 2-1.  
Figure 2-1 A full breakdown of participants used in each of the studies, including reasons for exclusion 
 
2.2 METHODS 
2.2.1 Inclusion Criteria 
In order to be eligible to participate, subjects must have been referred to one of the SLaM memory 
clinics for suspected dementia. All health records from SLaM patients are funnelled into the Clinical 
Record Interactive Search (CRIS) system and there is an opt-out option available.  There must be 
significant impairment of daily activities consistent with a diagnosis of mild to moderate dementia or 
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Mild Cognitive Impairment (MCI).  Because all participants were referred to SLaM memory clinics, all 
records were present on the hospital’s EHR system and therefore accessible by CRIS. As of February 16, 
2017, there are 2,712 subjects in the cohort. For the purpose of this study, we decided to use the first 
1,000 subjects.  
2.2.2 MRI Acquisition 
As per standard examination in the SLaM memory clinics, all participants received a standard T1-
weighted MPRAGE volumetric structural scan, a T2 Fluid attenuation inversion recovery (FLAIR) 
propeller and T2 propeller scan. T1 weighted scans are known for high spatial resolution and good grey 
matter and white matter contrast, and are particularly good for visualizing atrophy. FLAIR scans have an 
inversion time such that the signal of water in the scan is suppressed. This gives the scan low white-grey 
matter contrast, which allows visualisation of lesions in cortical and subcortical regions (Barkhof, 2011). 
Lastly, T2 weighted scans result in very high signal of cerebrospinal fluid (CSF) compared to the other 
tissues, and is particularly useful for observing tissue oedema and lesions.  
Scans were acquired using a 1.5T GE Signa HDx system, using the ADNI-1 (Clifford R. Jack, Bernstein, et 
al., 2008) and AddNeuroMed (Lovestone et al., 2009; Simmons et al., 2011) acquisition parameters. The 
3D T1-weighted MPRAGE images were acquired using a magnetization-prepared rapid gradient echo 
sequence (MPRAGE) using the following: TE = 3.8 ms, TR = 8.592 ms, TI = 1000 ms, matrix size 192x192, 
flip angle 8o, FoV = 240 mm, voxel dimension .9375 x .9375 x 1.2 mm. Full brain and skull coverage was 
required for the MRI datasets and detailed quality control carried out on all MR images from both 
studies according to previously published quality control criteria (Simmons et al., 2009, 2011) which 
included ensuring there was no wrap-around artefacts affecting the brain, motion artefacts, image 
inhomogeneity, or inadequate contrast between grey and white matter. Any images that did not pass 
visual inspection quality control were not included in further analyses. 
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2.2.3 Cognitive Testing 
As per standard practice, any patients (and/or carers) accepted to the memory clinic are interviewed in 
an initial assessment. This initial interview is designed to measure cognitive and functional assessment, 
and is given by a doctor, nurse, psychologist, occupational therapist, or social worker trained in 
dementia diagnosis. The assessment includes cognitive concerns, mental state and symptoms, daily 
functioning and psychopathology, and personal, educational, family and medical history. Additionally, a 
variety of cognitive exams are administered, which may include: Addenbrooke’s cognitive examination 
(ACE), the standardised mini-mental state examination (MMSE), Neuropsychiatric Inventory (NPI), 
Bristol Activities of Daily Life Scale, the Geriatric Depression Scale (GDS), and Geriatric Anxiety Inventory. 
Results from this initial interview are discussed with the multi-disciplinary memory service team to 
determine further assessment and treatment.  
Assessments may be redone with follow up appointments over time, for example after six or twelve 
months. All results from initial and follow-up cognitive testing are listed in the memory clinic patient’s 
electronic health records.  
2.2.4 Consent 
This study includes patients from the SLaM Trust, who were referred to one of the trust’s participating 
memory clinics. Patients were asked if they would authorise use of their anonymised MRI images for 
research purposes. Consent forms are included on every safety form, and all participants scanned for 
any reason are asked if they would allow their MRI images to be used, regardless of reason of visit. In 
order to be eligible to participate, subjects must have been referred to one of the SLaM memory clinics 
for suspected dementia. All health records from SLaM patients are funnelled into the Clinical Record 
Interactive Search (CRIS) system and there is an opt-out option available, as described in the next 
section.  There must be significant impairment of daily activities consistent with a diagnosis of mild to 
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moderate dementia or MCI. Because all participants were referred to SLaM memory clinics, all records 
were present on the electronic Patient Journey System (PJS) and therefore accessible by CRIS.  
Ethical approval for this study was granted by the National Health Service (NHS) Health Research 
Authority (09/H0606/84). 
2.3 STRENGTH OF THE BRCMEM COHORT 
While there has been significant advancement in the diagnostics of AD and dementia in the last few 
years, it has been acknowledged that many research studies suffer from cohort biases (Sperling et al., 
2011). Biomarker and cognitive studies, the most popular types of studies in AD, may not be based on 
cohorts that are truly representative of the older population. The majority of these cohorts are made up 
of people who are willing to volunteer for MRI research, which tend to be highly educated and come 
from higher socioeconomic backgrounds. As they have been described by Sperling et. al, they may be 
considered samples of convenience and have the so-called “volunteer gene”, and be more active than 
typical of other people that age (Sperling et al., 2011). Additionally, due to specific exclusion and 
inclusion criteria, these subjects are less likely to have typical age-related comorbidities that could 
influence cognitive decline.  
This PhD aims to combat these potential biases in previous dementia studies by using a clinical cohort. 
The SLaM memory services cover a wide catchment area that serves a variety of people across 
education levels and socioeconomic backgrounds. Because these patients are already present for their 
scan, and only need to sign a consent form included on their MRI safety sheet to indicate whether or 
not, the bias of the “volunteer gene” is most likely not present, as these people were not actively 
seeking to participate in research. Lastly, all patients referred to one of the memory clinics are included 
in this cohort. There are no restrictions based on a specific type of dementia diagnosis, or other 
comorbidities that may contribute to their cognitive decline. The hope is that current research 
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techniques provide inside into potential new diagnostic tools that are just as effect in the clinic as they 














3 CORRELATION OF MMSE SCORE AND HIPPOCAMPAL VOLUME IN A 
MEMORY CLINIC COHORT 
3.1 INTRODUCTION 
3.1.1 The Mini Mental State Examination 
The Mini Mental State Examination (MMSE) is the most commonly used cognitive test for patients 
experiencing memory deficiencies (Arevalo-Rodriguez et al., 2015), and is widely used for diagnosing 
Alzheimer’s Disease (AD) and dementia. In addition to being used widely across clinical settings, it is also 
one of the most commonly used neuropsychological assessments in dementia research. The MMSE gives 
insight to the severity of cognitive decline amongst patients and participants, but is not sufficient to 
make a diagnosis alone.  
3.1.2 Hippocampal Volume and Dementia 
Hippocampal atrophy is a characteristic feature of AD and can even be evident in patients with Mild 
Cognitive Impairment (MCI) as well. Hippocampal volume, and thus hippocampal atrophy, can be 
measured using structural MRI. Hippocampal atrophy has been found to be predictive of further  
cognitive decline and dementia (Clifford R. Jack et al., 1999; P. J. Visser et al., 1999). Because 
hippocampal atrophy can be reflective of memory deficits (Schröder & Pantel, 2016; Wolf et al., 2001), it 
is likely to be correlated with MMSE score. Indeed, this has been demonstrated in a variety of studies 
both looking at AD and dementia (C.R. Jack et al., 2002; Peng et al., 2015; Yavuz et al., 2007) and other 
conditions (Sawyer, Corsentino, Sachs-Ericsson, & Steffens, 2012; Steffens et al., 2002).  
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3.1.3 Rationale and Hypotheses 
The goal of this study was to integrate EHR and automated analysis of clinical neuroimaging for the first 
time. As a specific initial exemplar to examine the feasibility of attaching EHR data with automated MRI 
results from clinical imaging, the correlation between hippocampal volume and MMSE score was 
examined. Based on past research, it is expected that MMSE score will be positively correlated with 
hippocampal volume. Within a clinical setting, it would be useful for clinicians to have access to relevant 
data aside from the images themselves, such as volumetric measurements listed previously. However, 
potentially more importantly, this repository of information allows researchers to have access to wider 
samples of a clinical nature. Allowing researchers access to clinical samples is a vital part of translating 
research into the clinic.  
3.2 METHODS 
3.2.1 Memory Clinic Cohort  
As previously described, the memory clinic cohort includes any patients that have been referred to one 
of the trusts participating memory clinics: Croydon Memory Service, Lewisham Memory Service, or 
Southwark and Lambeth Memory Service. From our original sample, 536 participants had an MMSE 
score within ± 3 months of a structural MRI scan that passed quality control. This subset included 217 
males and 319 females.  
3.2.2 Electronic Health Records 
EHR linkage has been done for research purposes, not in conjunction with neuroimaging data. This 
section describes the procedures done to create the EHR database used. While this database creation 
was not specifically for this PhD, it was an integral part of the analyses. The following section (3.2.2 
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Electronic Health Records) is based on the work by Stewart, Fernandes, and colleagues (Fernandes et al., 
2013; Stewart et al., 2009) 
3.2.2.1 The South London Mausley Hospital & Clinical Record Interactive Search System 
The South London and Madusley (SLaM) National Health Service (NHS) Foundation trust is one of the 
largest mental health care providers in Europe, servicing a catchment area of over 1.2 million residents 
over four south London boroughs (Croydon, Lambeth, Lewisham, and Southwark) in addition to some 
specialist services at a regional/national level. All patient records at SLaM have been paperless since 
April 2006, when the trust’s electronic Patient Journey System (PJS) was introduced. The PJS is a 
comprehensive electronic health record system, unique to SLaM, that follows the patient’s journey 
through the trust’s services and includes all relevant clinical information such as: demographic and 
contact information, dates of referrals and transfers, detailed clinical assessments, care plans, 
medication, and clinical activity and reviews. It consists of both structured field based data and 
unstructured free text – including assessments, progress notes, and correspondence. This database is 
used and maintained by a variety of healthcare professionals throughout the trust.  
The Clinical Record Interactive Search (CRIS) system was created in order to provide an anonymized 
database for clinical auditing and research purposes.  It pulls records directly from the trust’s PJS. The 
system is representative of all of SLaM care, including all patients’ records. An opt-out system is 
available and advertised publicly but as of 2013 only three people had requested this (Perera et al., 
2016). CRIS allows researchers and clinicians to specify criteria to define the cohort of interest, such as 
those with a specific diagnosis or that contain a keyword of interest. Once a cohort of interest is 
specified, clinicians and researchers can then decide what variables are of interest, such as clinical status 
or trust movement. The CRIS system then returns anonymised records of relevant participants, with any 
variables that were deemed important. In addition, CRIS links with a variety of resources such as the 
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Mental Health Minimum Dataset, Hospital Episode Statistics (HES) for England and Wales, Primary Care 
information (Lambeth DataNet), the Department of Education National Pupil Database, and the Office 
for National Statistics (ONS) for mortality data, creating an even more powerful database. As of 31 
December 2014 there were more than 250,000 clinical records accessible on the CRIS system (Perera et 
al., 2016). 
CRIS uses a dual de-identification algorithm and security model to ensure patients’ anonymity is 
protected. This is especially important in psychiatric case registers because the nature of the data is 
potentially stigmatising. In order to create the data store of de-identified records linked directly to PJS, a 
systematic process was followed to mask all potentially personally identifying information - designated 
as personal identifiers (PIs). The Health Insurance Portability and Accountability Act (HIPAA) in the 
United States lists 18 different PIs that must be masked in order to use health records in research 
(Malin, Benitez, & Masys, 2011; Neamatullah et al., 2008). The UK does not have specific stipulations on 
the types of information that need to be masked, but do encourage appropriate de-identification based 
on context (The Academy of Medical Sciences, 2006). In the UK, each NHS trust is assigned a “Caldicott 
Guardian” and committee which represents both clinical and service users. The main duty of the 
Caldicott Guardian is to guarantee patient confidentiality within their specified trust (Greenough & 
Graham, 2004). 
3.2.2.2 De-identification Process 
Any information input on the HTML front-end of PJS is processed and stored in a secure Structured 
Query Language (SQL) database, which is continually updated as new information is entered into PJS by 
clinicians or other relevant service users.  CRIS was built in partnership with BearingPoint™ and uses 
FAST™ search technology. Before data can be searched via the CRIS system, the data from PJS must be 
converted into Extensible Mark-up Language (XML). All content is extracted from a replicated SQL Server 
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using a custom program called SQL extractor in order to convert this data in to XML. The SQL extractor 
code then generates one XML document per patient, storing relevant clinical information in this 
document while maintaining the tiered structure found on PJS. Once source SQL data has been 
extracted and formatted accordingly, the records are then stored on a disk before they are passed to 
FAST for ingesting, eventually providing a searchable index. XML records are modified during this 
process using a transformation pipeline. This pipeline, written in Python, is accessed from within FAST. 
The de-identification process is handled by two pipeline stages which determine not only what needs to 
be removed from the XML but also where in the XML any PI content can be found. The process is as 
follows: 
1) A list of fields is created that contains PIs. In this list both field name and field type are defined. 
Field type will later define how the algorithm treats the field when adding it to the cleaning 
dictionary (what will be removed later on). A field is either a) added to the dictionary and 
completely stripped from CRIS (for example, the patient’s name) or is b) added to the dictionary 
and truncated in CRIS (for example, the last three characters of the patient’s post code are 
stripped from CRIS) as to protect the identity of the patient yet retain relevant geographical 
information. This differs from other de-identification algorithms as the cleaning dictionary isn’t 
obtained from registries (Meystre, Friedlin, South, Shen, & Samore, 2010) but directly from the 
patient forms on the EHRs themselves. This creates a cleaning dictionary that is unique for each 
patient and includes: first names, last names, middle names, nicknames, contact numbers, key 
person contacts, addresses, trust IDs, and date of birth. Additionally, copies of the PIs are 
stripped of delimiters (such as apostrophes or hyphens) and also added to the cleaning 
dictionary. (Table 3-1) 
2) To save time on processing, the de-identification algorithm is not run on the entire XML file but 
instead on specific predefined areas delineated through the use of XML tags or XML scopes. 
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These tags are used to by the program to determine where the de-identification algorithm is 
necessary. This includes any free text entries, such as case notes and summaries and core 
patient info and summary fields.  
3) A masking string is used to replace words that have been identified as to be removed. Direct 
patient identifiers replaced with a ZZZZZ string while relative or close contact identifiers are 
replaced with QQQQQQ in order to not confuse who the entered information belongs to.  
4) A list of address aliases is created in order to ensure things that are not entered identically to 
what is in the address field, such as road/rd and street/st, are still masked. 
Using the above processes, the python code uses the newly configured fields to populate the cleaning 
dictionary. Heuristics are used to identify different PI formats or patterns, such as a telephone number 
being written as 00000-000-000 or 00000000000, which is particularly useful for free-text fields. Once 
the cleaning dictionary is complete the python code reads the XML tags to determine what information 
within the tags needs to be removed. This is done based on a set of rules to determine where each 
token of PI begins and ends. Once a token is identified, it is compared against the cleaning dictionary. If 
there is a match it is replaced with the appropriate masking string. The code is flexible, and fields or tags 
















Table 3-1 – List of example personal identifiers (PIs) and cleaning dictionary. * an actual CRIS cleaning dictionary would include 
more variations on date of birth etc; and this example list is not exhaustive but for illustrative purposes. Adapted from 
Fernandes et al. 2013.  




Date of Birth 
Trust ID 
Post Code 
Nick Name  






SW4  XLT 
Charlie 
Barrett 









24th Mar 1990 
24th of Mar 90 
24 March 1990 
24 Mar 1990 
12-34-56 






3.2.2.3 Security Model 
In addition to the de-identification process, a multifaceted security model was developed in order to 
address the ethical and legal considerations that come along with using patients’ confidential data and 
records. The first in this process was the development of the CRIS Oversight Committee which is chaired 
by a mental health service user, and also includes a child and adolescent mental health clinical 
68 
 
representative, a representative of the Trust’s Caldicott Guardian, a Research Ethics representative, and 
the CRIS academic project lead and CRIS project manager.  
Use of the CRIS system is application based, meaning researchers must submit an application to the 
oversight committee detailing their project and variables of interest. If the application is to conduct an 
audit of clinical services within the trust, it will be presented to the relevant audit committee within 
SLaM before being reviewed by the CRIS Oversight Committee. Projects that are researcher based must 
have a senior university or NHS affiliated supervisor to take responsibility for the project before it is 
viewed by the oversight committee. All applicants must have affiliation with the trust in the form of an 
honorary or substantive contract with the hospital or university previous to applying for CRIS, which in 
turn formally hold the applicant to the NHS duty of confidentiality. Applications are assessed based on 
the suitability by evaluating the need for the project and scientific robustness of application. Any 
potential confidentiality concerns are identified, and if there is a potential to identify patients these 
concerns are discussed with both the researcher and their supervisor. Potential alternatives, such as 
obtaining patient consent, are presented if possible. 
Once an application is accepted by the oversight committee, researchers are required to access CRIS 
only within the SLaM security firewall. Users must follow specific rules to ensure responsible handling of 
data and guarantee confidentiality of the patients. Projects are audited on a weekly basis, and if projects 
are being carried out inappropriately approval can be revoked. This close examination of ongoing 
projects and strict regulation of access to CRIS ensure data handling obeys the guidelines set out by 
CRIS, and safeguard the anonymity of patients within the trust. 
69 
 
3.2.3 Hippocampal volume analysis 
3.2.3.1 FREESURFER automated volumetric analysis 
The T1 images were analysed with the FREESURFER pipeline version 5.3.0 
(http://surfer.nmr.mgh.harvard.edu/), which includes removal of non-brain tissue using a hybrid 
watershed/surface deformation procedure (F. Ségonne et al., 2004), automated Talairach 
transformation, segmentation of the subcortical white matter and deep grey matter volumetric 
structures (Bruce Fischl et al., 2002; Bruce Fischl, Salat, et al., 2004; F. Ségonne et al., 2004) intensity 
normalization (Sled, Zijdenbos, & Evans, 1998), tessellation of the grey matter white matter boundary, 
automated topology correction (B. Fischl, Liu, & Dale, 2001; Ségonne, Pacheco, & Fischl, 2007), and 
surface deformation following intensity gradients to optimally place the grey/white and 
grey/cerebrospinal fluid borders at the location where the greatest shift in intensity defines the 
transition to the other tissue class (A. M. Dale, Fischl, & Sereno, 1999; Anders M. Dale & Sereno, 1993; B. 
Fischl & Dale, 2000). Once the cortical models are complete, registration to a spherical atlas takes place 
which utilizes individual cortical folding patterns to match cortical geometry across subjects (B. Fischl, 
Sereno, Tootell, & Dale, 1999). This is followed by parcellation of the cerebral cortex into units based on 
gyral and sulcal structure (Desikan et al., 2006; Bruce Fischl, van der Kouwe, et al., 2004). The pipeline 
generated 68 cortical thickness, cortical volume, surface area, mean curvature, gaussian curvature, 
folding index and curvature index measures (34 from each hemisphere) and 21 regional subcortical 
volumes (Table 3-2). This segmentation approach has been used for multivariate classification of 
Alzheimer’s disease and healthy controls (Westman, Wahlund, Foy, et al., 2011), neuropsychological-
image analysis (Yawu Liu, Paajanen, Zhang, et al., 2010; Yawu Liu et al., 2011), imaging-genetic analysis 
(Yawu Liu, Paajanen, Westman, Wahlund, et al., 2010; Yawu Liu, Paajanen, Westman, Zhang, et al., 
2010) and biomarker discovery (Thambisetty et al., 2010). For the purpose of this study, only left and 
right hippocampal volumes were used, but all other data is available.  
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All FREESURFER segmentation outputs were visually inspected by myself. During my undergraduate 
degree, I was trained in manual hippocampal segmentation in the lab of Dr. Jens Pruessner, and it was 
therefore decided that my anatomical knowledge of the hippocampus would be sufficient as a quality 
control of the FREESURFER segmentation outputs.  
 
Table 3-2 - List of FREESURFER outputs, including all Cortical Thicknesses and Subcortical structures used in the OPLS analysis 
Cortical Thicknesses (both Right and Left) Subcortical structures 
Banks of superior temporal sulcus 
Caudal anterior cingulate 




Inferior parietal cortex 
Inferior temporal gyrus 
Isthmus of cingulate cortex 
Lateral occipital cortex 
Lateral orbitofrontal cortex 
Lingual gyrus 
Medial orbitofrontal cortex 





Triangular part of inferior frontal gyrus 
Pericalcarine cortex 
Postcentral gyrus 
Posterior cingulate cortex 
Precentral gyrus 
Precuneus cortex 
Rostral anterior cingulate cortex 
Rostral middle frontal gyrus 
Superior frontal gyrus 
Superior parietal gyrus 









Corpus callosum anterior 
Corpus callosum central 
Corpus callosum midanterior 
Corpus callosum midposterior 






Cerebellum white matter 
Hippocampus 









3.2.3.2 Hippocampal Volume Normalisation 
Hippocampal volumes used in the analysis were normalised by total intracranial volume (ICV) as 
determined by FREESURFER segmentation, to control for differences in head size. This was done by 
creating a ratio of hippocampal volume divided by total ICV, to remain consistent with other studies 
from our group. This has been found to be essential in 67 structural MRI studies, as differences in head 
size can create gender differences and influence the results (Scahill et al., 2003; J. L. Whitwell, Crum, 
Watt, & Fox, 2001). It has also been found that method used for both ICV volume estimation 
(Nordenskjöld et al., 2013), and ICV volume correction can yield different results (Arndt, Cohen, Alliger, 
Swayze, & Andreasen, 1991; Barnes et al., 2010; Malone et al., 2015; O’Brien et al., 2011), and therefore 
results must be interpreted with this limitation in mind.  
3.2.4 Statistical Analysis 
All statistical analyses were performed with SPSS 21 software package, and considered significant at the 
P < 0.05 level.  
3.2.4.1 Memory Clinic Cohort  
From our original sample, 536 participants that had an MMSE score within ± 3 months of a structural 
MRI scan that passed quality control. This subset included 217 males and 319 females. To test for group 
differences between genders, average MMSE score, normalised hippocampal volumes, and age were 
calculated for each gender. One-way Analysis of variance (ANOVA) was used to examine if significant 
differences existed between the genders.  
The memory clinic was further broken down by ultimate diagnosis found in their EHRS. Of the 536 
participants, 419 had a diagnosis listed on their clinical record. These subjects were then placed into one 
of the following categories: AD, MCI, Vascular Dementia (VaD), Mixed Dementia (MD), other dementia 
(such as dementia from Parkinson’s or Dementia in Pick’s disease), unspecified dementia, other 
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psychiatric disorder (such as depression or anxiety), and no diagnosis (such as person with mental health 
complaints). Group differences between age, average MMSE, and average total normalised hippocampal 
volume were measured using a one-way ANOVA, with Bonferroni corrected post-hoc tests. 
3.2.4.2 MMSE and Hippocampal Volume Correlation 
Pearson partial correlation of MMSE score and combined normalised hippocampal volume (right + left 
hippocampal volume / total ICV), while controlling for age at the time of scan, was run on the entire set 
of participants.  
Correlations between MMSE and hippocampal volume while controlling for age were calculated for each 
diagnostic group (AD, MCI, VaD, MD, other, and unspecified dementia) with a dementia related 
diagnosis. Normalised volumes for each the right and left hippocampus were created, and correlated 
with MMSE score as well.  
3.3 RESULTS 
3.3.1 Memory Clinic Cohort 
536 participants were used in this analysis, out of the original cohort of 934. The average age at scan 
was 78.82 years, with no significant differences between the age of males and females. The average 
MMSE score of the cohort was 23.35, again with no significant differences between males and females 
(Table 3-3). There were significant differences between male and female normalised hippocampal 
volumes, but this is to be expected as this is found in the literature (Nordenskjöld et al., 2015; 
Voevodskaya et al., 2014). The memory clinic was further broken down by ultimate diagnosis found in 
their EHRS, and as expected there were many significant differences between age, average MMSE, and 
average total normalised hippocampal volume between the groups (Table 3-4). Because of the 




Table 3-1 – Memory Clinic Cohort Demographics. Age, Normalised HC Volume, and MMSE score = Mean (Standard Deviation). 
Gender differences between Age, Normalised HC Volume, and MMSE score were measure by ANOVA. * denotes mean difference 
between genders significant a p<0.05 level.  
 
Number Age Normalised HC Volume MMSE 
Memory Clinic 
536 78.82 (10.23) .00409 (.001) 23.35 (5.14) 
Females 
319 78.55 (10.57) .00417 (.001)* 23.17 (5.12) 
Males 
217 79.21 (9.72) .00397 (.001)* 23.61 (5.16) 
 
3.3.2 MMSE and Hippocampal Volume 
Patients were broken down to sub groups based on diagnosis which included AD, MCI, MD, VaD, other 
form of dementia, and other psychiatric condition or no diagnosis. AD patients revealed the strongest 
correlation (r=.198, p=.009) (Figure 3-1). Patients in the VaD, MCI, and MD groups did not display a 
significant correlation between MMSE and normalised hippocampal volume (Table 3-4).  
 
Figure 3-1 – Scatter-plot of MMSE and Total (Left + Right) Normalised Hippocampal Volume for only patients in the memory 
clinic cohort. A. Alzheimer’s Disease B. Mild Cognitive Impairment C. Mixed Dementia D. Vascular Dementia E. Unspecified 





Table 3-2 – Correlation between MMSE score and total normalised hippocampal volume. Broken down by diagnostic category. 
Age, MMSE, and normalised HC volume = Mean (Standard Deviation). * Denotes significant correlation at p < 0.05 level 
Disease 












































51 71.96 (11.89) 
23.96 
(5.13) .00449 (.001) - - 
No Diagnosis 16 78.47 (7.79) 
26.06 
















Furthermore, MMSE was correlated with each side of the hippocampus individually. The normalised 
volumes for the left hippocampus were more highly correlated than the right hippocampus across the 
AD (left HC: r=.224, p=.003 – Figure 3-4; right HC: r=.150, p=.048 – Figure 3-5) and AD + MCI groups (left 
HC: r=.305, p<.001; right HC: r=.253, p<.041), which was not seen for the other dementia subtypes 
(Table 3-5). 
Figure 3-2 – Scatter-plot of MMSE and Normalised Left Hippocampal Volume for only AD patients in the memory clinic cohort 





Figure 3-3 – Scatter-plot of MMSE and Normalised Right Hippocampal Volume for only AD patients in the memory clinic cohort 












Table 3-5– Correlation between MMSE score and Left and Right normalised hippocampal volumes. * denotes significant 












correlation P- value 
Alzheimer’s 




.00212 .160 .231 .00217 .193 .146 
Vascular 
Dementia .00204 -.271 .156 .00208 -.133 .490 
Mixed 
Dementia .00188 .060 .679 .00184 .145 .316 
Unspecified 
Dementia .00197 -.141 .500 .00200 -.016 .939 
Other 
Dementia .00204 -.343 .332 .00217 .219 .554 
 
3.4 DISCUSSION 
In this study, we have successfully linked a large cohort of memory clinic patient’s scans with their EHRs. 
This is, as far as we are aware, the first time that EHRs have been linked with fully automated analysis of 
regional MRI volumes and paves the way for further research studies. MMSE score was positively 
correlated with hippocampal volume in AD patients, as expected.  
3.4.1 Hippocampal Volume and MMSE score 
There have been several studies examining the relationship of hippocampal volume and cognitive 
functioning in healthy controls, and AD and MCI patients, and most have found the same positive 
correlation between hippocampal volume and various cognitive measures (Arlt et al., 2013; Mungas et 
al., 2002; Peng et al., 2015; Ridha et al., 2008; Sencakova et al., 2001; Yavuz et al., 2007). There is also 
evidence of correlation between other areas that are vulnerable to atrophy in AD, such as ventricular 
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enlargement or global atrophy rate (Ridha et al., 2008), however these are less explored and therefore 
hippocampal volume was chosen for this study. 
3.4.1.1 Gender Differences in Normalised Hippocampal Volumes 
It is well documented that there are gender differences between head size and brain volumes (Gur et 
al., 1999). Findings have shown females have larger normalised hippocampal volumes than men, despite 
having smaller raw volumes (Filipek, Richelme, Kennedy, & Caviness, 1994; Maller, Réglade-Meslin, 
Anstey, & Sachdev, 2006; Ystad et al., 2009). As this finding has been well documented, it was not an 
unexpected result in the current study. 
Method of subcortical volume normalisation has been shown to influence gender differences 
(Nordenskjöld et al., 2015), and therefore method of volume normalisation should be taken into 
consideration when reviewing any study results. Normalisation methods, and subsequent potential 
confounds are further discussed in section 3.4.2.2. 
3.4.1.2 Correlation between Hippocampal Volume and MMSE score  
One study be Peng and Colleagues found baseline hippocampal volumes positive correlated with MMSE 
in both AD and MCI patients.  Several studies have found that hippocampal volume is positively 
correlated with cognitive measures in MCI patients (Arlt et al., 2013; Peng et al., 2015), however these 
studies were only using amnesic MCI patients, whereas our memory clinic cohort did not only include 
patients with amnesic MCI, but any type of MCI.  
Interestingly, while many studies have found this positive correlation between hippocampal volume and 
MMSE or other cognitive and memory measures, some found this relationship dissipates when looking 
at change in hippocampal volume or atrophy rate and either baseline cognitive measures or change in 
score (Ridha et al., 2008). This is most likely due to the lack of a linear relationship between change in 
hippocampal volume and MMSE score, or the lack of sensitivity in a MMSE (Mitchell, 2009).  
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Additionally, several studies have found unique relationships between hippocampal volume, MMSE 
score, and depression (Sawyer et al., 2012; Steffens et al., 2002). The patients in this memory clinic 
cohort did not have any depression measures, such as the Geriatric Depression Scale, to use in the 
analysis but it would be interesting to add such measures into a regression model in the future.  
While the difference in correlation between hippocampal volume and MMSE is different by diagnosis, 
this finding could be expected. Hippocampal volume is seen to be smaller in VaD patients compared to 
normal controls, however it was also found to be significantly larger than AD patients (Kim et al., 2015). 
This lack of correlation between hippocampal volume and MMSE in VaD and Mixed Dementia patients 
that was seen in AD and MCI patients has also been observed previously (Mungas et al., 2002). VaD does 
not have the same clear neuropathology that seems to centralise in the MTL and hippocampus (O’Brien 
& Thomas, 2015a). It has previously been found that hippocampal volume is related to baseline 
cognition in cases without lacunes, an indication of cerebral vessel disease, white matter damage and 
VaD, but not those with lacunes (Mungas et al., 2002). Taken together, these findings could suggest 
diagnosis may be a significant mediating factor in the relationship between MMSE score and 
hippocampal volume, however this would need to be formally tested with a regression analysis to 
examine the interaction before drawing conclusions from the results presented here.  
3.4.1.2.1 Correlation between Left versus Right Hippocampal Volume and MMSE score 
There is substantial literature that right - left hippocampal asymmetry exists in healthy controls, 
pathological brains, and subjects with memory complaints (Geroldi et al., 2000; Pedraza, Bowers, & 
Gilmore, 2004; van der Flier et al., 2004). Similar to the current study, Peng and Colleagues found 
smaller left hippocampal volumes compared to right hippocampal volumes in subjects (Peng et al., 
2015). This left right asymmetry was found to increase in conjunction with cognitive decline (Wolf et al., 
2001). Rate of atrophy in the left hippocampus has been shown to correlate with performance on 
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MMSE, and change in MMSE score (Arlt et al., 2013). Lastly, there is evidence that the left hippocampus 
has more diagnostic accuracy than right hippocampal volume in AD (Slavin, Sandstrom, Tran, 
Doraiswamy, & Petrella, 2007). While the findings described in this study suggest there is a hippocampal 
asymmetry, as there was a higher correlation between left hippocampal volume and MMSE score in AD 
patients that was found, this was purely exploratory as no formal interaction was tested. This should 
however be taken into consideration into future, more in-depth studies, looking at mediating factors of 
the relationship between MMSE score and hippocampal volume.  
3.4.2 Limitations 
3.4.2.1 Electronic Health Records  
The majority of the limitations of this study are related to the current state of use of EHRs in research 
and clinical practices. Many times, especially in the mental health fields, patient information is recorded 
in the form of free-text and not structured subfields. In turn, the quality of information recorded is 
heavily based on the clinician inputting it, and therefore recorded data may be incomplete (Perera et al., 
2016). For example, our study had a total of 117 participants that had no diagnosis listed, this figure may 
be comprised of both people who did not receive a diagnosis at this time (but may later go on to receive 
one), people who were discharged before diagnosis, and those who potentially had a diagnosis but it 
was missing from their EHR. Another study found while EHRs lead to greater identification of suitable 
cases for research use, it also produced more missing fields (Newgard, Zive, Jui, Weathers, & Daya, 
2012). This also creates the need for free-text searchers and algorithms to allow researchers to find 
relevant data, which can take a substantial amount of time to develop. While this was not directly an 
issue for the current study because CRIS has such systems in place (Perera et al., 2016; Stewart et al., 
2009) it could make wider EHR research harder to implement. Majority of the limitations of EHR use lies 
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in implementation, because systems sufficient to handle research are not yet in place, however these 
should be considered short term as they would be alleviated with sustained use.  
Another extremely important matter about the use of EHRs in research is the privacy concerns. There is 
the fear of stigmatization against those with mental health issues, making confidentiality one of the 
most important parts of EHR recording (Fernandes et al., 2013). The CRIS system has a complex security 
structure that removes any identifying information for patients, and furthermore only allows 
researchers to access such information within the SLaM firewall (Fernandes et al., 2013; Perera et al., 
2016; Stewart et al., 2009).  There is still concern whether or not anonymization of patient data is 
enough to keep information confidential (Rothstein, 2010). Reidentifcation of participants is possible 
with a combination of multiple databases, however this is predominantly an issue when data is allowed 
to be taken off site. 
3.4.2.2 Hippocampal Volume Normalisation 
Here, we have normalised hippocampal volumes by using a ratio of hippocampal volume divided by total 
intracranial volume. While this procedure has been used extensively, and has been cited as one of the 
most commonly used methods (Goldstein et al., 1999; O’Brien et al., 2011; Seidman et al., 1999), there 
are some concerns that this may not be the best way to normalise brain volumes as head size and 
subcortical volumes may not be related linearly (Barnes et al., 2010; Nordenskjöld et al., 2015; 
Voevodskaya et al., 2014). 
Other approaches include regression and residual approaches (C. R. Jack et al., 1989; O’Brien et al., 
2011; Voevodskaya et al., 2014). The regression approach uses the total ICV as a covariate in the 
regression model, while the residual model uses a linear regression between the volume of interest and 
total ICV to predict the adjusted volume of interest (C. R. Jack et al., 1989; Nordenskjöld et al., 2015). 
There is evidence that while systematic errors in ICV can affect means based on this proportion method, 
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the statistical power associated with group differences remains unchanged (Sanfilipo, Benedict, 
Zivadinov, & Bakshi, 2004). The regression and residual approaches have the flexibility to model a 
quadratic effect of ICV, allowing for non-linear relationships between regions of interest and head size 
(O’Brien et al., 2011). More specifically, the regression approach allows interactions to be modelled as 
well, for example if there was a relationship between total ICV and diagnostic group) (O’Brien et al., 
2011; Sanfilipo et al., 2004). All of the methods listed can create biases under various scenarios, and 
each method can provide different results (Arndt et al., 1991; Barnes et al., 2010; Malone et al., 2015; 
O’Brien et al., 2011), which is important to remember when interpreting the results reported here. 
Additionally, there is some evidence that subcortical volumes do not need to be normalised when 
predicting AD (Zhou et al., 2014). In the future, it would be best to compare the three various correction 
methods to find the most suitable one for the current analysis.  
3.4.2.3 The MMSE 
While the MMSE is the most commonly used cognitive test in the diagnosis of AD and dementia 
(Arevalo-Rodriguez et al., 2015), there are over 20 brief (less than 20 minutes) cognitive tests used for 
people with suspected dementia that have diagnostic validity data. At least five of these have been 
validated for use in both primary care and specialist memory services (Velayudhan et al., 2014).  The 
MMSE has shown to provide modest accuracy, however it is found to be best for ruling out dementia 
when identifying potential MCI in a secondary specialist centre (Mitchell, 2009).  The Addenbrooke’s 
Cognitive Examination III (ACE-III) has been shown to be a valid test for distinguishing dementia 
disorders, such as AD and Fronto-temporal Lobe Dementia (FTLD), and has better diagnostic accuracy 
than the MMSE (Hsieh, Schubert, Hoon, Mioshi, & Hodges, 2013; Larner & Mitchell, 2014). 
The MMSE has several limitations such as a floor-effect in patients with advanced dementia, those with 
little formal education, and non-English speaking groups (Schultz-Larsen, Kreiner, & Lomholt, 2007; 
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Vertesi et al., 2001), and ceiling effects in those with very mild dementia (Simard, 1998). Additionally, 
12% of variance in MMSE scores can be contributed to age and education alone, indicating other tests 
may be more sensitive to cognitive changes due to AD. 
Because of the nature of the memory clinic cohort, many subjects may be assessed whilst only having 
slight memory impairment, and may be subject to the ceiling effects of the MMSE previously 
mentioned. This correlation analysis does not account for this ceiling effect of the MMSE, and this 
should be considered when interpreting the results. In the future, modelling techniques such as specific 
forms of multiple regression may be useful in taking these ceiling effects into consideration (Matthew 
McBee, 2010). 
In our cohort, the MMSE was the only widely used cognitive examination. Even then, only slightly less 
than 60% of memory clinic patients had an MMSE score in their EHR, illustrating the difficulty in finding 
a widely used cognitive test in memory clinics. It would be interesting to work towards the 
standardisation of memory clinic neuropsychological batteries and cognitive examinations, to more 
deeply explore the relationship of brain structure and cognitive functioning in this type of cohort.  
3.4.3 Future Directions 
While this study concentrated on the feasibility between linking clinical EHRs with MRI data, the 
possibilities extend far past that. We were able to take a large clinical sample of over 500 patients, and 
link their analysed MRI scans with the hospital’s repository. Neuroimaging plays a prominent role in the 
diagnosis of AD and dementia, however, it is not sufficient on its own and must be used in conjunction 
with the other core clinical criteria for diagnosis (G. M. McKhann et al., 2011). The current guidelines for 
dementia diagnoses state that biomarkers, including those that are imaging based, are in need of 
further study and validation before they can be used in the core clinical criteria. This study is one of first 
steps in validating such methods in a clinical setting instead of using a research cohort.  
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Our next plan is to extend this study to use more advanced analysis, such as machine learning 
techniques that have demonstrated good classification of AD and MCI individuals versus healthy 
controls using other brain regions of interest and cortical measures, and have potential in predicting 
which MCI patients will go on to develop AD (Aguilar et al., 2013a; Khan et al., 2015; Westman, Cavallin, 
Muehlboeck, et al., 2011b; Westman, Simmons, Zhang, et al., 2011). There are several potential 
confounds that lie with using a research based cohort as they are not generally representative on the 
general older population (Sperling et al., 2011) that may be alleviated by using this clinical sample. If 
such techniques are validated, we can move forward to potentially combine all available health data 
(such as aforementioned CSF measures) and create more comprehensive indices (Spulber et al., 2013; 
Westman et al., 2012) that may aid clinicians. If such biomarkers do become validated, having a linkage 
system in place will allow clinicians to run automated volumetric analyses and link them to other health 
records with ease, ultimately streamlining the entire diagnostic process.  
Another advantage of aggregating health information, for both researchers and clinicians, in one 
centralized location is the ability to obtain more information. Specifically, in AD there is evidence that 
combining CSF measures with volumetric data is more effective and classifying AD and MCI versus 
healthy individuals than either measure on their own (Westman et al., 2012). Because AD is such a 
complex disease, there is much to be learned about less validated biomarkers. EHRs provide the 
opportunity to include genetic markers such as APOE status (Mahley & Rall, 2000), other blood based 
bio-markers that potentially indicate dementia due to AD, or even other neuroimaging data such as PET 
and resting-state fMRI. Most biomarkers have not been validated against one-another, and therefore 
the research on the use of combinations of biomarkers is fairly limited (Albert et al., 2011). For example, 
ADNI is an impressive cohort with over 800 subjects with neuroimaging data (www.adni-info.org) but 
only roughly half of the sample has CSF measurements. EHRs can help bridge this gap and create a 
database with a more complete dataset for individuals.   
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Numerous studies have been made possible due to the new case registrar system in place at SLaM. CRIS 
has provided researchers with a large repository of data that allows for extra information not normally 
obtained through traditional research cohorts. The potential uses of such a linkage go far beyond AD 
and dementia. In recent years, there has been a surge in the use of neuroimaging data in disease 
diagnosis, prognosis and stratification (Arbabshirani, Plis, Sui, & Calhoun, 2016). Other psychiatric and 
neurological disorders such as schizophrenia, depressive disorders, Autism Spectrum Disorder, and 
ADHD may also benefit from congregating neuroimaging data with electronic health records from both 
the perspective of clinician use and research use.  
The possibilities extend far past psychiatric disorders and neuroimaging. Here we have demonstrated 
some of the useful information that can be extracted from structural neuroimaging, but there is also 
potential for use of other types of structural imaging such as lesion load in white matter diseases such as 
multiple sclerosis or stroke, and functional neuroimaging such as function MRI, PET, spectroscopy or 
electroencephalography (EEG). Because clinical imaging does not stop at the brain there is a variety of 
opportunity to link imaging data to further research other disease such as cancers and other injuries. 
This is a proof of principal to integrate any type of imaging with EHRs; further disciplines such as 
oncology, pathology, cardiology, and countless others can benefit from the research potential that this 
study poses. While here we have connected data extracted from patient scans, there may be 
opportunity in the future to link actual scans to allow researchers more flexibility with what specific 
analyses they wish to carry out.  
Furthermore, this implementation of anonymized EHRs provide researchers with a platform to identify 
patients that may be interested in participating in future studies. This has begun to be implemented in 
the CRIS system already (Callard et al., 2014), however may benefit from added information due to the 
new linkages we have employed in this study.  
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3.5 CONCLUSION  
This study demonstrated that connecting electronic health data with clinical neuroimaging data is 
indeed possible, and could benefit both future research endeavours and diagnostic techniques.  
Furthermore, as expected MMSE and hippocampal volume are significantly positively correlated in 











4 OPLS IN A MEMORY CLINIC COHORT 
4.1 INTRODUCTION: MULTIVARIATE ANALYSIS IN DEMENTIA 
Advents in both imaging techniques and image analysis have led to the development of ways to explore 
the large amount of data that can come from a single magnetic resonance imaging (MRI) scan. Because 
of the complexity and heterogeneity of Alzheimer’s Disease (AD) pathology, it is unlikely that a single 
region will give comprehensive information about disease progression. This has prompted researchers 
to examine systematic changes in both structure and function of the brain, and other different 
biomarker modalities such as cerebrospinal fluid (CSF) and blood measures. Because of the large 
amount of information that comes from these examinations, more complex multivariate analyses and 
machine learning techniques have developed to analyse a large amount of data simultaneously, 
exposing inherent patterns in the data. As a result, it is possible to determine patterns that respond to a 
specific group, determine what variables are responsible for the separation, and ultimately make 
predictive models. Most commonly, these algorithms are able to distinguish AD patients from healthy 
control subjects. Furthermore, these techniques have also been used to predict conversion from Mild 
Cognitive Impairment (MCI) to AD, reiterating the importance and potential use for detecting AD at the 
prodromal stage, before any kind of clinical indications.  
4.1.1 Types of Multivariate Analyses in Dementia 
Multivariate analysis techniques provide analysis methods to measure multiple quantitative variables at 
once, giving a more comprehensive outlook. This kind of test can be used to support clinical diagnoses, 
and may provide more detailed information due to its quantitative nature, rather than current visual 
assessments and rating scales (Westman, Cavallin, Muehlboeck, et al., 2011b).  In multivariate analysis 
techniques, one simultaneous test is performed on all variables at once, providing an opportunity to 
88 
 
view intrinsic patterns in the data. This allows for a number of correlations between pairs of MRI 
measures to be considered which is not possible in univariate modelling. Because it is one test, it 
circumvents the need for multiple comparisons correction. Since there are quite a large number of 
biomarkers that are related to dementia and Alzheimer’s disease specifically (medial temporal lobe 
(MTL) volumes and CSF measures such as p-tau, t-tau, and Aβ-42 for example) a multivariate analysis 
technique is more appropriate to ensure all relevant variables are considered (Westman, Simmons, 
Zhang, et al., 2011; Westman et al., 2012). Multivariate analysis can take a large set of data, including 
imaging and the aforementioned measures, and summarise it into one score. This could provide easier 
interpretability for clinicians, and could aid diagnostic processes in the future.  
There are a variety of supervised classifiers used for model prediction containing MRI data. Supervised 
classifiers use previous knowledge about group characteristics to learn from a training set of data. 
Following training, the classifier is then able to label new, previously unseen data. Support vector 
machines (SVM) are the most commonly used classifier algorithm (Falahati, Westman, & Simmons, 
2014), but others such as orthogonal projection to latent structures (OPLS) (Trygg & Wold, 2002), linear 
discrimination analysis (LDA), artificial neural networks (ANN), decision trees (DT) and ensemble or 
regression-based methods.  None of these techniques were developed specifically for neuroimaging 
data, however they all show promising classification results  
After deciding on a classifier method and algorithm, the subset of variables that will be used as input 
data must be chosen. Features can come from a variety of data sources, including both structural and 
functional imaging, and aim to provide the most relevant information on disease patterns. Currently, 
most attention is focused on structural imaging and features can range anywhere from single voxels to 
broader ROIs or structures, to whole brain characteristics. Most commonly, volumetric and thickness 
measurements of both cortical and subcortical regions are used (Simmons et al., 2011; Westman, 
Aguilar, Muehlboeck, & Simmons, 2013). Feature extraction is a crucial part of the method as analysis 
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techniques can directly affect classification performance, therefore segmentation techniques must be 
accurate and robust (Cuingnet et al., 2011). 
Following feature extraction, the most relevant features must be selected for use in the classification 
analysis. With the new advents in neuroimaging, a myriad of information can come from a single image. 
Because of the high dimensionality of the data, computing all the information can be difficult. Large 
amounts of data or features can create over-fitted models, where the classifier is too closely fit for a 
small number of subjects. Additionally, adding irrelevant features in the classification model can 
introduce noise and diminish accuracy. This can be combated by using feature selection, where only the 
most relevant data to the disease are included in the model. In addition to creating a more accurate 
model, feature selection can reduce computational power and time needed, and may make the final 
result less complex and easier to interpret.  
Several methods can be used to evaluate the classifiers. The first method is cross-validation (CV), and 
can be done in several different ways.  Part of the data set is used as a training set and the rest is used as 
an unseen, unclassified dataset to test the algorithm. This process of taking a portion of the data out and 
using the rest as the test set is repeated several times (Westman, Simmons, Zhang, et al., 2011). CV is 
well-suited for small datasets when it is not possible to leave out a large portion of the data exclusively 
for training.  If samples sizes are large enough, a training set can be created using a set of the data and 
CV is used to create the model. Following model creation, the rest of the data is used as a test set.  
Comparing different methods of multivariate analyses can be difficult because there are a large variety 
of variables that may influence accuracy. Aside from methodological factors such as extraction methods, 
feature selection, classification and validation techniques, there can be differences due to cohort 
properties such as demographics, number of subjects, and image quality.  
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4.1.2 OPLS in Dementia Imaging Studies: Research Cohorts  
There has been extensive review of multivariate data analysis and machine learning techniques in AD. 
The techniques mentioned earlier, SVM, OPLS, and LDA, have all been shown to provide accuracy over 
or just below 90% in distinguishing structural MRI of AD patients versus healthy controls (Falahati, 
Westman, & Simmons, 2014). The consensus is that a diagnostic biomarker must achieve a sensitivity of 
at least 80%, and distinguish between both healthy controls and other types of dementia, to be clinically 
useful (“Consensus Report of the Working Group on,” 1998; Hampel, Frank, et al., 2010; Hampel, Lista, 
& Khachaturian, 2012).  
There is some evidence that OPLS performs better than other methods such as ANN and DT, and was 
therefore chosen for this specific study (Aguilar et al., 2013b). OPLS has been used extensively in 
research cohorts, including combining multiple cohorts such as AddNeuroMed and the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) (Westman, Simmons, Muehlboeck, et al., 2011). 
In terms of potential clinical use, OPLS has proven to be better at distinguishing AD patients than visual 
rating scales (VRS) alone (Westman, Cavallin, Muehlboeck, et al., 2011). It is able to distinguish between 
MCI patients that remain stable and those who go on to convert to AD, proving it may have clinical 
utility (Spulber et al., 2013). Disease severity indices have been created through OPLS analyses, and are 
even sensitive to people with subjective memory decline (Daniel Ferreira, Falahati, et al., 2017; Spulber 
et al., 2013). Furthermore, OPLS can use more than structural imaging measures alone. Combining other 
measures such as CSF biomarkers may improve classification and be promising for clinical use 
(Westman, Wahlund, Foy, et al., 2011; Westman et al., 2012). 
4.1.3 Rationale and Hypotheses 
Today, structural MRI is most often standard in routine memory clinic diagnostics. Because of this, in 
combination with the fact that structural MRI multivariate image analysis has proven to provide good 
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sensitivity and specificity in research cohorts, we have extended the application of OPLS to a clinical 
cohort. Research cohorts have very strict inclusion and exclusion criteria, and therefore eliminates the 
natural heterogeneity that is found in the population. To have clinically efficacy, multivariate analysis 
tools must be useful on clinical cohorts, that do not have such rigid criteria and may include patients 
with one or more comorbidities. Additionally, OPLS models are trained on AD and healthy control data, 
and there are few studies looking at multivariate analysis techniques for distinguishing different types of 
dementia, one of the main challenges clinicians face. The goal is to test the applicability to memory 
clinics, and examine the diagnostic value of this tool. While classification is expected to be less accurate 
than shown in research cohorts, the model should show decent classification sensitivity and accuracy in 
classifying AD patients as having an AD-like brain. Because of AD-like pathology in mixed dementia (MD) 
patients, it is expected that they will also be highly classified as AD-like. Those diagnosed with MCI are 
expected to have a fairly mixed classification result, as this may reflect those who go on to develop AD 
versus those who revert back to normal cognition or go on to develop another form of dementia. Other 
dementias, such as Vascular Dementia (VaD), are not expected to have the same classification profiles, 
and may be more classified as control-like.  
4.2 METHODS 
4.2.1 Participants 
4.2.1.1 ADNI / ADDNEUROMED Training Datasets 
Our training dataset included a total of 637 participants, 402 from the ADNI dataset and 235 from the 
AddNeuroMed dataset (Lovestone et al., 2009; Mueller et al., 2005). 
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4.2.1.1.1 Inclusion Criteria 
Both the ADNI and AddNeuroMed cohorts have similar recruitment methods and inclusion criteria (R C. 
Petersen et al., 2010; Simmons et al., 2011). Dementia was diagnosed following the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (American Psychiatric Association, 1994), 
while probable AD was diagnosed according to the National Institute of Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) criteria (G. McKhann et al., 1984), as well as a clinical dementia rating (CDR) score of 0.5 or 
above. MRI imaging was not taken into consideration during diagnosis. To be qualified as a healthy 
control (HCS), participants needed an MMSE score between 24 and 30, a CDR score of 0, and a Geriatric 
Depression Scale (GDS) score of less than 5. Participants, from any of the groups were not permitted to 
have significant neurological or psychiatric illnesses, or any significant unstable systemic illness or organ 
failure. Additionally, no history of alcohol or substance abuse or dependence was required for all three 
groups.  
4.2.1.1.2 Demographics 
The training set included 297 diagnosed AD participants, and 340 healthy controls. There were 337 
females and 300 males, with an age range of 52-90 years (Table 4-2).  
4.2.1.2 Memory Clinic Cohort 
The memory clinic cohort was comprised of patients from the South London and Maudsley NHS trust 
(SLaM), who had been referred to a memory clinic after experiencing memory difficulties. The 
demographic information for the memory clinic cohort and inclusion criteria can be found in Chapter 2: 
The Biomedical Research Centre Memory Clinic Cohort, section 2.2.1. For this study, we used a total of 




4.2.2.1 MRI Acquisition 
4.2.2.1.1 ADNI/AddNeuroMed Training Set 
The AddNeuroMed study was designed specifically to be comparable with ADNI, and therefore have the 
same acquisition parameters (Clifford R. Jack, Bernstein, et al., 2008; Clifford R. Jack et al., 2015; 
Simmons et al., 2011). Both protocols include a high resolution sagittal 3D T1-weighted magnetization-
prepared rapid acquisition with gradient echo (MPRAGE) volume and axial proton density/T2-weighted 
fast spin echo images. MPRAGE images were acquired with 1.1×1.1×1.2 mm3 voxel size. All images 
needed full brain and skull coverage, and were further analysed for full quality control measures as 
described previously (Lovestone et al., 2009; Simmons et al., 2011).  
4.2.2.1.2 Memory Clinic Cohort 
The image acquisition and quality control procedures for the BRCMEM cohort was based on ADNI and 
AddNeuroMed parameters, and is described in detail in Chapter 2: The BRCMEM Cohort, section 2.2.2.  
4.2.2.2 Tissue Segmentation 
The T1 images were analysed with the FREESURFER pipeline version 5.3.0 
(http://surfer.nmr.mgh.harvard.edu/) to produce regional cortical thickness and subcortical volume 
measures. The pipeline includes removal of non-brain tissue using a hybrid watershed/surface 
deformation procedure (F. Ségonne et al., 2004), automated Talairach transformation, segmentation of 
the subcortical white matter and deep grey matter volumetric structures (Bruce Fischl et al., 2002; Bruce 
Fischl, Salat, et al., 2004; F. Ségonne et al., 2004) intensity normalisation (Sled et al., 1998), tessellation 
of the grey matter white matter boundary, automated topology correction (B. Fischl et al., 2001; Florent 
Ségonne et al., 2007), and surface deformation following intensity gradients to optimally place the 
grey/white and grey/cerebrospinal fluid borders at the location where the greatest shift in intensity 
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defines the transition to the other tissue class (A. M. Dale et al., 1999; Anders M. Dale & Sereno, 1993; 
B. Fischl & Dale, 2000). Once the cortical models are complete, registration to a spherical atlas takes 
place which utilises individual cortical folding patterns to match cortical geometry across subjects (B. 
Fischl et al., 1999). This is followed by parcellation of the cerebral cortex into units based on gyral and 
sulcal structure (Desikan et al., 2006; Bruce Fischl, van der Kouwe, et al., 2004). The pipeline generated 
68 cortical thickness (34 from each hemisphere) and 21 regional subcortical volumes (Table 4-1). This 
segmentation approach has been used for multivariate classification of Alzheimer’s disease and healthy 
controls (Westman, Wahlund, Foy, et al., 2011), neuropsychological-image analysis (Yawu Liu et al., 
2011; Yawu Liu, Paajanen, Zhang, et al., 2010), imaging-genetic analysis (Yawu Liu, Paajanen, Westman, 
Wahlund, et al., 2010; Yawu Liu, Paajanen, Westman, Zhang, et al., 2010) and biomarker discovery 































Table 4-1 – List of FREESURFER outputs, including all Cortical Thicknesses and Subcortical structures used in the OPLS analysis 
Cortical Thicknesses (both Right and Left) Subcortical structures 
Banks of superior temporal sulcus 
Caudal anterior cingulate 




Inferior parietal cortex 
Inferior temporal gyrus 
Isthmus of cingulate cortex 
Lateral occipital cortex 
Lateral orbitofrontal cortex 
Lingual gyrus 
Medial orbitofrontal cortex 





Triangular part of inferior frontal gyrus 
Pericalcarine cortex 
Postcentral gyrus 
Posterior cingulate cortex 
Precentral gyrus 
Precuneus cortex 
Rostral anterior cingulate cortex 
Rostral middle frontal gyrus 
Superior frontal gyrus 
Superior parietal gyrus 









Corpus callosum anterior 
Corpus callosum central 
Corpus callosum midanterior 
Corpus callosum midposterior 
Corpus callosum posterior 





Cerebellum white matter 
Hippocampus 





Ventral diencephalon (DC) 
 
4.2.2.2.1 Volume Normalisation  
All subcortical volumes were normalised by dividing by each subject’s intracranial volume (ICV), while 
leaving all cortical thickness measures in their raw form. This method has been used previously in OPLS 
analyses, and provides the best models (Westman et al., 2013).   
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4.2.3 OPLS Analysis 
4.2.3.1 Preprocessing 
To begin, data are preprocessed to centre the mean and scale to unit variance. Mean centring subtracts 
the variable average from the data, repositioning it about the origin. This serves to improve 
interpretability of the data later on.  Because large variance variables are more likely to be prominent in 
the model than low variance variables, unit variance scaling is used to balance the data appropriately. In 
this technique, standard deviation of each variable is calculated, and then the inverse standard deviation 
is used as a scaling weight for each variable (Eriksson et al., 2006; Westman, Cavallin, Muehlboeck, et al., 
2011b; Westman, Simmons, Zhang, et al., 2011; Westman et al., 2012). Finally, prior to OPLS analysis, all 
data was reviewed in a scatter plot of first and second PCA components, with a Hotelling’s T2 elliptical 
range with 95% confidence intervals to ensure data was normally distributed and identify outliers 
(Iwashita, 1997).  
4.2.3.1.1 Age Correction 
There are global and regional brain changes that are thought to be related to healthy ageing in the 
absence of dementia. Because of this confound, these factors may negatively affect model performance 
(Dukart, Schroeter, Mueller, & Alzheimer’s Disease Neuroimaging Initiative, 2011; Falahati et al., 2016). 
OPLS studies have shown excellent classification performance, even without performing age corrections 
(Simmons et al., 2011; Westman, Cavallin, Muehlboeck, et al., 2011b; Westman, Simmons, Muehlboeck, 
et al., 2011; Westman, Simmons, Zhang, et al., 2011; Westman et al., 2013, 2012). More recently, 
Falahati and colleagues demonstrated that age correction can improve both classification and prediction 
performance using a research-based cohort (Falahati et al., 2016). For this study, both age corrected and 
the standard method without age correction were used and then later compared.  
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To carry out the age correction, a linear detrending algorithm based on age-related changes was used. 
This algorithm fits a generalized linear model (GLM) to the MRI variables and age in the control group, 
and models any age-related changes as a linear drift. This linear drift is expressed as the regression 
coefficient of the GLM model, and serves to remove age related changes in all participants, namely 
those in the memory clinic cohort. This model was based on an age-related linear decrease in global 
grey matter volume in healthy individuals (Good et al., 2001). The correction measures the age-related 
changes in the control group, and remove these age-related changes to allow better analysis of only 
disease-related changes in the AD group. In the current study, the linear detrending algorithm was 
based on the healthy controls in the ADNI/AddNeuroMed training set, and then applied to both the AD 
subjects in the training set (to ensure appropriate modelling) and the BRCMEM memory clinic test set.  
4.2.3.2 OPLS 
OPLS is a supervised multivariate data analysis method that has been extensively used locally because of 
its high, cross-validated sensitivity, specificity, and likelihood ratios, indicating a good diagnostic tool 
(Simmons et al., 2011; Westman, Cavallin, Muehlboeck, et al., 2011b; Westman, Simmons, Muehlboeck, 
et al., 2011; Westman, Simmons, Zhang, et al., 2011; Westman et al., 2013, 2012). OPLS tries to 
maximise covariance between dependent and independent variables through the inherent relationship 
between latent variables. OPLS is a method based on partial least squares to latent structures (PLS) and 
orthogonal signal corrections (OSC) (Trygg & Wold, 2002). PLS utilises attributes from and combines 
both principal component analysis and multiple linear regression. This method has been used to analyse 
MR data successfully in the past (Levine et al., 2008; McIntosh & Lobaugh, 2004; Westman et al., 2009). 
PLS models the relationship between two sets of variables by fitting and aligning two models, one for 
independent variables and another for dependent variables simultaneously. Ultimately, the PLS aims to 
model both independent and dependent variables, and predict the dependent variables from the 
independent variables. PLS can mathematically be described as:  
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𝑋 = 1 ∗ 𝑥ᇱഥ + 𝑇 ∗ 𝑃ᇱ + 𝐸 
Equation 4-1 - Description of X variables in PLS model 
 
𝑌 = 1 ∗ 𝑦ᇱഥ + 𝑈 ∗ 𝐶′ + 𝐹 
Equation 4-2 – Description if Y variables in PLS model 
In this equation, 1 ∗ 𝑥ᇱഥ  and 1 ∗ 𝑦ᇱഥ  represent the variable averages (X being independent variables and Y 
being dependent variables) calculated in the preprocessing step of mean centring. 𝑇 and 𝑈 represent 
matrices related to the observations, describing their similarity or dissimilarity depending on the given 
model. Matrices 𝑃ᇱ and 𝐶′, X-loading and Y-loading respectively, contain information about the 
variables. Finally, the 𝐸 and 𝐹 terms describe the residual matrices that contain the noise, or unmodeled 
data (Eriksson et al., 2006). 
OPLS takes the PLS methodology, and combines it with OSC. The purpose of the orthogonal correction 
methods is to remove the variation in the independent variable matrix that is not correlated to the 
dependent variable matrix. This method allows for the separation of the independent variable matrix 
into two blocks based on the data in the 𝑌 or dependent variable matrix: one of structured or correlated 
variation and the other uncorrelated variation that is classified as orthogonal to the dependent variable 
matrix. There are three criteria these orthogonal correction methods poses on the component including: 
1) the component must address large systemic variations in 𝑋 2) the component must be predictive by 
𝑋, to apply to future data and 3) the orthogonal component must be orthogonal to 𝑌. The first two 
criteria are easily computed with by running a PCA of 𝑋, while the third is more difficult but can be 
accomplished using the aforementioned OSC (Trygg & Wold, 2002; Westman et al., 2012).  
OPLS and PLS are very similar, and give the same predictive accuracy. However, OPLS has an advantage 
where the model created to compare groups is rotated, meaning the information related to class 
separation is found in the predictive, or first, component of the model. If there are other orthogonal 
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components, they relate to variation in the data not connected to class separation. This part of the 
process makes data interpretation significantly easier (Westman, Simmons, Zhang, et al., 2011; Wiklund 
et al., 2008). 
The OPLS method can also be described mathematically as: 
 
𝑋 = 𝑇௉𝑃௉் + 𝑇ை𝑃ை் + 𝐸 
Equation 4-3 – Description of X variables in OPLS model 
𝑌 = 𝑇௉𝐶௉் + 𝐹 
Equation 4-4 – Description of Y variables in OPLS model 
 
Here, 𝑇௉𝑃௉் represents the correlated variation (or the Y-predictive block) and 𝑇ை𝑃ை் represents the 
uncorrelated variation (or Y-orthogonal block). 
OPLS analysis results is characterised by a Q2(Y) value that describes the predictability of the model, or 
the significance for separating groups (Eriksson, Byrne, Johansson, Trygg, & Vikström, 2013). Q2(Y) the 
portion of total variation in expected class values that can be predicted by CV. Q2(Y) values > 0.05 are 
regarded as significant (Eriksson et al., 2006). This can be described as: 
𝑄ଶ(𝑌) = 1 − (𝑃𝑅𝐸𝑆𝑆 − 𝑆𝑆𝑌) 







The predicted residual sum of squares (PRESS) can be described as: 
 
𝑃𝑅𝐸𝑆𝑆 =  ෍(𝑌௔௖௧௨௔௟ − 𝑌௣௥௘ௗ௜௖௧௘ௗ)ଶ 
Equation 4-6 – Predicted Residual Sum of Squares 
 
and SSY describes the total variation in the 𝑌 matrix after mean centering and variance scaling (Eriksson 
et al., 2006). 
Q2(Y) is based on CV, and depicts how well the model can predict new data.  CV is a statistical technique 
used to verify predictive models. This involves building a number of parallel models that differ from each 
other by leaving out a specified piece of the data set each time, which is then predicted by the 
respective model. Based on experimenter preference, a number is chosen for cross validation. In the 
instance of Westman et al. 2012, seven-fold cross validation was used, meaning 1/7th of the data was 
removed for each cross validation round, and seven rounds were completed (each portion of data being 
left out only once) (Westman et al., 2012).  
Additionally, there is an R2(Y) parameter that describes the goodness of fit of the model. R2(Y) describes 
the fraction of the variation in the training components that is explained by the various components of 
the model (Eriksson et al., 2013), essentially describing how well the model fits the training set of data.  
In the context of this study, the ADNI and AddNeuroMed data were used to create and train the model 
using 7-fold CV. The memory clinic data was then tested using this model created, and for each new 
subject a prediction value (ypred) was created based on the model. 
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4.2.3.2.1 OPLS Cut-off Values 
The ypred, or AD Atrophy score, for a subject ranges from 0 to 1, whereas 0 is maximum likelihood for 
one group (controls), 1 is the maximum likelihood for the other group (AD), and 0.5 is considered the 
appropriate cut off value for accepting the observation as correctly predicted (Westman, Cavallin, 
Muehlboeck, et al., 2011b; Westman, Simmons, Zhang, et al., 2011; Westman et al., 2012).  
Recent studies have explored using a different cut-off that is more representative of the inherent 
homogeneity of AD (Falahati et al., 2017). This second cut-off was calculated by taking the average AD 
Atrophy score for heathy controls, and adding one standard deviation. The new cut-off of 0.390 (average 
AD Atrophy score of controls = 0.20 + one standard deviation = 0.19) is based off a previous study that 
used deviation from healthy controls to define cognitive impairment. This study found that using one 
standard deviation from healthy controls had the highest predictive power for subsequent development 
of dementia (Busse, Hensel, Guhne, Angermeyer, & Riedel-Heller, 2006). This new cut-off was derived 
from the average uncorrected AD Atrophy scores of the healthy controls from the ADNI/AddNeuroMed 
Training set (Figure 4-1). Using corrected AD Atrophy scores, calculated from the age correction method 
described in section 4.2.3.1.1, revealed the same cut-off of 0.390 (average AD Atrophy score = 0.20 + 




















Figure 4-1 – Histogram of age-uncorrected AD Atrophy score for healthy controls from ADNI/AddNeuroMed training set. 
Average AD Atrophy score = 0.20; Standard Deviation = 0.19 which created a new cut-off of 0.39 
 
 
4.2.3.2.2 Variable Importance in Group Separation 
An additional feature of OPLS analysis is variables can be plotted according to their contribution to 
group separation (Figure 4-2). Variables are ordered according to their importance, and covariance is 
plotted on the y-axis. Jack-knifed confidence intervals are included to estimate bias and standard errors. 
Various sub-models from cross validation results are used to calculate standard error of different 
variables, and n are converted into confidence intervals via the t-distribution (Eriksson et al., 2006). 
Parameters with high covariance are more likely to have a significant impact on group separation than 
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variables with low covariance, and variables whose confidence intervals cross zero can be considered to 
have low reliability (Wiklund et al., 2008). The covariance is plotted along the y axis and can be 
described as: 
 
𝐶𝑜𝑣(𝑡, 𝑋௜) = 𝑡்𝑋௜ ∕ (𝑁 − 1) 
Equation 4-7 – Covariance of given OPLS variable, denoting importance for group separation 
 
The transpose of the score vector t in the OPLS model is represent by 𝑡, 𝑖 is the centered variable in the 
data matrix 𝑋, and 𝑁 is the number of variables (Wiklund et al., 2008). A 𝐶𝑜𝑣(𝑡, 𝑋௜) a below zero in the 
plots represents measures that have lower values in AD subjects compared to CTL subjects, while those 
measures above zero indicate a higher value in AD subjects compared to CTL subjects in the model. 
For this OPLS analysis, all 89 volumes and cortical thickness measures (34 right and 34 left cortical 
thicknesses, and 21 subcortical volumes) from the FREESURFER output were used. To perform this 
analysis, including mean centring and variance scaling described in section 4.2.3.1, SIMCA version 13.0.3 
(Umetrics AB, Umea, Sweden) was used. 
 
4.2.4 Statistical Analysis 
All statistical analyses on the memory clinic were performed with SPSS 21 software package, while 
analyses done on the training data were completed with SPSS 24. Results were considered significant at 
the P < 0.05 level.  
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4.2.4.1 Group Differences  
4.2.4.1.1 ADNI/AddNeuroMed Training Set 
Differences between the groups (healthy controls and AD subjects) were calculated for age, MMSE 
score, and years of education using an analysis of variance (ANOVA). Differences between gender 
distribution between the groups was measured with a Χ2 test. 
4.2.4.1.2 Memory Clinic Cohort 
Out of the 668 participants for our memory clinic, 508 had some form of diagnosis in their clinical health 
records. 135 people had no diagnosis listed, and 25 received no diagnosis (such as person with mental 
health complaints). Because of the wide array of diagnoses, patients were categorised into one of the 
following groups: AD, MCI, MD, VaD, unspecified dementia, other dementia (such as Parkinson’s or 
dementia in Pick’s disease), or other psychiatric disorder (anxiety, depression, PTSD, or others). A one-
way ANOVA was carried out to calculate differences between diagnostic groups for age and MMSE 
score, while a Χ2 test was used to analyse the differences in gender distribution between the groups.  
4.2.4.2 OPLS Model Analysis 
Sensitivity, specificity, accuracy, predictive value, receiver operating characteristic (ROC) curves, and 
likelihood ratios are all statistical tools useful for assessing whether or not a diagnostic test is good. 
These measures were calculated for each the age corrected and uncorrected models from the cross-
validated prediction values of the OPLS models.  
4.2.4.2.1 Sensitivity and Specificity 
Sensitivity is defined as the true positive or recall rate. It measures the proportion of actual positives 
that are correctly identified as such, for example: those with diagnosed with AD being classified as 
having AD via the OPLS models. Specificity is the true negative rate, or the proportion of actual negatives 
that are correctly identified as not having the disease. In this example, specificity would be the number 
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of healthy controls correctly classified as healthy controls (D. G. Altman & Bland, 1994a).  Accuracy, or 
more specifically classification accuracy is the percentage of total number of correct classifications, out 
of all of the classifications. 
4.2.4.2.2 Predictive Values 
The positive predictive value (PPV), often called precision, is the ratio of true positives over all subjects 
that were classified as positive. This is used to indicate the probability that a patient actually has AD if 
they are put in the AD group by the classification technique being measured. Negative predictive value 
(NPV) is the ratio of true negatives over all subjects classified as negative (both true and false negatives). 
Predictive values are not only intrinsic to the test, but also heavily depend on actual disease prevalence 
in the sample (D. G. Altman & Bland, 1994b).   
4.2.4.2.3 Receiver Operating Curves 
ROC curves plot the true positive rate, or sensitivity as a function of the false positive rate (100-
specificity) for various cut off points of a given test. The area under the curve (AUC) is used as an 
indicator of the quality of separation, with a score of .5 being completely random predictions and 1.0 
being perfect separation (Hanley & McNeil, 1983; Metz, 2006).  
4.2.4.2.4 Likelihood Ratios 
Likelihood ratios are used for assessing the value of preforming a diagnostic test or classification, and 
determining whether the result reflects the probability of having a given condition. Positive likelihood 
ratios are equal to the sensitivity / (1 – specificity), and negative likelihood ratios are equal to (1 – 
sensitivity) / specificity. A likelihood ratio of greater than one indicates the test result is associated with 
the disease, while a ratio of less than one is associated with absence of the disease. Tests that have 
likelihood ratios equal to one have little practical significance, the further a likelihood ratio is from one, 
the stronger the evidence for the presence, or absence, of a disease. (Deeks & Altman, 2004). Positive 
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likelihood ratios between five and ten, or negative likelihood ratios between 0.1 and 0.2 are said to give 
a moderate increase in diagnostic values and ratios higher than 10 or lower than 0.1 considerably 
increase the diagnostic value of a test (Qizilbash et al., 2002; Westman et al., 2012). 
4.2.4.3 Correlation between MMSE and AD Atrophy score 
To follow up on the previous chapter’s (Chapter 3: Correlation of MMSE Score and Hippocampal Volume 
in a Memory Clinic Cohort) findings, correlations were calculated between each participant’s AD Atrophy 
score (both age corrected and age uncorrected) and MMSE score using Pearson correlations.  
4.3 RESULTS 
4.3.1 Demographics 
4.3.1.1 ADNI / ADDNEUROMED Training Datasets 
The training set included 297 diagnosed AD participants, and 340 HCS. There were 337 females and 300 
males, with an age range of 52-90 years (mean =75.30 ±6.34; HCS=74.99 ±5.71, AD=75.67 ±6.97). There 
was no difference between age in the two groups. Only 622 participants had MMSE score information, 
which significantly differed between the two groups; (HCS=29.09 ±1.09, AD=22.22 ±3.70; p<.001). Years 
of education was also significantly different between AD and controls (HCS=14.25 ±4.38, AD=12.04 













Table 4-2 - Demographics for the ADNI/AddNeuroMed Training Set. Age, MMSE, and Years of Education = Mean (Standard 
Deviation). Differences between groups were measured by ANOVA, except for gender which was measured with Χ2. * denotes 
significance at p <.001.  
  
Healthy Controls AD P-VALUE 
Number 340 297  
Age 74.99 (±5.71) 75.68 (±6.97) 0.174 
Gender (M/F) 168/172 132/165 0.241 
MMSE 29.09 (±1.09) 22.22 (±3.70) <0.001* 
Years of Education 12.08 (±4.83) 14.25 (±4.38) <0.001* 
 
4.3.1.2 Memory Clinic Cohort 
The memory clinic cohort consisted of 668 patients that had structural T1 scans that passed quality 
control to run volumetric analyses. The average age was 73.40 (±10.55), with 195 males, 288 females, 
and 185 participants missing gender on their EHR. A total of 483 patients out of the 668 had a valid 
MMSE score (average=23.54±4.95) (Table 4-3).  
 
Table 4-3 – Demographics for the Memory Clinic Cohort.  
  Memory Clinic 
Number 668 
Age 73.40 (±10.55) 
Gender (M/F/Missing) 288/195/185 
MMSE 23.54 (±4.95) 
 
A full breakdown of group differences based on diagnoses for the sample can be found in Table 4-4.  As 
expected, there were significant differences in age, MMSE score, and gender distribution across groups. 




Table 4-4 - Diagnosis Breakdown for the Memory Clinic Cohort. Age and MMSE = Mean (Standard Deviation). Differences between groups were measured by ANOVA, except for 
gender which was measured with Χ2. * denotes significance at p <.001. 
  











Number 212 90 63 28 33 10 72 25 135  

















(M/F/Missing) 69/91/52 24/34/32 11/32/20 9/13/6 5/5/0 11/12/10 19/30/23 7/7/11 40/64/31 0.210 



















4.3.2 Training Model Assessment 
4.3.2.1 Age Uncorrected Model  
The OPLS model without using age correction gave a Q2(Y)=0.549 and a R2(Y)=0.598, which is in line with 
other studies and regarded as a good model (Westman et al., 2012). The variables used in the model are 
plotted based on their importance to group separations with their corresponding jack-knifed confidence 
intervals, and are also very similar to previous models (Figure 4-2)(Westman, Simmons, Zhang, et al., 
2011; Westman et al., 2012). The training model’s predictive value was calculated using 7-fold CV in 
SIMCA to determine AD Atrophy scores for each of the training model subjects. Using these values and 
the same 0.5 cut-off, sensitivity, specificity, accuracy, NPV, PPV, likelihood ratios, and AUC were then 
calculated for training model. A graphic representation of classification of each group can be seen in 
Figure 4-3, with the grey dashed line representing the 0.5 cut-off. The training model gave a sensitivity 
and specificity in line with other studies (sens=90.00%; spec=84.40%), and can be seen in Table 4-5 
(Falahati et al., 2014; Westman, Cavallin, Muehlboeck, et al., 2011b; Westman, Simmons, Muehlboeck, 




Figure 4-2 – Structural MRI measures of importance for the separation between AD and healthy controls in the age uncorrected model. Measures with high variance (each end) 
are more likely to have an impact on group separation. Structures with a negative covariance have a lower value in AD subjects, while structures with positive covariance have 








Figure 4-3 – Class separation of the age uncorrected training model using 7-fold CV; grey dashed line 





Table 4-5 – Age Uncorrected Model Description 
Sensitivity  Specificity  Accuracy  LR+ LR - PPV NPV AUC Q2 R2 
90.00% 84.40% 86.70% 5.77 0.12 90.10% 84.40% 0.937 0.549 0.598 
 
4.3.2.2 Age Corrected Model  
The OPLS model using the age correction method described in section 4.2.3.1.1 gave a slightly improved 
of Q2(Y)=0.551 and a R2(Y)=0.576. Again, the variables used in the model are plotted based on their 
importance to group separations with their corresponding jack-knifed confidence intervals. While there 
are slight differences in variable importance, it is still the medial temporal lobe structures that are most 
important (Figure 4-4). The model’s predictive value was again calculated using 7-fold CV in SIMCA to 
determine AD Atrophy scores for each of the training model subjects, and sensitivity, specificity, 
accuracy, NPV, PPV, likelihood ratios, and AUC were then using the same 0.5 cut-off. A graphic 
representation of classification of each group can be seen in Figure 4-5, with the grey dashed line 
representing the 0.5 cut-off. The age corrected training model also gave a slightly improved sensitivity 
and specificity compared to the uncorrected model (sens=91.00%; spec=85.20%), and can be seen in 





Figure 4-4 – Structural MRI measures of importance for the separation between AD and healthy controls in the age corrected model. Measures with high 
variance (each end) are more likely to have an impact on group separation. Structures with a negative covariance have a lower value in AD subjects, while 
structures with positive covariance have higher values in control subjects. Measures are listed with jack-knifed confidence intervals, and those that include zero 







Figure 4-5  – Class separation of the age corrected training model using 7-fold CV; grey dashed line represents 0.5 cut-off. Orange triangles represent AD subjects and Blue 




Table 4-6 – Age Corrected Model Description 
Sensitivity  Specificity  Accuracy  LR+ LR - PPV NPV AUC Q2 R2 
91.00% 85.20% 87.60% 6.15 0.11 90.98% 81.52% 0.945 0.551 0.576 
 
4.3.3 Application of OPLS in a Memory Clinic Cohort 
4.3.3.1 OPLS application with 0.5 cut-off 
Because this model is based on AD and healthy controls, the model can only predict whether a given 
participant (or brain) is classified as more AD-like or more control-like.  
Using the same 0.5 cut-off, we used the AD Atrophy score to determine whether a subject had a more 
control-like (AD Atrophy score < 0.5) or more AD like (AD Atrophy score > 0.5) brain. We did this with 
two AD Atrophy scores for each person, one using the age correction method described earlier, and one 
without (Falahati et al., 2016). For age corrected AD Atrophy score, the average age for participants 
classified as control-like was 71.89 (±11.50) and 74.79 (±9.41) for AD-like. For age uncorrected AD 
Atrophy score, the average control-like participant was 68.92 (±11.31) and 77.50 (±7.83) for AD-like 
participant (Table 4-7). It is clear the age correction removes the atrophy due to normal ageing, and 
therefore brings the average ages of AD-like and control-like participants closer together.  
 
Table 4-7 – Differences in average age between groups using age corrected versus uncorrected ages. 
 
Uncorrected Corrected 
AD-Like 77.50 (±7.83) 74.49 (±9.41) 
Control-Like 68.92 (±11.31) 71.89 (±11.50) 
 
Participants were broken down into AD-like and control-like categories by diagnosis, as previously 
described. The AD diagnostic group had a substantial percentage of patients with AD-like classifications 
for both age corrected (67.0%) and age uncorrected (72.6%) AD Atrophy scores. A complete list 
116 
 
percentages of AD-like versus control-like participants (both age corrected and age uncorrected) for 
each diagnosis are listed in Table 4-8. Graphs of the distribution of AD-like and Control-like participants 
for each diagnosis is depicted in Figure 4-6 for age uncorrected figures, and Figure 4-7 for age corrected 
figures. 
Table 4-8 – Classifications of AD-Like and Control-Like based on Diagnosis using a 0.5 cut-off 
 Uncorrected Corrected  
 AD-Like CTL-Like AD-Like CTL-Like 
Alzheimer’s Disease 72.6% 27.4% 67.0% 33.0% 
Mild Cognitive Impairment 33.3% 66.7% 34.4% 65.6% 
Mixed Dementia 73.0% 27.0% 61.9% 38.1% 
Vascular Dementia 42.9% 57.1% 46.4% 53.6% 
Other Dementia 30.0% 70.0% 30.0% 70.0% 
Unspecified Dementia 60.6% 39.4% 63.6% 36.4% 
Other Psychiatric Condition 41.7% 58.3% 51.4% 48.6% 































4.3.3.2 OPLS application with 0.39 cut-off 
Recent studies have shown that it may be more appropriate to use a 0.39 cut-off instead of a 0.5 cut-off, 
as there is more variation within AD patients than within healthy controls. Much of the variation in 
healthy controls is due to age related atrophy, which should be minimised using the age correction 
method described earlier (Falahati et al., 2017). This cut-off is created based on one standard deviation 
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greater than the average AD Atrophy score for a healthy control, as described in section 4.2.3.2.1.  This 
cut-off did improve classification, with the AD diagnostic category having 76.9% (age corrected) and 
82.1% (age uncorrected) of participants being classified as having an AD-like brain. A complete list 
percentages of AD-like versus control-like participants (both age corrected and age uncorrected) for 
each diagnosis, with this lower cut-off, are listed in Table 4-9. Graphs of the distribution of AD-like and 
Control-like participants for each diagnosis is depicted in Figure 4-8 for age uncorrected figures, and 
Figure 4-9 for age corrected figures. In order to better visualise the changes due to this new 0.39 cut-off, 
Table 4-10 includes the % increase in AD-like classification for each disease category.  
 
Table 4-9 – Classifications of AD-Like and Control-Like based on Diagnosis using a 0.39 cut-off. 
 Uncorrected Corrected  
 AD-Like CTL-Like AD-Like CTL-Like 
Alzheimer’s Disease 82.1% 17.9% 76.9% 23.1% 
Mild Cognitive Impairment 52.2% 47.8% 43.3% 56.7% 
Mixed Dementia 82.5% 17.5% 79.4% 20.6% 
Vascular Dementia 67.9% 32.1% 57.1% 42.9% 
Other Dementia 50.0% 50.0% 40.0% 60.0% 
Unspecified Dementia 69.7% 30.3% 72.7% 27.3% 
Other Psychiatric Condition 47.2% 52.8% 66.7% 33.3% 
















































Table 4-10 – Change in classification percentage using a 0.39 versus a 0.5 cut-off. 
 Uncorrected corrected 
 0.5 0.39 % CHANGE 0.5 0.39 % CHANGE 
 AD-Like AD-Like  AD-Like AD-Like  
Alzheimer’s Disease 72.6% 82.1% 9.5 67.0% 76.9% 9.9 
Mild Cognitive Impairment 33.3% 52.2% 18.9 34.4% 43.3% 8.9 
Mixed Dementia 73.0% 82.5% 9.5 61.9% 79.4% 17.5 
Vascular Dementia 42.9% 67.9% 25.0 46.4% 57.1% 10.7 
Other Dementia 30.0% 50.0% 20.0 30.0% 40.0% 10.0 
Unspecified Dementia 60.6% 69.7% 9.1 63.6% 72.7% 9.1 
Other Psychiatric Condition 41.7% 47.2% 5.5 51.4% 66.7% 15.3 
No Diagnosis 68.0% 80.0% 12.0 72.0% 80.0% 8.0 
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4.3.3.3 MMSE vs Y Predicted value – correlation 
To follow up on the previous chapter’s (Chapter 3: Correlation of MMSE Score and Hippocampal Volume 
in a Memory Clinic Cohort) findings, correlations were calculated between a participants AD Atrophy 
score (both age corrected and age uncorrected) and MMSE score. The correlations and p-values for each 
disease category can be found in Table 4-11, and a scatter-plot depicting the correlation between age 
corrected AD Atrophy scores and MMSE score for the AD patient group can be found in Figure 4-11 
 
 
Table 4-11 – Correlation of MMSE and AD Atrophy score within diagnostic categories. * denotes significance at 
p<.001 level 
 Uncorrected Corrected  
 R
2 p-value R2 p-value 
Alzheimer’s Disease -0.349 <0.001* -0.411 <0.001* 
Mild Cognitive Impairment -0.251 0.580 -0.198 0.136 
Mixed Dementia -0.182 0.243 -0.287 0.062 
Vascular Dementia -0.089 0.693 0.070 0.756 
Other Dementia -0.573 0.083 -0.457 0.185 




















4.4.1 Model Performance 
The model’s sensitivity of 90.0% indicates it performed well at distinguishing AD and healthy control 
brains. Several other studies have used similar models based on the ADNI and AddNeuroMed datasets, 
and found the same or similar results (Spulber et al., 2013; Westman, Cavallin, Muehlboeck, et al., 
2011b; Westman, Simmons, Muehlboeck, et al., 2011; Westman, Wahlund, Foy, et al., 2011; Westman 
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et al., 2013). The classification of memory clinic patients did not perform as well as the training set, but 
this is to be expected due to the heterogeneity of a memory clinic cohort. This may be due to the strict 
inclusion criteria in research cohorts that is not present in the clinic, such as lack of comorbidities or 
specific neuropsychiatric test scores.  
An interesting point is that 80% (at 0.39 cut-off) of patients that ultimately received no diagnosis (such 
as ‘Persons encountering health services for examination and investigation’) were classified as more AD-
like. At first glance, this can be interpreted as a misclassification, however it is important to remember 
there are no healthy controls in this sample. It makes sense that many may be classified as more AD-like 
when they are suffering from subjective memory complaints, and ultimately visiting a memory service. It 
may be that they go on to develop MCI or AD in the future.  
OPLS models based on healthy controls and AD patients are able to predict conversion to AD from MCI 
reasonably well in research cohorts with longitudinal data (Spulber et al., 2013). Conversely, it is 
expected that the classification of MCI patients would be quite mixed (corrected 0.39 cut-off for MCI: 
56.7% Control-like; 43.3% AD-like) because most patients with MCI would not have the pronounced 
atrophy of someone with AD yet. This mixed classification result may be a representation of MCI 
patients who will convert versus those who will not, and it would be very interesting to follow these 
patients and examine their diagnoses at one year follow up. Additionally, this mixed classification could 
be due to the heterogeneity of pathology that underlies MCI. While 60-70% of cases of amnestic MCI 
can be attributed to AD pathology mixed with another type of dementia pathophysiology such as white 
matter changes and cerebrovascular disease, or Lewy body disease (Jicha et al., 2006; Ronald C. 
Petersen et al., 2006).  MCI patients in this cohort did not only included amnestic MCI, but may include 




MD patients were also highly classified as AD-like (corrected 0.39 cut-off: 79.4%). This was expected as 
MD patients are considered to have both neuropathologies of AD and VaD present in one patient. 
Because any vascular changes are not accounted for in classification, they would be classified as AD 
rather than healthy controls.  
Lastly, it is important to remember the gold standard for an AD diagnosis is still histological confirmation 
of neuropathology defined by Braak and Braak (Braak & Braak, 1991; G. McKhann et al., 1984). While 
there is movement away from this as the standard, clinical diagnosis is also not flawless. One study 
found that clinician diagnosis only achieves a sensitivity somewhere between 70.9% and 87.3% (Beach, 
Monsell, Phillips, & Kukull, 2012). Clinician diagnoses consider very many factors, including anecdotal 
evidence from caretakers and family, which can be useful for identifying more subtle changes that may 
not yet have manifested in brain morphometry.  
4.4.2 Age-Correction 
While other studies have found age-correction to improve models, the AD group classification was lower 
when using age-corrected values versus uncorrected values (0.5 cut-off= 67.0% vs 72.6%; 0.39 cut-
off=76.9% vs 82.1% respectively). This is probably due to the heterogeneity of a clinical cohort as 
compared to a research cohort. The previous studies used ADNI and AddNeuroMed, which have strict 
inclusion criteria, such as patients must have an MMSE between 20-26 to be in the AD group.  These 
studies found misclassified participants had significantly higher MMSE scores than those in the AD and 
MCI group that were correctly classified. Because this is a purely clinical cohort, diagnoses are based 
purely on clinician discretion, and it was found that many patients diagnosed with AD had an MMSE 
score above 26. The age-correction in our cohort might be factoring out the existing changes, that may 
be being classified as neuropathological by clinicians, despite the fact that these few have a higher than 
average MMSE for an AD patient.  There are several issues with MMSE, including ceiling effects and the 
126 
 
lack of ability to pick up very subtle changes in highly cognitively able people, such as those with many 
years of education (Mitchell, 2009). Clinicians may be aware of these issues with the MMSE, and have 
better insight on diagnosing patients that may indeed have AD while performing reasonably well on the 
MMSE.   
4.4.3 Cut-off Values 
While previous work has been based on a 0.5 cut-off for AD Atrophy score categorisation, there is some 
recent work that has moved to using a 0.39 cut-off. The argument is while there is intersubject 
variability in normal values, AD is a heterogenous disorder and there is probably greater variation with 
the AD group than within the healthy control group. Therefore, using the 0.5 cut-off may not account for 
the likely much larger variation in AD patients than healthy controls. Previous work has showed how 
heterogenous AD pathology and atrophy can be in AD, and this may be better reflected in the use of a 
lower cut-off (D. Ferreira et al., 2015; Lam, Masellis, Freedman, Stuss, & Black, 2013; Noh et al., 2014; 
Pereira et al., 2014a). Part of the variation in healthy controls is due to normal ageing, which can be 
reduced by applying the age correction technique used in the current study. This lower cut-off based on 
one standard deviation above an average value for healthy controls was shown to increase the 
sensitivity for classifying AD subjects, and it may be beneficial to consider using this instead of the 
previously used 0.5 cut-off in the future (Falahati et al., 2017).  
Generally, more patients are classified as AD-like instead of control-like, and this is true for the other 
diagnostic categories that listed in this analysis as well. Interestingly, for the uncorrected AD Atrophy 
scores the largest percent change in sensitivity due to the revised cut-off value was seen in the VaD and 
Other Dementia categories (25% and 20% respectively). Since only the people who fall into this mid .39 - 
.5 range would change, hence the largest patient groups that have this range most populated are not in 
the AD category. Those in the AD group are likely to be clustered on the higher end of the 0-1 range, 
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with just a few that fall on the lower end and would be influenced by the new cut-off. For age-corrected 
AD Atrophy scores, the largest percent changes were found in MD and other psychiatric conditions 
(17.5% and 15.3% respectively), however there was a substantial increase in the VaD category (10.7%).  
4.4.4 AD Atrophy score and MMSE Correlation 
As expected, AD Atrophy scores and MMSE score were positively correlated in the AD group, but not the 
other groups. This is expected, as cognitive functioning, as measured by MMSE, in AD is closely related 
to brain atrophy (G. Frisoni et al., 2002). Unlike the classification, correlation improved with age-
correction. As previously discussed, this makes sense because of the large number of AD patients with 
higher MMSE scores. Since the age-correction removed atrophy due to natural ageing, the remaining AD 
Atrophy score is more representative of atrophy due to AD, which would be reflected in the MMSE 
score.   
4.4.5 Limitations  
4.4.5.1 Healthy Controls  
Nearly all previous studies of this nature compare AD and MCI patients to healthy controls, while this 
study did not have a healthy control group. Some might consider this a limitation; however it is more 
representative of a clinical setting as clinicians will not have to distinguish between AD and healthy 
controls, but different forms of dementia.  
However, one limitation is the age correction was based on the normal controls from the ADNI / 
AddNeuroMed sample and may not be representative of a population based sample.  
4.4.5.2 Educational Differences 
There was a significant difference between years of education between healthy controls and AD subjects 
in the ADNI/AddNeuroMed training set. While the exact relationship is unclear, years of education can 
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influence hippocampal atrophy in AD (Shpanskaya et al., 2014). Additionally, low education levels have 
been found to be a potential risk factor for dementia (Meng & D’Arcy, 2012). According to a recent 
study, less education (defined as no secondary school) poses a relative risk of 1.59 for developing 
dementia, and has the second highest population attributable factor (the theoretical percent reduction 
in new cases over a given time if the risk factor was eliminated completely (Livingston et al., 2017).  
Because of the obvious importance of education level in dementia development, a significant difference 
between the groups could potentially introduce a bias in the model.  However, previous models 
including years of education as a variable have not been shown to perform differently (Aguilar et al., 
2013).  
4.4.6 Future Directions  
As mentioned earlier, the mixed classification of MCI patients may be representative of which patients 
will go on to develop AD in the future. As previously shown, similar algorithms are  capable of 
distinguishing patients who go on to convert to AD from those who either revert back to normal 
cognition or remain in the MCI diagnostic category (Westman et al., 2012). It would be interesting to 
follow these patients longitudinally, and compare their current classification to any future diagnoses.  
In the future, it would be interesting to train the OPLS algorithm on different types of dementia instead 
of one type versus healthy controls. Creating a model that uses VaD and AD, instead of AD versus 
healthy controls, could create scores based on volumetric data and white matter hyperintensity and 
vascular data. Scores could then predict if someone was more AD or VaD like, or a middle score of 0.5 
could suggest a diagnosis of MD.  
As other studies have found improvement in classification with the addition of other modalities, it may 
also improve classification in a clinical cohort (Westman, Wahlund, Foy, et al., 2011; Westman et al., 
2012). MMSE and other neuropsychiatric tests, blood biomarkers, and potentially CSF measures may be 
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present in EHR and could improve the classification results. Additionally, if future research techniques 
such as segmentation of white matter hyperintensities in vascular dementia become included in EHR, 
these could also be used in the analysis. 
4.5 CONCLUSION  
The multivariate analysis technique, OPLS has now been successfully performed in a memory clinic 
cohort. While the models did not classify AD patients from a memory clinic cohort with as high of an 
accuracy as they did in research cohorts such as ADNI and AddNeuroMed, they still performed 
reasonably well. Especially with the addition of other measures such as CSF or cognitive scores, OPLS 










5 WHITE MATTER HYPERINTENSITIES AND THE UNDERDIAGNOSIS OF MIXED 
DEMENTIA IN MEMORY CLINIC COHORTS.  
5.1 INTRODUCTION 
5.1.1 Mixed Dementia  
While Alzheimer’s Disease (AD) is considered the most common form of dementia, most dementia cases 
have been found to exhibit mixed pathologies, with both AD and vascular components (Gustavo C. 
Román, 2002; Schneider, Arvanitakis, Bang, & Bennett, 2007). Despite this large portion of dementia 
patients that suffer from mixed dementia (MD), compared to AD there is relatively little research on the 
disorder.  
While vascular etiologies cause a large proportion of dementia cases, exact figures can be difficult to 
calculate due to the varied criteria for vascular cognitive impairment (VCI) (De Reuck et al., 2016; 
Rockwood et al., 2000). There is debate over what pathologies to include in the diagnosis of vascular 
dementia (VaD) or MD, and this can include any kind of vascular brain injury such as: large macroscopic, 
lacunar, or microscopic infarcts, haemorrhages, and vessel pathologies such as cerebral amyloid 
angiopathy, and intracranial atherosclerosis.  
Many of these vascular problems occur in the general population. It is estimated that somewhere 
between 16-46% of elderly people have microinfarcts, and this increases to 51% in the oldest old 
(Arvanitakis, Leurgans, Barnes, Bennett, & Schneider, 2011; Corrada, Sonnen, Kim, & Kawas, 2016; Ince 
et al., 2017; Kapasi, DeCarli, & Schneider, 2017; Lenore J. Launer, Hughes, & White, 2011; Schneider, 
Arvanitakis, et al., 2007). Two community based cohorts, the Religious Order Study and the Memory and 
Aging Project, have shown nearly 75% of people with a pathological dementia diagnosis have one or 
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more vascular pathologies in addition to their cognitive impairment (Bennett et al., 2013; Bennett, 
Schneider, Buchman, et al., 2012; Bennett, Schneider, Arvanitakis, & Wilson, 2012; Kapasi et al., 2017).  
Autopsy studies show many patients have both vascular and degenerative causes of dementia, and MD 
may be a more common form of dementia than currently recognised (K. A. Jellinger & Attems, 2007; 
Korczyn, 2002). The literature states MD prevalence varies widely in autopsy studies, from 0-55% (Zekry, 
Hauw, & Gold, 2002).  
5.1.2 Vascular Pathologies and Cognitive Impairment 
There are many questions raised by the literature on MD, such as which kinds of vascular brain injury 
induce cognitive impairment and lower the threshold for AD development, and do specific vascular 
pathologies potentiate AD development and drive the neurodegenerative processes, does AD potentiate 
the vascular changes, or both (Kapasi et al., 2017). 
There are several studies that indicate the presence of multiple macroscopic infarcts has more impact 
on cognitive impairment than the size of a single infarct (Schneider, Boyle, Arvanitakis, Bienias, & 
Bennett, 2007; Troncoso et al., 2008; White, 2009). The overall size, number, and position of 
microinfarcts can also have significant impact on cognitive ability, and are important when determining 
a dementia diagnosis (Arvanitakis et al., 2011; Troncoso et al., 2008).  Various autopsy and positron 
emission tomography (PET) studies indicate that AD pathology and VBI contribute additively to the risk 
of dementia, but through independent processes (Chui & Ramirez-Gomez, 2015). Many individuals 
suffer both types of pathologies, as seen in MD, and this may have an additive effect on cognitive 
impairment (Snowdon et al., 1997).  
5.1.3 Current Diagnostic Standards  
The current diagnostic categories for VaD are based on a severity threshold, which are used for disease 
diagnosis at the later stages, when treatments are not as effective.  There has been discussion of moving 
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towards the use of Vascular Cognitive Impairment (VCI), to identify impairments at an earlier phase 
(Hachinski & Bowler, 1993; O’Brien et al., 2003; Sachdev et al., 2014). While it is clear vascular etiologies 
cause a significant portion of dementia, the exact figures remain unclear because there is varied criteria 
for what constitutes VCI (De Reuck et al., 2016; Rockwood et al., 2000). Unlike AD, the cognitive 
impairment profiles for VCI and VaD are highly variable, and dependent on the size and location of the 
vascular brain injury (VBI) (Sachdev et al., 2014). VaD is not one disease, there are various etiologies, not 
all of which are well characterised, and white matter changes in magnetic resonance imaging (MRI) do 
not always correspond with symptoms (Hunt et al., 1989; Kurt A. Jellinger, 2008). The official diagnostic 
criteria for VaD as stipulated by the Neuroepidemiology Branch of the National Institute of Neurological 
Disorders and Stroke (NINDS) and Association Internationale pour la Recherche et l’Enseignement en 
Neurosciences (AIREN) only requires a patient to experience severe cognitive decline that impedes daily 
functioning and indication of cerebrovascular disease (CVD) by clinical examination or brain imaging (G. 
C. Román et al., 1993).  
VaD diagnoses are normally based on cardiovascular risk factors and interviews, and often may not 
assess underlying pathology (Barkhof, 2011). Non-significant white matter changes may also be 
mistaken for VaD, and lead to overdiagnosis (Niemantsverdriet et al., 2015). This may lead to MD being 
misdiagnosed as VaD, because there is little to no assessment of underlying AD pathology. Additionally, 
misdiagnosis may work in the opposite direction, as once an AD diagnosis is obtained, there may be less 
concentration on the investigation of cardiovascular risk factors or white matter changes. One study 
looking at varying degrees of CVD showed that CVD was often clinically underestimated in people with 
an AD diagnosis (Reed et al., 2004). The reform of these diagnostic standards potentially have great use, 
as there is evidence that reduction of vascular risk factors may lead to a decline in the incidence of 
dementia (Satizabal, Beiser, & Seshadri, 2016). 
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5.1.3.1 Use of Visual Rating Scales for White Matter Changes 
In clinical practice, visual rating scales are often used to determine the severity of white matter changes 
in memory clinic patients. The Fazekas scale (Fazekas et al., 1987) and the Scheltens WMC (white matter 
changes) scale (P. Scheltens et al., 1993) are the most popular (Xiong & Mok, 2011). The Fazekas scale is 
simple and easy for clinicians to use quickly. More complex scales exist such as the Age Related White 
Matter Changes (ARWMC) scale, which can be used to assess WMH in various regions, but these can be 
time consuming and therefore are not always practical for clinical use (L. O. Wahlund et al., 2001). A 
wide array of visual rating scales exist, with varying regional areas of interest (such as deep WHM or 
periventricular WMH), but because the criteria vary they can provide diverse scores for the same patient 
(Mäntylä et al., 1997). Discrepancies between these various scales may cause inconsistencies. Visual 
rating scales are also subject to ceiling effects, and do not provide quantitative evidence as automated 
methods do.  
5.1.4 White Matter Hyperintensities 
White matter hyperintensities (WMH) are the most used indication of vascular changes and VBI on MRI 
(Wardlaw et al., 2013). They can be indicative of cerebral small vessel disease, and may originate from a 
variety of pathologies including ischemic tissue damage caused by arteriosclerosis, vasogenic edema 
induced by periventricular venous collagenosis, or cerebral amyloid angiopathy (Black, Gao, & Bilbao, 
2009; Alida A. Gouw et al., 2011; Haglund & Englund, 2002; Moody, Brown, Challa, & Anderson, 1995; 
O’Sullivan et al., 2008; Pantoni, 2010; E. E. Smith & Eichler, 2006; Viswanathan & Chabriat, 2006; 
Wardlaw et al., 2013). WMH as a biomarker are associated with increased age, cardiovascular risk 
factors, and future development of Mild Cognitive Impairment (MCI) and AD (C. DeCarli et al., 2001; 
Ramirez, McNeely, Scott, Stuss, & Black, 2014; Yoshita et al., 2006). Due to their use in the current 
dementia literature, WHM lesion load was used in this study to examine the effects of VBI on dementia 
diagnosis in a memory clinic cohort.  
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5.1.5 Rationale and Hypotheses 
MD is categorised by neuropathologies typical of AD, such as hippocampal atrophy or a high AD severity 
score derived from the previous orthogonal projection to latent structure (OPLS) multivariate image 
analysis using regional FREESURFER measurements, and VaD, such as WMH. Following this logic, 
patients in our current memory clinic cohort were broken down into four categories based on 
theoretical neuropathologies: normal-like (no abnormal hippocampal atrophy/low AD severity score or 
WMH), AD-like (pronounced hippocampal atrophy/high AD severity score with no WMH), VaD-like (little 
hippocampal atrophy/a normal AD severity score but a large amount of WMH), and MD-like (both 
pronounced hippocampal atrophy/high AD severity score and presence of significant WMH). 
In this study, two different sets of cut-offs were used, one using the Memory Clinic’s median value, and 
one using a one-third cut-off, both described below in section 5.2.3. For each of these cut-offs, two 
different sets of groups were formed. One used average normalised hippocampal volume as a measure 
of AD pathology, while the other uses the AD severity score as measured by OPLS (as described in 
Chapter 4: OPLS in a Memory Clinic Cohort). This resulted in four separate exploratory analyses: 1. Group 
separation determined by WMH load and hippocampal volume using a median score as a cut-off, 2. 
Group separation determined by WMH load and AD severity score using a median score as a cut-off, 3. 
Group separation determined by WMH load and hippocampal volume using a 33rd percentile score as a 
cut-off, and finally 4. Group separation determined by WMH load and AD severity score using a 33rd 
percentile score as a cut-off. All groups were then compared to ultimate diagnosis received in the 
memory clinic. The goal of this study was to investigate the distribution of mixed dementia diagnoses 
depending on severity of AD-like atrophy and VaD pathologies, and investigate the potential under-





The memory clinic cohort was comprised of patients from the South London and Maudsley NHS trust 
(SLaM), who had been referred to a memory clinic after experiencing memory difficulties. The 
demographic information for the memory clinic cohort and inclusion criteria can be found in Chapter 2: 
The Biomedical Research Centre Memory Clinic Cohort. For this study, we used a total of 589 participants 
whose scans passed quality control checks as described in Chapter 2 (section 2.2.2), and diagnostic 
information. Additionally, as in previous chapters, the memory clinic cohort was broken down into 
diagnostic categories. Out of the 589 subjects that were included in this study, 334 had a diagnosis in 
their electronic health record. These 334 subjects had a diagnosis that fit into one of the following 
categories: AD, MCI, MD, VaD, unspecified dementia, other dementia (such as Parkinson’s Dementia or 
Pick’s disease) and other psychiatric condition (such as anxiety or depression). 
5.2.2 Imaging 
5.2.2.1 MRI acquisition 
The image acquisition and quality control procedures for the BRCMEM cohort was based on ADNI and 
AddNeuroMed parameters, and is described in detail in Chapter 2: The Biomedical Research Centre 
Memory Clinic Cohort, section 2.2.2.   
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5.2.2.2 FREESURFER Volumetric Analysis 
The T1 images were analysed with the FREESURFER pipeline version 5.3.0 
(http://surfer.nmr.mgh.harvard.edu/) to produce regional cortical thickness and subcortical volume 
measures. The pipeline includes removal of non-brain tissue using a hybrid watershed/surface 
deformation procedure (F. Ségonne et al., 2004), automated Talairach transformation, segmentation of 
the subcortical white matter and deep grey matter volumetric structures (Bruce Fischl et al., 2002; Bruce 
Fischl, van der Kouwe, et al., 2004; F. Ségonne et al., 2004) intensity normalisation (Sled et al., 1998), 
tessellation of the grey matter white matter boundary, automated topology correction (B. Fischl et al., 
2001; Florent Ségonne et al., 2007), and surface deformation following intensity gradients to optimally 
place the grey/white and grey/cerebrospinal fluid borders at the location where the greatest shift in 
intensity defines the transition to the other tissue class (A. M. Dale et al., 1999; Anders M. Dale & 
Sereno, 1993; B. Fischl & Dale, 2000). Once the cortical models are complete, registration to a spherical 
atlas takes place which utilises individual cortical folding patterns to match cortical geometry across 
subjects (B. Fischl et al., 1999). This is followed by parcellation of the cerebral cortex into units based on 
gyral and sulcal structure (Desikan et al., 2006; Bruce Fischl, van der Kouwe, et al., 2004). The pipeline 
generated 68 cortical thickness (34 from each hemisphere) and 21 regional subcortical volumes (Table 5-
1). This segmentation approach has been used for multivariate classification of Alzheimer’s disease and 
healthy controls (Westman, Wahlund, Foy, et al., 2011), neuropsychological-image analysis (Yawu Liu et 
al., 2011; Yawu Liu, Paajanen, Zhang, et al., 2010), imaging-genetic analysis (Yawu Liu, Paajanen, Zhang, 







Table 5-1 – List of FREESURFER outputs, including all Cortical Thicknesses and Subcortical structures used in the OPLS 
analysis 
Cortical Thicknesses (both Right and Left) Subcortical structures 
Banks of superior temporal sulcus 
Caudal anterior cingulate 




Inferior parietal cortex 
Inferior temporal gyrus 
Isthmus of cingulate cortex 
Lateral occipital cortex 
Lateral orbitofrontal cortex 
Lingual gyrus 
Medial orbitofrontal cortex 





Triangular part of inferior frontal gyrus 
Pericalcarine cortex 
Postcentral gyrus 
Posterior cingulate cortex 
Precentral gyrus 
Precuneus cortex 
Rostral anterior cingulate cortex 
Rostral middle frontal gyrus 
Superior frontal gyrus 
Superior parietal gyrus 









Corpus callosum anterior 
Corpus callosum central 
Corpus callosum midanterior 
Corpus callosum midposterior 






Cerebellum white matter 
Hippocampus 







5.2.2.2.1 Hippocampal Volume Normalisation 
Hippocampal volumes used in the analysis were normalised by total intracranial volume (ICV) as 
determined by FREESURFER segmentation, to control for differences in head size. This was done by 
creating a ratio of hippocampal volume divided by total ICV. This has been found to be essential in 
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structural MRI studies, as differences in head size can create gender differences and influence the 
results (Scahill et al., 2003; J. L. Whitwell et al., 2001). Right and left hippocampal volume was averaged, 
and then divided by ICV to create one volume for each participant.  
5.2.2.3 OPLS analysis  
Following the previous chapter (Chapter 4: OPLS in a Memory Clinic Cohort) uncorrected y predictive 
values (ypred) from the Orthogonal Projection to Latent Structures (OPLS) analysis were also used in this 
study. These ypred values represents a more comprehensive AD atrophy score, indicating whether a 
patient’s brain is more AD-like (a score closer to 1) or more control-like (a score closer to 0). This 
approach is more thorough than using hippocampal volumes alone, as all cortical thickness and 
subcortical volumes (Table 5-1) from the FREESURFER output are used to create the score. For complete 
OPLS methodology, see the Imaging and OPLS analysis sections of the previous chapter (Section 4.2.2 
and 4.2.3 respectively). 
5.2.2.4 WMH Analysis 
Lesions were segmented by the lesion prediction algorithm as implemented in the LST toolbox version 
2.0.15 (www.statistical-modelling.de/lst.html) for SPM 12. This algorithm consists of a binary classifier in 
the form of a logistic regression model trained on the data of 53 MS patients with severe lesion 
patterns. Data were obtained at the Department of Neurology, Technische Universität München, 
Munich, Germany. As covariates for this model a similar lesion belief map as for the lesion growth 
algorithm (Schmidt et al., 2012) was used as well as a spatial covariate that takes into account voxel 
specific changes in lesion probability. Parameters of this model fit are used to segment lesions in new 
images by providing an estimate for the lesion probability for each voxel (Schmidt & Wink, 2017). For 
the analysis, FLAIR images were used from each subject, and a T1 MPRAGE was used as a reference 
image. The LST toolbox was chosen as it is a validated, freely available WMH segmentation analysis tool, 
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which has been used to analyse WMH in prodromal AD patients previously (Svärd et al., 2017). Because 
the software was originally intended for, and trained on MS patients, all WHM segmentations were 
visually inspected for quality.  
5.2.3 Memory Clinic Group Divisions 
The memory clinic cohort was broken down into groups based on markers of AD pathology and VaD 
pathology using either hippocampal volume or AD atrophy score, and WMH lesion load. When creating 
cut-off values for group analyses, the entire memory clinic (n=589), including those without a final 
diagnosis listed, was used.  
Using the cut-offs described in the subsequent subsections (5.2.3.1 and 5.2.3.2) participants were given 
a score of ‘low’ or ‘high’. This use of cut-off values based on percentiles in the cohort of interest has 
been used previously when analysing WHM in dementia (Eckerström et al., 2011; Tuladhar et al., 2015). 
5.2.3.1 Cut-off 1 for discriminating ‘low’ and ‘high’ groups: Median Values 
The first set of groups was created using the median for each measure within the entire memory clinic 
group (n=589) (Table 5-2). If the participant had a normalised hippocampal volume, AD atrophy score, or 
WMH lesion load greater than the median they were classified as ‘high’ and if the value was lower than 
the median they were classified as ‘low’. Using these measures, four groups were created: Normal-like, 
AD-like, MD-like, and VaD-like (Table 5-3 and Table 5-4).    




Normalised Hippocampal Volume 0.00207 
White Matter Hyperintensity Load 6.99 







Table 5-3 – Group Division based on Hippocampal Volume and White Matter Hyperintensity Lesion Load. High is classified as 
greater than the Memory Clinic Cohort’s median value (0.00207 for hippocampal volume and 6.99 mL for WMH load), whereas 
Low is classified as less than the median value.  
 
Hippocampal Volume White Matter Hyperintensity Load 
Normal-like High Low 
AD-like Low Low 
MD- like Low High 
VaD-like  High High 
 
Table 5-4 - Group Division based on AD atrophy score and White Matter Hyperintensity Lesion Load (0.507 for AD Atrophy score 
and 6.99 mL for WMH load). High is classified as greater the Memory Clinic Cohort’s median value, whereas Low is classified as 
less than the median value. 
 
AD Atrophy score White Matter Hyperintensity Load 
Normal-like Low Low 
AD-like High Low 
MD- like High High 
VaD-like  Low High 
 
5.2.3.2 Cut-off 2 for discriminating ‘low’ and ‘high’ groups: 33rd Percentiles 
The second set of groups was created based on values that represented 33% percentiles for each 
variable (Table 5-5). The problem with using median values is that such a cut-off is not completely 
representative of disease pathologies in these conditions. For instance, while hippocampal volume is 
significantly smaller for individuals with AD compared to healthy controls, it is also significantly smaller 
in patients with VaD when compared to healthy controls, albeit higher than those with AD (Kim et al., 
2015). Conversely, AD patients are on average found to have a larger amount of WHM compared to 
healthy controls (Barber et al., 1999; Benedictus et al., 2014; Maillard et al., 2012). Using a 33rd 
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percentile cut-off takes these findings into account, and prioritises discrimination between VaD and AD, 
rather than a form of dementia versus healthy controls.  
Table 5-5 – 33% and 66% percentile value for each variable of interest, further used as cut-off values for group separation. 
Strike-through values indicated these numbers were not used in the cut-offs. WMH load measured in mL. 
 
33% 66% 
Normalised Hippocampal Volume 0.00186 0.00226 
White Matter Hyperintensity Load 3.22 11.62 
AD Atrophy score 0.340 0.659 
 
AD Atrophy scores or WMH lesion loads higher than the 66th percentile value, or a normalised 
hippocampal volume measure greater than the 33rd percentile value were classified as ‘high’. 
Conversely, if they were below these values they were considered ‘low’. Using these measures, four 
groups were created again: Normal-like, AD-like, MD-like, and VaD-like (Table 5-6 and Table 5-7).  
Table 5-6 – Group Division based on Hippocampal Volume and White Matter Hyperintensity Lesion Load. High and Low is 
classified using the cut-offs above (0.00186 for hippocampal volume and 11.62 mL for WMH load). 
 
Hippocampal Volume White Matter Hyperintensity Load 
Normal-like High Low 
AD-like Low Low 
MD- like Low High 
VaD-like  High High 
 
Table 5-7 – Group Division based on AD Atrophy score and White Matter Hyperintensity Lesion Load. High and Low is classified 
using the cut-offs above (0.659 for AD atrophy score and 11.62 mL for WMH load). 
 
AD Atrophy score White Matter Hyperintensity Load 
Normal-like Low Low 
AD-like High Low 
MD- like High High 




5.2.4 Statistical Analysis 
5.2.4.1 Demographics and Imaging Analyses  
Average age, MMSE score, WMH load, normalised hippocampal volume and AD Atrophy score were 
calculated for each diagnostic category. To test for differences between diagnostic groups a one-way 
analysis of variance (ANOVA) was run with Bonferroni post-hoc tests. 
Furthermore, average age, MMSE score, WMH load, hippocampal volume and AD Atrophy score were 
calculated for each group created. 
5.2.4.2 Cut-off 1 for discriminating ‘low’ and ‘high’ groups: Median Values 
Average age, MMSE score, WMH load, normalised hippocampal volume and AD Atrophy score were also 
calculated for each group created with the median value cut-offs (Normal-like, AD-like, MD-like, and 
VaD-like). Two sets of groups were created, one using hippocampal volume and WMH load, and the 
other using AD Atrophy score and WMH load.  
Each group was then broken down by ultimate diagnosis in the memory clinic. Only participants that had 
a diagnosis listed in their electronic health record (including ‘no diagnosis’, such as ‘Persons 
encountering health services for examination and investigation’) were included in this portion of the 
analysis (N=334).  
5.2.4.3 Cut-off 2 for discriminating ‘low’ and ‘high’ groups: 33rd Percentiles 
Average age, MMSE score, WMH load, normalised hippocampal volume and AD Atrophy score were also 
calculated for each group created with the 33rd percentile cut-offs (Normal-like, AD-like, MD-like, and 
VaD-like). Two sets of groups were created, one using hippocampal volume and WMH load, and the 
other using AD Atrophy score and WMH load.  
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Each group was then broken down by ultimate diagnosis in the memory clinic. Only participants that had 
a diagnosis listed in their electronic health record (including ‘no diagnosis’, such as ‘Persons 
encountering health services for examination and investigation’) were included in this portion of the 
analysis (N=334). 
5.3 RESULTS 
5.3.1 Demographics and Imaging Analyses 
Average age, MMSE score, WMH load, normalised hippocampal volume and AD Atrophy score were 
calculated for each diagnostic category (Table 5-8). To test for differences between diagnostic groups a 
one-way ANOVA was run with Bonferroni post-hoc tests. Because of the large number of contrasts, this 













Table 5-8 – Number of participants (N) and average age, MMSE, WMH load (measured in mL), normalised hippocampal volume, 
and AD Atrophy score for each diagnostic category. Age, MMSE, WMH Load, normalised hippocampal volume, and AD Atrophy 
score all = Mean (Standard Deviation). * Denotes equal group differences at p < 0.001 significance, Bonferroni post-hoc tests can 
be found in appendix 3. ** Average hippocampal values based on participants who had MMSE score available (N=428). 
 









(3.57) 9.73 (12.99) 0.00218 (0.000476) 
0.401 
(0.382) 
No Diagnosis 13 73.54 (8.02) 
26.46 
























































(5.00) 9.70 (10.55) 0.00226 (0.000413) 
0.353 
(0.372) 
Total 589 73.63 (9.97) 
23.59 




5.3.2 Cut-off 1 for discriminating ‘low’ and ‘high’ groups: Median Values 
Furthermore, average age, MMSE score, WMH load, normalised hippocampal volume and AD Atrophy 
score were calculated for each cut off group created. Two separate sets of groups were created using 
this cut-off, one using hippocampal volume and WMH load and one using AD Atrophy score and WMH 
load.  
5.3.2.1 Hippocampal Volume and WMH load 
Average age, MMSE score, WMH load, normalised hippocampal volume and AD Atrophy score are listed 
for the groups based on hippocampal volume and WHM load below (Table 5-9). All measures 
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significantly differed between the groups, and complete ANOVA results with Bonferroni post-hoc test 
can be found in appendix 4. 
Table 5-9 – Each group created with Median value cut-offs (using hippocampal volume and WMH load): number of participants 
(N) and average age, MMSE, WMH load (measured in mL), normalised hippocampal volume, and AD Atrophy score for each 
diagnostic category. Age, MMSE, WMH Load, normalised hippocampal volume, and AD Atrophy score all = Mean (Standard 
Deviation). * Denotes equal group differences at p < 0.001 significance, Bonferroni post-hoc tests can be found in appendix 4. ** 
Average based on participants who had MMSE score available (N=428).  
 








(1.94) 0.00252 (0.000299) 
0.184 
(0.301) 




(1.97) 0.00178 (0.000222) 
0.699 
(0.295) 
MD-like 195 79.20 (6.38) 
21.99 
(5.15) 19.72 (12.97) 0.00172 (0.000229) 
0.737 
(0.275) 
VaD-like 99 77.38 (7.40) 
23.86 




Using these cut-offs, groups were then broken down by their ultimate memory clinic diagnosis (Table 5-
10) (Figure 5-1). Only those that had a diagnosis (including no diagnosis, such as ‘Persons encountering 
health services for examination and investigation’) in their electronic health record was included in this 
analysis (N=334). Out of the 334 participants with a diagnosis 90 participants were classified as normal-
like, 61 were classified as AD-like, 124 were classified as MD-like, and 59 were classified as VaD-like 






Table 5-10 – Groups (based on hippocampal volume and white matter hyperintensity load) broken down by Memory Clinic diagnosis, only including those patients with a final 




















Count 3 31 18 4 4 6 4 20 90 
% within group 3.3% 34.4% 20.0% 4.4% 4.4% 6.7% 4.4% 22.2% 100.0% 
% within Diagnosis 
Category 23.1% 21.5% 35.3% 10.5% 23.5% 28.6% 50.0% 47.6% 26.9% 
AD-like 
Count 5 34 7 4 1 5 0 5 61 
% within group 8.2% 55.7% 11.5% 6.6% 1.6% 8.2% 0.0% 8.2% 100.0% 
% within Diagnosis 
Category 38.5% 23.6% 13.7% 10.5% 5.9% 23.8% 0.0% 11.9% 18.3% 
MD-like 
Count 5 65 11 20 5 7 1 10 124 
% within group 4.0% 52.4% 8.9% 16.1% 4.0% 5.6% 0.8% 8.1% 100.0% 
% within Diagnosis 
Category 38.5% 45.1% 21.6% 52.6% 29.4% 33.3% 12.5% 23.8% 37.1% 
VaD-
like 
Count 0 14 15 10 7 3 3 7 59 
% within group 0.0% 23.7% 25.4% 16.9% 11.9% 5.1% 5.1% 11.9% 100% 
% within Diagnosis 
Category 0.0% 9.7% 29.4% 26.3% 41.2% 14.3% 37.5% 16.7% 17.7% 
Total 
Count 13 144 51 38 17 21 8 42 334 
% within group 3.9% 43.1% 15.3% 11.4% 5.1% 6.3% 2.4% 12.6% 100% 
% within Diagnosis 




 Figure 5-1 – Number of patients in each diagnostic category. Median values (based on hippocampal volume and white matter 
hyperintensity load) used as cut-offs. 
 
Within the 61 subjects that were classified as AD-like, 34 (55.7%) received a diagnosis of AD from the 
memory clinic. For the 124 subjects that were classified as MD-like, only 20 (16.1%) received a diagnosis 
of MD, while 65 (52.4%) received a diagnosis of AD. The VaD group was the smallest, with only 59 
subjects. Of these 59 subjects, only 7 (11.9%) were given a diagnosis of VaD, while 14 (23.7%) received a 
diagnosis of AD and 10 (16.9%) received a diagnosis of MD.  
When looking at subjects based on diagnosis, only 34 of the 144 (23.6%) subjects that received a 
diagnosis of AD were categorised as having an AD-like brain. The largest portion of patients who 
received a diagnosis of AD were categorised as MD-like (45.1%). 
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5.3.2.2 AD Atrophy score and WMH load 
Average age, MMSE score, WMH load, hippocampal volume and AD Atrophy score are listed for the 
group based on AD Atrophy score and WHM load below (Table 5-11). All measures significantly differed 
between the groups, and complete ANOVA results with Bonferroni post-hoc test can be found in 
appendix 5. 
Table 5-11 – Each group created with Median value cut-offs (using AD Atrophy score and WMH load): number of participants 
(N) and average age, MMSE, WMH load (measured in mL), normalised hippocampal volume, and AD Atrophy score for each 
diagnostic category. Age, MMSE, WMH Load, normalised hippocampal volume, and AD Atrophy score all = Mean (Standard 
Deviation). * Denotes equal group differences at p < 0.001 significance, Bonferroni post-hoc tests can be found in appendix 5. ** 
Average based on participants who had MMSE score available (N=428). 
 








(1.63) 0.00264 (0.000311) 
-0.030 
(0.166) 




(1.93) 0.00205 (0.000361) 
0.592 
(0.272) 
MD-like 266 79.06 (6.59) 
22.07 
(5.23) 19.71 (13.20) 0.00187 (0.000322) 
0.6825 
(0.260) 
VaD-like 28 74.11 (7.06) 
26.92 




Groups were once again broken down by diagnostic category (Table 5-12) (Figure 5-2). Only those that 
had a diagnosis (including no diagnosis, such as ‘Persons encountering health services for examination 
and investigation’) in their electronic health record was included in this analysis (N=334). Using AD 
Atrophy score instead of normalised hippocampal volume significantly changed distribution of subjects 
across groups. With these variables, only 37 subjects were classified as normal-like, 114 were classified 






Table 5-12 - Groups (based on AD Atrophy score and white matter hyperintensity load) broken down by Memory Clinic diagnosis. Median values used as cut-offs. 




















Count 2 11 6 1 2 2 1 12 37 
% within group 5.4% 29.7% 16.2% 2.7% 5.4% 5.4% 2.7% 32.4% 100% 
% within Diagnosis 
Category 15.4% 7.6% 11.8% 2.6% 11.8% 9.5% 12.5% 28.6% 11.1% 
AD-like 
Count 6 54 19 7 3 9 3 13 114 
% within group 5.3% 47.4% 16.7% 6.1% 2.6% 7.9% 2.6% 11.4% 100% 
% within Diagnosis 
Category 46.2% 37.5% 37.3% 18.4% 17.6% 42.9% 37.5% 31.0% 34.1% 
MD-like 
Count 5 76 18 29 11 9 3 14 165 
% within group 3.0% 46.1% 10.9% 17.6% 6.7% 5.5% 1.8% 8.5% 100% 
% within Diagnosis 
Category 38.5% 52.8% 35.3% 76.3% 64.7% 42.9% 37.5% 33.3% 49.4% 
VaD-
like 
Count 0 3 8 1 1 1 1 3 18 
% within group 0.0% 16.7% 44.4% 5.6% 5.6% 5.6% 5.6% 16.7% 100% 
% within Diagnosis 
Category 0.0% 2.1% 15.7% 2.6% 5.9% 4.8% 12.5% 7.1% 5.4% 
Total 
Count 13 144 51 38 17 21 8 42 334 
% within group 3.9% 43.1% 15.3% 11.4% 5.1% 6.3% 2.4% 12.6% 100% 
% within Diagnosis 




Figure 5-2 – Number of patients in each diagnostic category. Median values (based on AD Atrophy score and white matter 
hyperintensity load) used as cut-offs.  
 
 
For those categorised as AD-like, 54 (47.4%) went on to receive a diagnosis of AD, and 19 (16.7%) 
received a diagnosis of MCI. Those categorised as MD-like were mostly diagnosed with AD (46.1%), with 
only 17.6% receiving a diagnosis of MD. Those categorised as VaD-like were most likely to receive a 
diagnosis of MCI (44.4%).  
52.8% of patients who received a final diagnosis of AD were categorised as MD-like, while 37.5% were 
classified as AD-like. Out of the 17 people who were ultimately diagnosed with VaD, 11 (64.7%) were 
classified as MD-like and only one was classified as VaD-like.  
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5.3.3 Cut-off 2 for discriminating ‘low’ and ‘high’ groups: 33rd Percentiles  
Averages were calculated for each cut off group created. Two separate sets of groups were created 
using this cut-off, one using hippocampal volume and WMH load and one using AD Atrophy score and 
WMH load. 
5.3.3.1 Hippocampal Volume and WMH load 
Average age, MMSE score, WMH load, hippocampal volume and AD Atrophy score are listed for the 
groups based on hippocampal volume and WHM load below (Table 5-13). All measures significantly 
differed between the groups, and complete ANOVA results with Bonferroni post-hoc test can be found 
in appendix 6. 
Table 5-13 – Each group created with 33rd percentile cut-offs (using hippocampal volume and WMH load): number of 
participants (N) and average age, MMSE, WMH load (measured in mL), normalised hippocampal volume, and AD Atrophy score 
for each diagnostic category. Age, MMSE, WMH Load, normalised hippocampal volume, and AD Atrophy score all = Mean 
(Standard Deviation). * Denotes equal group differences at p < 0.001 significance, Bonferroni post-hoc tests can be found in 
appendix 6. ** Average based on participants who had MMSE score available (N=428). 
 








(3.32) 0.00238 (0.000334) 
0.292 
(0.335) 




(3.11) 0.00165 (0.000183) 
0.787 
(0.276) 
MD-like 99 79.49 (6.64) 
21.60 
(5.28) 25.22 (13.47) 0.00160 (0.000189) 
0.813 
(0.264) 








Groups were once again broken down by diagnostic category (Table 5-14) (Figure 5-3). Only those that 
had a diagnosis in their electronic health record (including no diagnosis, such as ‘Persons encountering 
health services for examination and investigation’) was included in this analysis (N=334). These more 
stringent cut-offs created a significantly larger control-like group (154). 58 subjects were classified as 





























Count 5 58 31 14 6 8 6 26 154 
% within group  3.2% 37.7% 20.1% 9.1% 3.9% 5.2% 3.9% 16.9% 100% 
% within Diagnosis 
Category 38.5% 40.3% 60.8% 36.8% 35.3% 38.1% 75.0% 61.9% 46.1% 
AD-like 
Count 3 36 6 5 0 5 0 3 58 
% within group  5.2% 62.1% 10.3% 8.6% 0.0% 8.6% 0.0% 5.2% 100% 
% within Diagnosis 
Category 23.1% 25.0% 11.8% 13.2% 0.0% 23.8% 0.0% 7.1% 17.4% 
MD-like 
Count 5 34 3 12 2 3 1 4 64 
% within group  7.8% 53.1% 4.7% 18.8% 3.1% 4.7% 1.6% 6.3% 100% 
% within Diagnosis 
Category 38.5% 23.6% 5.9% 31.6% 11.8% 14.3% 12.5% 9.5% 19.2% 
VaD-
like 
Count 0 16 11 7 9 5 1 9 58 
% within group  0.0% 27.6% 19.0% 12.1% 15.5% 8.6% 1.7% 15.5% 100% 
% within Diagnosis 
Category 0.0% 11.1% 21.6% 18.4% 52.9% 23.8% 12.5% 21.4% 17.4% 
Total 
Count 13 144 51 38 17 21 8 42 334 
% within group  3.9% 43.1% 15.3% 11.4% 5.1% 6.3% 2.4% 12.6% 100% 
% within Diagnosis 





Figure 5-3 – Number of patients in each diagnostic category. 33rd percentile values (based on hippocampal volume and white 
matter hyperintensity load) used as cut-offs. 
 
The normal-like category saw the greatest increase in diagnostic categories, with 58 (37.7%) being 
diagnosed with AD, 31 (20.1%) being diagnosed with MCI, 11 (9.1%) being diagnosed with MD, and 6 
(3.9%) being diagnosed with VaD.  
A large portion of MD-like subjects received a diagnosis of AD (53.1%), while only 12 (18.8%) received a 
diagnosis of MD. Additionally, 27.6% of VaD-like subjects received a diagnosis of AD. Out of the 58 VaD-
like subjects, 11 (19%) received a diagnosis of MCI, 12 (18.8%) received a diagnosis of MD, and 9 (15.5%) 
received a diagnosis of VaD.  
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5.3.3.2 AD Atrophy score and WMH load 
Average age, MMSE score, WMH load, hippocampal volume and AD Atrophy score are listed for the 
group based on AD Atrophy score and WHM load below (Table 5-15). All measures significantly differed 
between the groups, and complete ANOVA results with Bonferroni post-hoc test can be found in 
appendix 7. 
Table 5-15 - Each group created with 33rd percentile cut-offs (using AD Atrophy score and WMH load): number of participants 
(N) and average age, MMSE, WMH load (measured in mL), normalised hippocampal volume, and AD Atrophy score for each 
diagnostic category. Age, MMSE, WMH Load, normalised hippocampal volume, and AD Atrophy score all = Mean (Standard 
Deviation). * Denotes equal group differences at p < 0.001 significance, Bonferroni post-hoc tests can be found in appendix 6. ** 
Average based on participants who had MMSE score available (N=428). 
 








(3.32) 0.00236 (0.000388) 
0.229 
(0.271) 




(3.08) 0.00179 (0.000267) 
0.884 
(0.177) 
MD-like 85 79.44 (6.54) 
19.81 
(5.68) 24.14 (12.50) 0.00168 (0.000282) 
0.909 
(0.193) 
VaD-like 111 78.61 (6.59) 
23.57 




Groups were once again broken down by diagnostic category (Table 5-16) (Figure 5-4). Only those that 
had a diagnosis (including no diagnosis, such as ‘Persons encountering health services for examination 
and investigation’) in their electronic health record was included in this analysis (N=334). Once again, 
using the 33rd percentile cut-offs created a larger normal-like group than the median cut-offs. A total of 
135 subjects were classified as normal-like, while 77 were classified as AD-like, 50 were classified as MD-



























Count 5 45 34 9 5 7 5 25 135 
% within groups  3.7% 33.3% 25.2% 6.7% 3.7% 5.2% 3.7% 18.5% 100% 
% within Diagnosis 
Category 38.5% 31.3% 66.7% 23.7% 29.4% 33.3% 62.5% 59.5% 40.4% 
AD-like 
Count 3 49 3 10 1 6 1 4 77 
% within groups  3.9% 63.6% 3.9% 13.0% 1.3% 7.8% 1.3% 5.2% 100% 
% within Diagnosis 
Category 23.1% 34.0% 5.9% 26.3% 5.9% 28.6% 12.5% 9.5% 23.1% 
MD-
like 
Count 2 31 2 9 1 1 0 4 50 
% within groups  4.0% 62.0% 4.0% 18.0% 2.0% 2.0% 0.0% 8.0% 100% 
% within Diagnosis 
Category 15.4% 21.5% 3.9% 23.7% 5.9% 4.8% 0.0% 9.5% 15.0% 
VaD-
like 
Count 3 19 12 10 10 7 2 9 72 
% within groups  4.2% 26.4% 16.7% 13.9% 13.9% 9.7% 2.8% 12.5% 100% 
% within Diagnosis 
Category 23.1% 13.2% 23.5% 26.3% 58.8% 33.3% 25.0% 21.4% 21.6% 
Total 
Count 13 144 51 38 17 21 8 42 334 
% within groups  3.9% 43.1% 15.3% 11.4% 5.1% 6.3% 2.4% 12.6% 100% 
% within Diagnosis 




Figure 5-4 – Number of patients in each diagnostic category. 33rd percentile values (based on AD Atrophy score and white 




 The majority of subjects who were classified as normal-like were diagnosed with AD (33.3%) or MCI 
(25.2%). 
Most subjects who were classified as AD-like were further diagnosed with AD (63.6%), with a small 
portion being diagnosed with MD (13%). While this cut-off and variable combination produced the least 
number of subjects classified as MD, out of the 50 subjects that were classified as such 31 (62%) were 
diagnosed with AD. VaD patients were mostly diagnosed with AD (26.4%) or MCI (16.7%), while MD and 
VaD had the same percentage of subjects (13.9%) 
157 
 
The subjects who received a diagnosis of MD were evenly split across the four group types (AD and VaD-
like 26.3%; Normal and MD like 23.7%). 
5.4 DISCUSSION 
Patients of the memory clinic cohort were all classified into one of four categories based on measures of 
AD (hippocampal atrophy or AD Atrophy score) and VaD pathology (WMH). These categories are only 
theoretical. There is more crossover between the disorders than accounted for with only four 
categories, as all patients fall somewhere on a continuum. Additionally, the use of strict cut-offs does 
not take into account the heterogeneity of disorders, and the fact that there is a continuum. Both time 
(early versus late stage of the disease) and severity of a given pathology influences where a patient will 
fall on the disease continuum. This was only the first step in investigating the use of cut-offs for these 
variables of interest, and gave some insight into the potential underdiagnosis of MD in a memory clinic 
cohort.  
Those who had hippocampal little atrophy or an AD Atrophy score closer to 0 (what is considered 
control-like) and little WMH as measured by automated methods were categorised as normal-like. 
Those who had high hippocampal atrophy or an AD Atrophy score closer to 1 (what is considered AD-
like) and little WMH were categorised as AD-like. Patients that had little hippocampal atrophy or an AD 
Atrophy score closer to normal, with a large amount of WMH were categorised as VaD-like. Finally, 
those who had severe hippocampal atrophy or an AD Atrophy score indicative of AD, and a large amount 
of WMH were categorised as MD-like.  
The difference in group distribution over the various cut-offs can be seen in figure 5-5.  
158 
 
Figure 5-5 – Number of patients in each group category (Normal-like, AD-like, MD-like, and VaD-like), based on the various cut-
off values and variables of interest used.  
 
5.4.1 Imaging Results for Diagnostic Categories  
As expected, those with a final diagnosis of AD or MD had the lowest hippocampal volumes across the 
diagnostic categories (0.00191 and 0.00190 respectively) (Table 5-8). Additionally, they had the highest 
AD atrophy scores (0.683 and 0.684 respectively). AD and MD are expected have similar scores, as both 
disorders exhibit the quintessential neuropathologies of AD. Furthermore, those with a final diagnosis of 
VaD had the largest amount of WMH (27.46 mL), followed by those with a final diagnosis of MD (17.05 
mL). AD had a greater amount of WHM (11.13 mL) than MCI and other psychiatric disorder, further 
supporting that AD experiences more WMH than those without a form of dementia (Barber et al., 1999).  
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Interestingly, AD did not have more WMH than those with no diagnosis. However, it is important to 
remember that even though these patients did not have a final diagnosis, they are still not to be 
considered healthy controls. The no diagnosis group did have a much higher MMSE score, indicating 
their cognitive decline may be related to a disorder other than dementia.  
5.4.2 Cut-off 1 for discriminating ‘low’ and ‘high’ groups: Median Values 
The first group cut-off used in this study was based on the median value of each variable of interest for 
the memory clinic cohort (Table 5-2). While this may seem arbitrary, there are several studies that have 
used this approach when grouping subjects in a similar matter, such as high and low white matter load 
groups (Eckerström et al., 2011; Mortamais et al., 2014; Tuladhar et al., 2015). In this memory clinic 
cohort,  the median value was quite close to what previous studies have found to be the average WMH 
load in healthy, age-matched adults plus one standard deviation (Benedictus et al., 2014; Gattringer et 
al., 2012; Maillard et al., 2012). This method of using mean plus one standard deviation has also been 
used in other studies looking at WMH burden in a dementia population (E. E. Smith et al., 2008). 
Additionally, the median normalised hippocampal volume is also close to the mean value, minus one 
standard deviation seen in the healthy control subset of the ADNI cohort used in the training set of the 
OPLS analysis in Chapter 4: OPLS analysis in a Memory Clinic Cohort (for full analysis, see appendix 8). 
Average normalised hippocampal volumes of healthy older adults can be challenging to find in the 
literature, as a result of the abundance of normalisation methods. Lastly, the AD Atrophy score median 
is very close to the 0.5 cut-off traditionally used in OPLS studies (Westman, Cavallin, Muehlboeck, et al., 
2011a; Westman, Simmons, Muehlboeck, et al., 2011; Westman, Simmons, Zhang, et al., 2011; 
Westman et al., 2013). 
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5.4.2.1 Using Hippocampal Volume as a Measure of AD pathology  
As expected, a large portion of subjects classified as AD-like using hippocampal volume and WMH were 
ultimately diagnosed with AD (55.7%). Interestingly, 52.4% of subjects classified as MD-like also received 
a diagnosis of AD and only 16.1% of these subjects received a diagnosis of MD.  
When looking at subjects classified as VaD-like, 23.7% had a diagnosis of AD, 25.4% had a diagnosis of 
MCI, and 16.9% received a diagnosis of MD. Only 11.9% of subjects categorised as VaD-like actually went 
on to receive a diagnosis of VaD. It has been suggested that the absence of MRI exams could lead to the 
overdiagnosis of AD, and the underdiagnosis of VaD (Caixeta, Soares, & Soares, 2009). While everyone in 
this cohort received MRI examination, there may be other factors at play and may reflect a different bias 
to over-diagnose AD.  
5.4.2.2 Using an AD Atrophy score as a Measure of AD pathology  
Using AD Atrophy score, there were more subjects classified as AD-like overall compared to the use of 
hippocampal volume (114 vs 61 respectively), however the increase in AD-like patients was not only 
seen in those with an AD diagnosis, but in all diagnostic categories. 47.4% of those categorised as AD-
like received a diagnosis of AD.  
Of those who did receive a diagnosis of AD, 37.5% were categorised as AD-like, which is a larger 
percentage than using hippocampal volume as a measure of AD pathology (23.6%). 52.8% of those with 
an AD diagnosis were classified as MD-like.  
Additionally, out of those diagnosed with VaD, 64.7% were classified as MD-like. Using an AD Atrophy 
score score with the median value cut-off, 49.4% of subjects were classified as MD-like. This suggests a 
median cut-off may not be effective at distinguishing AD and VaD, and is instead grouping these patients 
as MD-like.  
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5.4.3 Cut-off 2 for discriminating ‘low’ and ‘high’ groups: 33rd percentiles  
While means plus one standard deviation may be a good cut-off for distinguishing healthy controls from 
patients, it does not take into account the variability within disorders. AD patients seem to have 
significantly more WHM than healthy controls, and studies have seen this WMH volume to be on 
average somewhere between 7 and 10 mL (Benedictus et al., 2014; Maillard et al., 2012). Using the 
previous median cut-off of 6.99, AD patients may be wrongly classified as MD-like. Similarly, VaD 
patients have hippocampi that are significantly larger than those of AD patients, but significantly smaller 
than healthy controls (Kim et al., 2015). To take into account these differences from healthy controls, 
the memory clinic was divided into three (33rd percentiles). We then only used the lowest third (33rd 
percentile) for HC volume, and the very highest third (66th percentile) for WHM load and AD Atrophy 
score (Table 5-5).  
These new cut-offs may be more representative of the actual underlying pathologies. A cut-off of 11.62 
mL for WMH instead of 6.99 will now take into account those AD patients with higher WHM load. The 
lowest third for hippocampal volume will now factor in those VaD patients that have smaller 
hippocampi. This is likely the reason that the MD-like group had the largest number in both 
(hippocampal volume and AD Atrophy score) median cut-offs.  
The 33rd percentile cut-off redistributed roughly half of the patients previously classified as MD-like, and 
there was a more equal distribution of AD-like and VaD-like subjects compared to using median values 
as a cut-off. This indicates the new cut-off may be better at distinguishing AD and VaD. It does not 
classify AD subjects as MD-like because there more WMH than normal that is actually due to AD, and 
does not classify VaD subjects as MD-like because of a slightly smaller than normal hippocampal volume 
due to VaD.  
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Conversely, these stricter cut-offs may not take into consideration the variation within the disorders, 
and that there is a continuum of symptom severity. Using the 33rd percentile cut-offs nearly doubled the 
number of subjects classified as normal-like.  As this is a memory clinic, with no truly healthy controls, it 
does not make sense that the largest classification group would be normal-like. The previous chapter 
(Chapter 4: OPLS in a Memory Clinic Cohort) discussed the most reliable cut-off for AD Atrophy score to 
distinguish between healthy controls and AD patients (section 4.3.3.1, section 4.3.3.2, and section 4.4.3). 
It was discussed that because the heterogeneity of AD pathology, a lower cut-off of 0.39 would better 
reflect this (D. Ferreira et al., 2015; Lam et al., 2013; Noh et al., 2014; Pereira et al., 2014b). When 
looking at AD Atrophy score alone, a cut-off of 0.34-0.39 may be better for distinguishing between AD 
and healthy controls, but 0.6-0.7 may be better for distinguishing between AD and VaD patients.  
5.4.3.1 Using Hippocampal Volume as a Measure of AD pathology  
In those with a final diagnosis AD, roughly the same number of patients were categorised as AD-like and 
MD-like (25% and 23.6% respectively), and a large portion were categorised as normal-like (40.3%). 
Despite the significantly stricter cut-off, 53.1% of patients categorised as MD-like were diagnosed with 
AD and only 18.8% were given a final diagnosis MD, suggesting there may be an underdiagnosis of MD.  
5.4.3.2 Using AD Atrophy score as a Measure of AD pathology  
Using AD Atrophy score score with 33rd percentile is the only cut-off group that created less MD-like 
than AD and VaD-like. Even then, out of those with categorised ad MD-like 62% were diagnosed with AD 
and only 18% were diagnosed with MD, further suggesting the underdiagnosis of MD. In those with VaD-
like brains, 26.4% were diagnosed as AD, and 13.9% diagnosed as VaD (and another 13.9% diagnosed as 
MD), which may point to a fundamental overdiagnosis in AD across the memory clinic.  
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5.4.4 Hippocampal Volume versus AD atrophy score as a Measure of AD Pathology  
For both cut-offs, AD Atrophy score categorised less subjects as normal-like than hippocampal volume 
did. This may be because of the more comprehensive nature of the OPLS analysis, where many 
subcortical structures and cortical thicknesses are taken into account when creating a score. 
Furthermore, AD is a heterogenous disorder, and some experience hippocampal-sparing forms of the 
disease (Daniel Ferreira, Verhagen, et al., 2017). Additionally, AD Atrophy score was heavily influenced 
by which cut-off was used, whereas using hippocampal volume created groups with similar numbers of 
AD-like and VaD-like patients, regardless of which cut-off was used.  
5.4.5 Underdiagnosis of MD 
Regardless of cut-off and variables used, there was a trend of patients classified as MD-like mostly 
receiving a diagnosis of AD. Because this was also the case even using the 33rd percentile with AD 
Atrophy score, which classified a much smaller portion of patients as MD-like (only 15%), there may be a 
fundamental underdiagnosis of MD or overdiagnosis of AD. It may also be the case that there may be a 
need for volumetric measures of WMH in addition to the current unstructured and structured 
radiological reporting, as it could eliminate ceiling effects seen in the use of visual rating scales (Mäntylä 
et al., 1997; Xiong & Mok, 2011). 
There is strong evidence that WHM correlates with cognition in AD (Bilello et al., 2015; Oppedal et al., 
2012) and in the healthy old (Fiford et al., 2017; Valdés Hernández et al., 2013). In MCI patients, 
hippocampal atrophy is correlated with white matter lesion load (Eckerström et al., 2011; Fiford et al., 
2017). Others have found this relationship between WMH and grey matter atrophy are only present 
when looking at total brain cortical grey matter, suggesting VaD and AD pathologies effect cortical 
atrophy differently (Du et al., 2005). Taken together, the need to consider white matter changes in all 
forms of dementia is clear.  
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There is evidence suggesting the treatment of vascular risk factors can influence the rate of decline in 
AD (Valenti, Pantoni, & Markus, 2014). In the underdiagnosis of MD and overdiagnosis of AD there is a 
lack of addressing the vascular changes, and this may influence patient care.   
Additionally, hippocampal atrophy but not white matter changes, predict cognitive changes in response 
of cholinesterase inhibitors (Cheng et al., 2015). MD presents with similar cholinergic deficiencies as AD, 
and these patients also seem to benefit from cholinesterase inhibitors (Perry, Ziabreva, Perry, Aarsland, 
& Ballard, 2005). While in the current study no underdiagnosis of MD due to an overdiagnosis of VaD 
was seen, it is important to note it is possible and could result in patients not receiving appropriate 
treatments.  
5.4.6 Limitations 
There are several limitations to this approach. As previously discussed, the median cut-off does not 
distinguish between AD and VaD well, whereas the stricter 33rd percentile cut-off creates an inaccurately 
large normal-like group. It may be that higher cut-offs are useful for defining strictly AD or strictly VaD, 
but the heterogeneity of the disorders results in lower cut-offs being more useful in defining disorders 
such as MCI or MD. It is plausible that while MD patients may not exhibit the same extent of 
neuropathological damage, they may be as severely cognitively impaired as those with AD or VaD 
because of the additive effects the individual pathologies have been seen to have on cognition 
(Snowdon et al., 1997). 
There are various subtypes of AD and not all of them include hippocampal atrophy (Daniel Ferreira, 
Verhagen, et al., 2017). Because not all AD subtypes follow the typical pattern atrophy that can be 
measured with hippocampal volume or a AD Atrophy score that is based on the common medial 
temporal lobe focused AD, it may not be applicable to the entire population. 
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Additionally, as mentioned previously, these strict cut-offs do not consider the heterogeneity of 
disorders, and that patients lie somewhere on a continuum. Position on this continuum is undoubtedly 
influenced by both time (an early versus later stage of the disease) and severity of a given pathology 
influences where a patient will fall on the disease continuum. 
5.4.6.1 Clinical Data 
These assessments are purely based on imaging data, and do not take clinical information into account. 
It may be advantageous to take into consideration cardio vascular risk factors, as they can significantly 
contribute to the further development of various subtypes of VaD and potentially even AD (O’Brien & 
Thomas, 2015b).  
Additionally, while MMSE was available and analysed when looking at group differences, it was not 
taken into account when categorising subjects. Neuropathologies of AD and VaD both influence 
cognitive ability, but they do so independently and may have an additive effect (Snowdon et al., 1997). 
Regardless of cut-off used, the MD-like group always had the lowest MMSE score compared to the other 
groups, which may be reflecting this additive effect. It may be useful to take MMSE score into 
consideration when grouping individuals, as it makes sense those with MD would have the lowest 
scores.  
5.4.6.2 White Matter Lesions  
As previously mentioned, VaD and VCI are extremely heterogenous, with a variety of causes (Hunt et al., 
1989; Kurt A. Jellinger, 2008; O’Brien & Thomas, 2015b). Previous studies have found that different 
types of WM lesions correlate differently with cognition. Subcortical lesions seem to have a significant 
effect on cognition, while periventricular lesions do not (Stenset et al., 2008). Type of WMH was not 
taken into account in this analysis, and which may account for different diagnoses.  
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Additionally, as previously stated the LST toolbox was not designed for use in dementia patients. While 
it has been used previously to quantify WMH in patients with cognitive impairment, results may differ if 
the LST toolbox algorithm was trained on white matter lesions more specific to VaD and this must be 
taken into consideration when interpreting the results (Svärd et al., 2017). 
5.4.6.3 Changes in Hippocampal Volume not due to Dementia  
While hippocampal atrophy is a well-known marker of dementia and AD, these are not the sole causes. 
Studies have found volume differences can be dependent on Apolipoprotein E (APOE) in healthy 
controls and AD patients (Manning et al., 2014). Other psychiatric conditions, such as depression, are 
also related to hippocampal atrophy in older adults (Taylor et al., 2014). Genotypic data and 
comorbidities were not taken into account for this analysis, but may have influenced categorisation of 
subjects.  
5.4.7 Future Directions  
5.4.7.1 Cut-offs for MCI  
Because the 33rd percentile was better suited for distinguishing between AD and VaD, but created too 
many normal-like controls, it would be interesting to create another set of cut-offs for MCI like 
individuals. This added category may give more insight to distribution of those experiencing symptoms, 
but do not yet have the pathology indicative of either AD, VaD, or MD.  
5.4.7.2 Using Age-corrected AD Atrophy score values 
There are global and regional brain changes that are thought to be related to healthy ageing in the 
absence of dementia that may negatively affect model performance in OPLS (section 4.2.3.2.1) (Dukart 
et al., 2011; Falahati et al., 2016). In the previous chapter, both age-corrected and age uncorrected 
models were created with the OPLS analysis (section 4.2.3). It may be better to use AD Atrophy score 
than hippocampal volume when creating such cut-offs, as the AD Atrophy score provides a more 
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comprehensive score of AD pathology in a patient. However, it would be interesting to regroup the 
subjects based on the age-corrected AD Atrophy score scores to see if that changes diagnostic category 
distribution.  
5.4.7.3 OPLS  
It would be possible to train the OPLS algorithm described in Chapter 4: OPLS in a Memory Clinic Cohort 
on different types of dementia instead of one type versus healthy controls. Creating a model that uses 
VaD and AD, instead of AD versus healthy controls, could create scores based on volumetric data and 
white matter hyperintensity and vascular data. Scores could then predict if someone was more AD or 
VaD like, or a middle score of 0.5 could suggest a diagnosis of MD.  
5.5 CONCLUSION  
Using imaging data, groups were created to identify the distribution of AD, VaD and MD pathology in 
memory clinic patients. Two different cut-off points were used, as well as two different variables to 
describe AD pathology. These cut-offs and grouping methods may be useful in a clinical setting with 
further research, however they are not robust enough currently. There is also substantial evidence 
supporting the hypothesis that MD is underdiagnosed in the clinic, and this is a problem that needs to 





6 BRAINMEASURE: AUTOMATED MORPHOMETRY FOR DEMENTIA 
DIAGNOSIS 
6.1 INTRODUCTION 
6.1.1 Current Clinical Diagnosis  
Dementia is a growing problem. In the United Kingdom alone, roughly 850,00 people have some form of 
dementia, and this number is expected to grow to well over one million by the year 2025 (Alzheimer’s 
Society, 2015). It is estimated that dementia costs the UK £26.3 billion a year, with that figure only 
expected to rise with the increase in cases (Alzheimer’s Society, 2015). 
Alarmingly, as of April of 2017 only 69.5% of people with dementia had a diagnosis (“Diagnoses in the 
UK,” 2015). There is also a lack of specific diagnoses, such as Alzheimer’s Disease (AD) or Vascular 
Dementia (VaD), which may contribute to the high cost of the disease as money is spent on follow-ups 
and repeat tests as the original diagnosis is unclear. For those who do receive a diagnosis, it is 
universally recognised that an earlier diagnosis is important both for patient experience and care, and 
from a public health perspective (G. M. McKhann et al., 2011; Samsi & Manthorpe, 2014; van Vliet et al., 
2013). With the steady increase of diagnoses per year, there is also an increased burden on both 
primary care and memory clinics. Between 2008 and 2014 number of memory service users rose by 
682% (Hodge & Hailey, 2015). This can be seen in increased time from referral to assessment (5.2 weeks 
in 2013 to 5.4 weeks in 2014) and increased time from assessment to diagnosis (8.4 weeks in 2013  to 
8.6 weeks in 2014) (Hodge & Hailey, 2015). There are additional factors that may play into the time to 
diagnosis, such as early onset dementia taking significantly longer to diagnose than late onset dementia 
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(van Vliet et al., 2013). Earlier diagnoses should be achievable given AD’s long prodromal stage  
(Figure 6-1).   
 
Figure 6-1 – Timeline of AD progression and diagnosis points on the disease continuum. From the Alzheimer’s Disease 
International World Alzheimer Report 2011: The benefits of early diagnosis and intervention (M. Price, Bryce, & Ferri, 2011). 
 
6.1.1.1 Current use of Magnetic Resonance Imaging in Dementia Diagnoses  
While current diagnostic criteria for AD focuses on clinical symptoms and evaluation, the National 
Institute for Health and Care Excellence (NICE) guidelines still recommend magnetic resonance imaging 
(MRI) scans, or computerised topography (CT) to rule out other brain disorders, unless the patient is 
presenting with moderate or severe dementia and the diagnosis is already clear (G. M. McKhann et al., 
2011; National Collaborating Centre for Mental Health., 2007). It has been acknowledged that structural 
MRI can be invaluable to dementia and AD diagnoses, and its role in the diagnostic process is growing 
(Albert et al., 2011; G. M. McKhann et al., 2011; Sperling et al., 2011). However, many of the radiology 




Currently memory clinics use MRI imaging in a variety of ways, from ruling out other disorders to visual 
rating scales (VRS) or more refined volumetric measurement methods. It is currently unclear exactly 
how many memory clinic patients receive any kind of brain scans, with some clinics referring nearly all 
patients and others referring only 40% (Burns, Wilkinson, & Peachey, 2014).  
6.1.2 Study Rationale 
It has been well established that there are a variety of benefits from timelier diagnoses of dementia, or 
one that is earlier than the current late stage diagnoses most often made. There is potentially great 
added value from earlier treatments and interventions. A timelier or earlier diagnosis, compared to one 
where symptoms are the moderate to severe stage, can allow patients and their families to better 
process the information about the disease, make any beneficial lifestyle changes, and more adequately 
plan for the future (Dubois, Padovani, Scheltens, Rossi, & Dell’Agnello, 2016). It may improve the overall 
quality of life for both the patient and the caregiver (Boise, Morgan, Kaye, & Camicioli, 1999; de Vugt & 
Verhey, 2013). Additionally, a timelier diagnosis may improve patient access to various support services 
and pathways of care, essentially making the disease more manageable (Dubois, Padovani, et al., 2016).  
There have also been several studies considering the cost benefits associated with earlier diagnostic 
evaluation, with the assumption early interventions can hypothetically slow disease progression or delay 
institutionalisation. While these are still models based on assumptions, they show the potentially 
extraordinary cost benefits of an earlier diagnosis (Getsios, Blume, Ishak, Maclaine, & Hernández, 2012; 
Weimer & Sager, 2009).  
While there a myriad of benefits to a timely diagnosis of AD, there are also a few potential challenges.  
There are potentially several ethical issues, including questions about competency before severe 
symptoms and potential discrimination and stigmatisation of patients (Lliffe & Manthorpe, 2004; 
Mattsson, Brax, & Zetterberg, 2010; Milne, 2010). Another major concern of earlier diagnoses is the 
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potential for a higher rate of misdiagnoses, that are either delayed, wrong, or completely diagnosis 
altogether. Misdiagnosis in general medical care create the potential for greater expense, and even 
patient harm (Gandhi et al., 2006; Graber, Franklin, & Gordon, 2005; Schiff et al., 2005; Singh, Naik, Rao, 
& Petersen, 2008). For AD and dementia more specifically, this could lead to a lost opportunity for 
treatment and both increased patient and carer burden (Bradford, Kunik, Schulz, Williams, & Singh, 
2009). This is a problem that could also result in inappropriate treatments, including taking dementia 
medication when it is not needed or not getting correct therapy for something that is treatable (Gaugler 
et al., 2013). 
Currently, clinical diagnoses have a sensitivity somewhere between 70.9% and 87.3% (Beach et al., 
2012). There is clearly room for improvement, and it has been suggested that imaging biomarkers may 
be the way forward with more validation (G. M. McKhann et al., 2011). It has been well documented 
that volume changes in various areas of the brain are predictive of clinical changes in AD and dementia. 
While brain atrophy is normal in healthy ageing, it is significantly accelerated in dementia. A variety of 
studies have documented this, and one meta-analysis has found 2.2-fold higher volume loss in the 
hippocampus (HC), and a 1.8-fold higher volume loss in the whole brain in MCI patients, demonstrating 
just how marked the volumetry differences can be (Tabatabaei-Jafari, Shaw, & Cherbuin, 2015). There 
are a multitude of volume methods used in research based cohorts that show volumetry measures can 
aid in diagnosis and perhaps even predict conversion from MCI to AD (Cui et al., 2011; Cuingnet et al., 
2011; Yawu Liu, Paajanen, Zhang, et al., 2010). While multivariate image analyses are better suited to 
this task, it seems that HC volumes can still do a reasonable prediction job on its own (Schmitter et al., 
2015; Westman, Simmons, Zhang, et al., 2011). Not only does HC volume have predictive value in clinical 
status, but it is also closely linked to progression of clinical symptoms such as memory (Stoub, Rogalski, 
Leurgans, Bennett, & deToledo-Morrell, 2010). Hippocampal volume is a well-known and well-validated 
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risk factor for progression from MCI to AD, making it very logical to include in the diagnostic process (Li 
et al., 2016).  
For many memory clinics that do use some sort of brain imaging in their diagnostic process, a radiology 
report is created from either visual inspection alone or with the aid of a VRS. VRS have demonstrated 
great value in clinics, but there is substantial evidence that volumetric analysis may be better than VRS. 
These scales can suffer interrater variability, which is normally eliminated by automated methods (G. B. 
Frisoni, Fox, Jack, Scheltens, & Thompson, 2010; Ph Scheltens et al., 1992). When comparing MCI 
patients to healthy controls, HC volume alone is better than a medial temporal lobe VRS (Varon et al., 
2015). Both manual HC segmentation and multivariate analysis using automatic segmentation showed 
better accuracy than validated VRS tools (Westman, Cavallin, Muehlboeck, et al., 2011a). 
There is substantial evidence for the use of MRI imaging, namely HC volume, in the diagnosis of AD (G. 
M. McKhann et al., 2011). However, nearly all of these studies use research based cohorts, and there are 
actually very few studies looking into the use of automated morphometry in a clinical setting. The 
general consensus is in order to be used as a diagnostic biomarker, a tool needs a sensitivity of at least 
80% in both distinguishing AD from healthy controls and distinguishing AD from other dementias 
(“Consensus Report of the Working Group on,” 1998; Hampel, Frank, et al., 2010; Hampel et al., 2012; 
Suppa et al., 2015). One of the few studies that did look at automated HC volume analysis in clinical 
populations found reasonable sensitivities, indicating there is potential for use as a clinical biomarker 
(Suppa et al., 2015). 
6.1.3 Clinical Trial Objectives 
This clinical trial aimed to evaluate the efficiency and usefulness of an automated brain morphometry 
tool, called ASSESSA®, as a clinical diagnostic aid for AD in a memory clinic setting. While this study 
assessed implementing automated brain morphometry in a clinical diagnostic routine, this was a pilot 
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project that aimed to gather initial information rather than a fully powered efficacy-type trial. The 
primary focus was to gain insight on the impact of this new technology on clinical practice. We aimed to 
ascertain if this technology was acceptable to clinicians in the memory services, in addition to the 
current traditional neuroradiology reports. The primary hypothesis was the additional automated 
morphometry report would give clinicians more confidence in their diagnosis, however we also aimed to 
see if a more specific diagnosis (such as AD versus unspecified dementia) was achieved. 
6.2 METHODS 
6.2.1 Ethics 
Ethical approval of this study was granted by the National Health Service (NHS) Health Research 
Authority, London – City & East ethics committee (14/LO/0668).  Copy of approval, and approval 
amendments, can be found in appendix 9.  
6.2.2 Power Calculations for Sample Sizes 
For the primary endpoint of change in diagnostic confidence a sample size of 80 (40 per arm) will be 
sufficient to achieve over 90% power to detect a clinically significant difference between groups 
(increase in confidence of at least 10% for the group with the morphometry report relative to the usual 
diagnosis control group, SD=15%) using a two-sided Student's independent t-test with equal group size 
and alpha = 0.05. 
The estimates for effect size are derived from Grundman et al (Grundman et al., 2013). The diagnostic 
confidence in that study was increased by 21.6% (SD = 15.2) by adding a florbetapir scan to usual 
protocol. These calculations assume a more conservative, but still clinically significant estimate of 10% 
mean increase in diagnostic confidence, resulting in a sample size of 37 patients per arm for the desired 
power, or 74 patients in total for 90% power.  
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6.2.3 Participants  
Similar to The BRCMEM Cohort, this pilot study used diagnostic-seeking patients from the South London 
and Maudsley NHS Trust (SLaM). These patients were referred to one of the memory services at the 
trust (Croydon Memory Service, Lewisham Memory Service, or Southwark and Lambeth Memory 
Service) by their general practitioner (GP) with suspicion of cognitive impairment.  
6.2.3.1 Inclusion Criteria  
The inclusion criteria are as follows: participants must have a working knowledge of English, the capacity 
to consent to both present and follow-up aspects of the study, no contraindications for an MRI scan, and 
an MMSE > 10 to rule out severe dementia. Patients must have been a minimum of 50 years old, to rule 
out early onset dementia due to genetic factors. Additionally, patients must be referred from one of the 
three aforementioned memory clinics.  
A total of 98 participants were recruited for the study, however due to the inclusion criteria only 91 
reached the randomisation stage of the study. Not participating in the study did not impact the patient’s 
clinical care in any way.  
6.2.4 Diagnostic Pathway 
6.2.4.1 Initial Assessment and Recruitment 
As per standard practice, if the GP referral has been accepted by the memory service, the patient and/or 
a carer was interviewed in an initial assessment. This initial interview is designed to measure cognitive 
and functional assessment, and is given by a doctor, nurse, psychologist, occupational therapist, or 
social worker trained in dementia diagnosis. The assessment includes cognitive concerns, mental state 
and symptoms, daily functioning and psychopathology, and personal, educational, family and medical 
history. Additionally, a variety of cognitive exams are administered, including: Addenbrooke’s cognitive 
examination (ACE), the standardised mini-mental state examination (MMSE), Neuropsychiatric 
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Inventory (NPI), Bristol Activities of Daily Life Scale, the Geriatric Depression Scale (GDS), and Geriatric 
Anxiety Inventory.  
After the initial assessment, the findings are discussed in a multidisciplinary team meeting the memory 
services regularly hold. This team is made up of senior medical professionals including the psychiatric 
consultants, as well as nurses, psychologists, occupational therapists and/or social workers. Here, the 
initial assessment results of patients are discussed, and it is determined whether cognitive impairment is 
present and further testing is needed. NICE guidelines recommend MRI scans in the investigation of 
cognitive impairment (National Collaborating Centre for Mental Health., 2007). In cases where there are 
contraindications for an MRI scan, such as metallic fragments in the eye or brain, magnetically activated 
pacemakers or other metallic pins or devices, or claustrophobia, a CT scan may be requested instead. 
Only patients who were then recommended for an MRI scan were sent the appropriate patient 
information sheet (PIS) for the current study. 
Patients received the study’s PIS at the same time as their MRI appointment time. The standard time 
between MRI referral and the scan is two weeks, giving all participants ample time to review the study 
and decide if they are interested in participating. Nearly all MRI scanning for SLaM memory services is 
done at the Centre for Neuroimaging Sciences (CNS), based at the Maudsley Hospital. When the patient 
arrived for the scan, they were prepared for their scan by the radiographers. After their scan was 
completed, they were approached by myself, the study coordinator. This brief meeting was to ensure 
interest in the study, assess capacity to consent to the study, and take informed consent if the patient 
was interested in participating. If consent was not obtained, for any reason including the patient was not 





The scanning procedure followed the standard memory clinic scans as described in the BRCMEM cohort 
chapter. This included the clinical high-resolution structural scan (T1 MPRAGE, ADNI sequence) 
previously described in Chapter 2, Section 2.2.2 MRI Acquisition. The scanning procedure was the same 
for all patients, regardless of which arm of the study they were randomised to.  
6.2.4.3 Randomisation 
Once the participant had consented to participation in the study, I confirmed the patient was eligible to 
participate and did not have an MMSE score < 10. Those with a MMSE less than 10 were dismissed from 
the study and those who were above were randomly assigned the participant to one of the study arms: 
intervention or control. Those in the control arm received treatment and diagnosis procedure as normal. 
Those in the intervention arm received the additional morphometry report.  
6.2.4.4 Radiological and Morphometric Assessment  
After patients were scanned, MRI images were evaluated by a trained neuroradiologist. The 
neuroradiologist creates a report with qualitative assessment, concentrating on brain appearance and 
any abnormal findings suggestive of neurodegeneration. This radiological report is currently part of 
standard diagnostic practice, and all patients received one regardless of participation in the study or arm 
of the study they were assigned to. This report was then sent back to the referring clinicians to aid in 
diagnosis.  
Patients that were assigned to the intervention arm received an additional morphometry report in 
addition to the neuroradiologist’s qualitative assessment. These patients in the intervention arm had an 
anonymised copy of their MRI scan, stripped of any identifying data, transferred to IXICO (London, UK). 
IXICO is the scientific partner company specialising in the provision of biomarkers for clinical trials, with 
a special expertise in the morphometric analysis of brain images for potential quantitative markers of 
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neurodegeneration. IXICO produced a report with volumetric markers most relevant to dementia 
including hippocampal volume and other brain areas (Figure 6-2). In addition to the volumetric 
measurements, patients’ values were compared against healthy age matched controls to see where 
































6.2.4.5 IXICO Automated Brain Morphometry Report 
IXICO’s ASSESSA® is a CE marked medical device intended to assist clinicians in making a dementia 
diagnosis. ASSESSA® produces full volumetric reports on several brain structures subjected to atrophy 
and changes in dementia including the hippocampus, amygdala, temporal horn and lateral ventricles. 
These volumes are used to calculate a Medial Temporal Atrophy Index (MTAI) and are present with age-
matched normal percentiles.  
ASSESSA’s® unique MTAI is calculated by using volumes attained from the Learning Embeddings for Atlas 
Propagation (LEAP) automated segmentation algorithm (Wolz et al., 2010). LEAP uses T1 MPRAGE to 
calculate volumes for the areas of interest. The MTAI is calculated as a weighted sum of volumes of both 
the left and right hippocampus, amygdala, temporal horns, and lateral ventricles. Volumes are 
normalised for head size using an affine scaling factor.  Spaces segmented as cerebrospinal fluid (CSF) 
are weighted negatively whereas grey matter regions are weighted positively. Baseline lateral ventricle 
volumes are weighted at zero, and are only used in calculating longitudinal MTAIs, which were not used 
in the present study (Austin et al., 2014).  
Age-matched normal percentiles were calculated by fitting a sigmoid model to the mean volumes of five 
year spans across a set of healthy people aged between 50 and 90 years old, from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) dataset. This allows an age-matched normal distribution to be 
created for each individual subject’s age. 
The final report includes volumes for each of the listed brain structures, as well as a percentage of 
where the patient’s volume falls on the normalise distribution. Additionally the MTAI is presented, with 
a lower number being indicative of more atrophy, alongside a percentile within a normal distribution of 
expected MTAIs. For all percentiles, colour coded cut-offs are provided for easier visualisation of where 
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a participant falls on the distribution, red for below 5th percentile and amber for below 17th percentile, 
while all other scores are coloured blue, indicating a normal percentile.  
Patient’s anonymised reports were then returned to me, and I linked the anonymised volumetric report 
to the individual patient and forwarded it on to the patient’s referring clinician. Clinicians then used this 
report to aid in the diagnosis of the patient, in addition to the standard radiography assessment. 
Previous studies show these cut-off points provide 64%/93% and 84%/83% sensitivity/specificity 
respectively (Austin et al., 2014; IXICO plc, 2015). 
6.2.4.6 Clinical Diagnosis and Outcomes 
After all tests, including morphometry report if applicable, are received by the clinical team, the 
patient’s care coordinator presents the results in the memory clinic’s weekly multi-disciplinary team 
(MDT) meeting. This diagnosis may or may not be dementia, and may include a more specific etiological 
subtype such as AD, VaD, or MCI. Diagnosis and test results are then discussed with the patient and 
carers by the care coordinator in a face-to-face interview. In addition, a care plan is created that is most 
suited for the patient.    
A flowchart of the clinical trial, including both control and intervention arms and overall diagnostic 








Figure 6-3 – Clinical Trial Flowchart. Purple boxes represent the normal diagnostic pathway, while blue boxes indicate clinical 




6.2.5 Clinician Survey 
After every MDT meeting, a member of the clinical team was asked to fill out a survey about the 
diagnosis of each individual patient participating in the study. This survey was filled out regardless of 
whether the participant received the additional automated brain morphometry report.  
This survey asks for an official diagnosis, on a scale from 1-5, how likely are the symptoms caused by 
either AD or VaD, and how confident the team is in their diagnosis. A full version of the survey can be 




















6.2.6 Statistical Analysis 
All statistical analyses were performed with SPSS 24 software package, and considered significant at the 
P < 0.05 level. Any Χ2 tests performed on a two x two table used continuity correction to measure 
significance.  
6.2.6.1 Demographics 
One way analysis of variance (ANOVA) was used to measure differences in age or MMSE score between 
the two conditions. A Χ2 tests was used to measure differences in gender distribution between the two 
groups. For further analysis, we broke down diagnosis into seven categories: AD, Mild Cognitive 
Impairment (MCI), Mixed Dementia (MD), Frontotemporal Lobe Dementia (FTD), VaD, no diagnosis, or 
other (mainly included depression and anxiety). All 91 participants received a diagnosis that fell into only 
one of these seven categories.  
6.2.6.2 Clinician Confidence in Diagnoses 
Primary analysis looked at clinician confidence for the diagnosis given to each patient as reported in 
clinician survey. Unpaired t-test was used to compare each group, patients with and without additional 
brain morphometry report. 
Finally, to ensure there were no biases, we compared mean clinician confidence for those surveys filled 
out by consultants versus another medical professional in the team, for each condition. Once again, 
unpaired t-tests were used.  
6.2.6.2.1 Clinician Confidence within diagnostic groups 
Using the separated diagnosis categories, clinician confidence in diagnosis was also compared between 
control and intervention arms using unpaired t-tests. The clinical trial was not originally powered for this 




6.2.6.3 Clinician Rating of Likelihood of Vascular Dementia or Alzheimer’s Disease.  
For each patient, clinicians were asked on a scale of one to five how likely the patient’s symptoms were 
to be caused by VaD or AD (1 being not likely at all, and 5 being extremely likely). Unpaired t-tests were 
used to compare the ratings for each group, as it has been used previously to measure increase in 
clinician confidence (Grundman et al., 2013). However, it should be noted that non-parametric testing, 
such as Wilcoxon or sign test, may also be appropriate given the ordinal nature of the data.  
Pearson Χ2 test was then used to determine the relationship between condition and diagnosis of VaD 
and AD, to test if one group was more likely to receive one of these diagnoses than the other. 
Participants were categorised as either receiving a diagnosis of AD and VaD or something else.  
6.2.6.3.1 Clinician Rating of Likelihood of Vascular Dementia or Alzheimer’s Disease within diagnostic 
groups.  
Average rating of likelihood that AD or VaD caused a patient’s symptoms was calculated for each 
diagnosis category. Differences between average in disease category was measured by one-way analysis 
of variance (ANOVA), excluding the FTD group as there was only one participant. Bonferroni post-hoc 
tests were used to measure which groups differed.  
Each disease category was then analysed individually, to examine differences in clinicians’ rating of 
likelihood a patient’s symptoms were caused by AD or VaD differed between the intervention and 
control arms, using unpaired t-tests. 
6.2.6.4 Number of Specific Diagnoses 
We believed brain morphometry would result in more specific diagnoses for patients, meaning 
diagnoses with etiological qualifiers such as AD or VaD as opposed to unspecified dementia. For this 
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purpose, we broke down diagnosis into seven categories: AD, MCI, MD, FTD, VaD, no diagnosis, or other 
(mainly included depression and anxiety). All 91 participants received a diagnosis that fell into only one 
of these seven categories.  
Pearson Χ2 test was then used to test the relationship between condition and specificity of the resulting 
diagnosis. For this analysis, we separated participants into one of two groups specific or non-specific 
diagnosis. The non-specific group comprised of patients who received ‘no diagnosis’. All other 
diagnoses, including non-dementia related ones such as depression and anxiety, were considered 
specific.  
6.2.6.4.1 Number of more Specific Dementia Diagnoses  
A subset of participants who ultimately received a dementia diagnosis (either AD, VaD, MD, FTD, or MCI; 
n=67) were also examined separately. Participants were categorised as either having a specific dementia 
diagnosis (AD, VaD, MD, or FTD) or a diagnosis of MCI. Pearson Χ2 test was used to measure if condition 
significantly impacted specificity of dementia diagnosis.  
6.3 RESULTS 
6.3.1 Demographics 
All sample characteristics are listed in Table 6-1. There were no significant differences between age, 
gender, or MMSE score between the two conditions. Table 6-2 lists the diagnostic breakdown of the two 







Table 6-1 – Demographics of the Clinical Trial cohort, divided into control arm and intervention arm. Age and MMSE score = 
Mean (Standard Deviation). Significance for Age and MMSE score as measured by ANOVA; significance in Gender distribution as 
measured by Χ2 tests. Only 36 in the control arm / 34 in the intervention arm had MMSE scores. 
 Control Intervention P-Value 
Number 48 43  
Age 75.58 (8.6) 74.16 (10.6) 0.483 
Gender  (M/F) 19/29  21/22 0.788 
MMSE Score  24.33 (4.62) 24.74 (3.89) 0.696 
 
Table 6-2- Diagnosis breakdown of the cohort, divided into control arm and intervention arm.  
 
Control Intervention Total 
No Diagnosis 7 10 17 
Alzheimer's Disease 18 13 31 
Mild Cognitive Impairment 7 9 16 
Mixed Dementia 11 5 16 
Frontotemporal Dementia 0 1 1 
Vascular Dementia 2 1 3 
Other 3 4 7 









6.3.2 Clinician Surveys 
6.3.2.1 Clinician Confidence  
6.3.2.1.1 Confidence Rating 
While clinicians appear to be slightly more confident with the automated volumetry reports 
(control=3.63 vs intervention=3.91) the difference was not significant (p=.278) (Table 6-3). 
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There were also no significant differences in clinician confidence depending on whether or not the 
consultant old age psychiatrist filled out the survey, or another member of the MDT team 
(consultant=3.73 vs non-consultant=3.92; p=.577).  
Table 6-3 – Clinician Survey Results. All represent the mean response (on a scale of 1-5; whereas 1 is not at all and 5 is 
extremely) and (standard deviation). * denotes significance at p < 0.05 level.  
 
Control Intervention P-Value 
How likely is this AD? 3.02 (1.26) 2.91 (1.39) 0.684 
How likely is this VaD? 2.35 (1.21) 1.83 (1.05) 0.029* 
How confident in final Diagnosis? 3.63 (1.23) 3.91 (1.24) 0.278 
 
6.3.2.1.2 Clinician Confidence Rating Within Diagnostic Groups 
When looking at clinician confidence in specific diagnostic categories, differences emerged which did 
not exist when analysing the sample as a whole. In patients that ultimately received a diagnosis of AD, 
clinicians were significantly more confident in their diagnosis with the addition of the automated 
morphometry report (intervention group) (control=3.83 vs intervention=4.53; p=0.026) (Table 6-4). 
Additionally, clinicians were more confident with the automated morphometry report in cases that were 
diagnosed with something other than dementia, such as depression or anxiety (control=2.00 vs 
intervention=4.50; p=0.022) (Table 6-4). Confidence did not differ in other diagnostic categories, and a 
full list of results is listed in Table 6-4. 
Table 6-4 – Clinician Confidence in diagnosis, broken down by ultimate diagnosis. All represent the mean response (on a scale of 
1-5; whereas 1 is not at all and 5 is extremely) and (standard deviation). * denotes significance at p < 0.05 level.  
 
Control Intervention P-Value 
  N Average N Average  
No Diagnosis 7 2.14 (1.57) 10 2.80 (1.81) 0.451 
Alzheimer's Disease 18 3.83 (0.99) 13 4.53 (0.52) 0.026* 
Mild Cognitive Impairment 7 3.86 (0.69) 9 3.78 (0.83) 0.842 
Mixed Dementia 11 4.36 (0.50) 5 4.00 (0.71) 0.256 
Frontotemporal Dementia 0 - 1 5.00 - 
Vascular Dementia 2 4.50 (0.71) 1 4.00 0.667 
Other 3 2.00 (1.00) 4 4.50 (1.00) 0.022* 
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6.3.2.1.3 Clinician Survey – Qualitative Evidence 
While the scaled survey format is useful, there are more subtleties with each diagnosis that cannot be 
determined from a simple numerical score.  The commentary clinicians gave on the surveys was perhaps 
even more telling than the confidence score.  
For specific cases, it was very clear that the morphometry report was indeed helpful, and pushed them 
to conclude a diagnosis: 
“Useful to have the volumetry in this case to firm up the diagnosis” 
“The morphometry confirmed [the neuroradiologist’s] report of vascular changes and no hippocampal 
problems – initial thoughts were this was likely to be more mixed.” 
“More confident with the normal hippocampi – looked like vascular MCI clinically …” 
“Helped as everything static except subjective complaint and the normal hippocampi strengthen 
diagnosis” 
“Morphometry shows OK hippocampal volumes – history very characteristic and some white matter 
change on MRI so went with a mixed type” 
And it is clear for certain cases in the control group, the volumetry report was needed: 
“Borderline cognitive issues and nothing much on scan… still awaiting neuropsych. This is one where the 
morphometry would have been of help.” 
“This is one where the morphometry report might have been able to bring a bit more clarity. Fairly 
normal scan – history classic AD – some vascular risk” 
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Additionally, it seems though the morphometry report helped rule out an AD diagnosis in some cases. 
While this may not be reflected in clinician confidence, or result in more specific diagnoses for the 
intervention group, it is still paramount in making sure patients receive the correct diagnosis.  
“The volumetry helped reduce the likelihood that this is AD” 
“Diagnosis not clear – awaiting neuropsych. The morphometry does back up the scan report that [it’s] 
probably not AD, so that helps but one remains unsure ..” 
Conversely, there were some patients assigned to the intervention group that seemed to not need the 
morphometry report: 
“History highly suggestive, report from radiologist says it too. Little to be gained from morphometry” 
“History + original MRI report enough to make confident” 
6.3.2.2 Clinician Rating of Likelihood of Vascular Dementia or Alzheimer’s Disease.  
When asked what is the likelihood that VaD caused the patient’s symptom, clinicians were significantly 
less likely to attribute the patients’ symptoms to VaD in the intervention group (control=2.35 vs 
intervention=1.83; p=.029) (Table 6-3).  
This difference was not found in the likelihood that AD caused the patient’s symptoms (control=3.02 vs 
intervention=2.91; p=.684) (Table 6-3). 
Table 6-3 – Clinician Survey Results. All represent the mean response (on a scale of 1-5; whereas 1 is not at all and 5 is 
extremely) and (standard deviation). * denotes significance at p < 0.05 level. 
  Control Intervention P-Value 
How likely is this AD? 3.02 (1.26) 2.91 (1.39) 0.684  
How likely is this VaD? 2.35 (1.21) 1.83 (1.05) 0.029* 




There were no significant differences between the likelihood to receive a diagnosis of AD or VaD versus 
another diagnosis, including another form of dementia, a psychiatric disorder, or no diagnosis, for either 
group (Table 6-5). 
Table 6-5 – Distribution of patient diagnosis between the two conditions, as measured by Χ2 = .497.  
  Control Intervention Total 
VaD or AD Diagnosis 20 14 34 
Other Diagnosis 28 29 57 
Totals 48 43 91 
 
6.3.2.2.1 Clinician Rating of Likelihood of Vascular Dementia or Alzheimer’s Disease within diagnostic 
groups.  
Average rating of likelihood that AD or VaD caused a patient’s symptoms was calculated for each 
diagnosis category (Table 6-6). As expected, there were significant differences between group averages, 
and the complete ANOVA with Bonferroni post-hoc tests can be found in appendix 10.  
Table 6-6 – Average clinician rating of likelihood that AD or VaD caused a patient’s symptoms.  
  
N How likely AD How likely VaD 
No Diagnosis 17 1.94 (0.97) 1.88 (0.86) 
Alzheimer's Disease 31 3.97 (0.98) 1.65 (0.88) 
Mild Cognitive 
Impairment 16 2.00 (0.63) 2.06 (1.18) 
Mixed Dementia 16 3.81 (0.83) 3.22 (1.11) 
Frontotemporal 
Dementia 1 3.00 (0.00) 3.00 (0.00) 
Vascular Dementia 3 2.33 (1.16) 4.00 (1.00) 
Other 7 1.57 (0.79) 1.29 (0.49) 
 
When examining those who received a final diagnosis of AD, clinicians were more likely to attribute a 
patient’s symptoms to AD with the addition of the automated morphometry report (control=3.67 vs 
intervention=4.39; p=0.026). No other diagnostic category showed this difference (Table 6-7) 
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Table 6-7 – Clinician likelihood to attribute a patient’s symptoms to AD (how likely is this AD?), broken down by ultimate 
diagnosis. All represent the mean response (on a scale of 1-5; whereas 1 is not at all and 5 is extremely) and (standard 
deviation). * denotes significance at p < 0.05 level. 
 
Control Intervention P-Value   
N Average N Average 
 
No Diagnosis 7 2.43 (1.13) 10 1.60 (0.70) 0.081 
Alzheimer's Disease 18 3.67 (1.14) 13 4.39 (0.51) 0.026* 
Mild Cognitive Impairment 7 1.86 (0.69) 9 2.11 (0.60) 0.445 
Mixed Dementia 11 3.64 (0.92) 5 4.20 (0.45) 0.222 
Frontotemporal Dementia 0 - 1 3.00 - 
Vascular Dementia 2 2.00 (1.41) 1 3.00 0.333 
Other 3 1.67 (0.58) 4 1.50 (1.00) 0.809 
 
Conversely, when looking at the same group of patients that received a diagnosis of AD, clinicians were 
less likely to contribute symptoms to VaD with the added morphometry report (control=1.89 vs 
intervention=1.31; p=0.045).  Again, no other diagnostic category showed this difference (Table 6-8). 
Table 6-8 – Clinician likelihood to contribute a patient’s symptoms to VaD (how likely is this VaD?), broken down by ultimate 
diagnosis. All represent the mean response (on a scale of 1-5; whereas 1 is not at all and 5 is extremely) and (standard 
deviation). * denotes significance at p < 0.05 level. 
 
Control Intervention P-Value 
  N Average N Average  
No Diagnosis 7 2.14 (0.90) 10 1.70 (0.82) 0.310 
Alzheimer's Disease 18 1.89 (1.02) 13 1.31 (0.48) 0.045* 
Mild Cognitive Impairment 7 2.29 (1.25) 9 1.89 (1.17) 0.524 
Mixed Dementia 11 3.09 (1.22) 5 3.50 (0.87) 0.513 
Frontotemporal Dementia 0 - 1 3.00 - 
Vascular Dementia 2 4.50 (0.71) 1 3.00 0.667 




6.3.3 Number of Specific Diagnoses 
6.3.3.1 All Diagnoses 
The majority of patients did receive a diagnosis, although not all were dementia related. In total, 74 of 
the 91 people were grouped as having a specific diagnosis. Chi-squared tests revealed specific diagnoses 
showed no evidence of a difference between the conditions (p=.429) (Table 6-9).  
Table 6-9 – Group distribution of specific diagnoses, as measured by Χ2 = .429. 
  Control Intervention Total 
Specific Diagnosis 41 33 74 
No Diagnosis 7 10 17 
Totals 48 43 91 
 
6.3.3.2 Dementia Diagnoses 
When only looking at the subset of patients whom received a dementia diagnoses (n=67), there were no 
significant differences between receiving a diagnosis of specific dementia (AD, MD, VaD, or FTD) versus 
MCI (p=.362) between the control and intervention condition (Table 6-10). 
 
Table 6-10- Group distribution of specific dementia diagnoses versus MCI, as measured by Χ2 = .362 
  Control Intervention Total 
Specific Dementia Diagnosis 31 20 51 
MCI 7 9 16 
Totals 38 29 67 
 
6.4 DISCUSSION 
Hippocampal volumetry use for dementia diagnosis has been gaining acceptance in recent years, and 
several studies have looked at the benefits of volumetric use versus standard neuroradiological 
reporting (Klöppel et al., 2008; Ross, Ochs, Seabaugh, Shrader, & Alzheimer’s Disease Neuroimaging 
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Initiative, 2013; Westman, Cavallin, Muehlboeck, et al., 2011a). Ross and colleagues found that 
automated methods were more sensitive at finding atrophy than neuroradiologists, however this was 
not in dementia cases (Ross et al., 2013). Multivariate image analyses, and even using hippocampal 
volume alone, have also been shown to be more sensitive at detecting dementia than neuroradiologists 
using a structured visual rating scale (Klöppel et al., 2008; Westman, Cavallin, Muehlboeck, et al., 
2011a). 
There are several approved tools for automated volumetry measurement in clinics, including ASSESSA® 
based on LEAP, and Neuroquant based on FREESURFER (Brewer, Magda, Airriess, & Smith, 2009). While 
they are based on different segmentation algorithms, their performance is similar (Yu et al., 2014). 
These methods are considered good, and useful to have when reviewing a patient’s case, but are not 
sufficient for a dementia diagnosis alone (Engedal, Brækhus, Andreassen, & Nakstad, 2012). 
6.4.1 Quantitative and Qualitative Survey Results 
6.4.1.1 Clinician Confidence in Diagnosis 
While statistical analyses showed there were no significant differences in clinician confidence overall, 
there was a plethora of qualitative evidence suggesting that this is still a potentially useful tool in a 
memory clinic setting. A few common themes can be found when reviewing the clinicians’ comments on 
the diagnostic process. It seems that often the report was very helpful, and pushed towards a specific 
diagnosis, or would have been helpful to have. For others, while it did not help result in a specific 
diagnosis, it was useful in ruling out AD. In addition, there were a number of patients that the clinicians 
felt did not need the morphometry report. These themes taken together suggest that it may be that a 
subset of patients benefit from such automated morphometry reports more than others.  
When looking at specific diagnostic categories, a significant difference was found in clinician confidence 
for those with AD or some other form of diagnosis. It is logical these two groups would benefit most 
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from the additional automated morphometry report, as hippocampal volume is directly related to AD. 
For those diagnosed with a non-dementia condition such anxiety or depression, the automated 
morphometry report may have assured clinicians they can rule out a diagnosis of AD or dementia. Both 
groups are likely to exhibit one of the extremes, either very little or significant atrophy, on the 
automated morphometry report. This added confidence may not be seen in other categories, as the 
automated morphometry report does not add new information related to these conditions, or because 
the automated morphometry report did not show pronounced (or little) atrophy in these subjects.   
It is always challenging implementing a new tool into routine healthcare streams, especially with 
concerns over cost, and both time and resources used for implementation. There is a clear set of 
benefits to some patients, namely those who do have AD, but it may not be necessary for everyone who 
finds themselves in a memory clinic. It is well documented that AD has a long prodromal stage, where 
brain changes are beginning to occur with minimal symptoms, that may be confused for another type of 
disorder (Sperling et al., 2011). Unlike most well-defined research cohorts, clinical cohorts can include 
people anywhere along this trajectory. Subjects who have yet to have produced atrophy, but have slight 
atrophy which may or may not be indicative of AD, may need a diagnosis based on other factors such as 
white matter changes as described on the neuroradiological report.  
For those who are further on the AD progression timeline, it makes sense that atrophy is easily 
visualised with the naked eye, and in combination with severe clinical symptoms there is little need for 
extra support, such as an automated volumetry report. According to NICE guidelines, MRI imaging may 
not be necessary for those presenting with moderate to severe dementia, if the diagnosis is already 
clear, suggesting the patients with the most pronounced atrophy may not have been scanned in the first 
place (National Collaborating Centre for Mental Health., 2007). The increase in confidence in AD patients 
may be due to the inability to discern the extent of the atrophy with an unstructured report, as 
compared to a volumetric measurement and a score that describes the percentile the patient fits 
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compared to healthy age matched controls. The automated volumetry reports potentially hold great 
promise in helping clinicians discern cases that are less clear cut, with atrophy present and mild 
subjective memory complaints, which most likely describe the patients in this cohort that ultimately 
received an AD diagnosis.  
Furthermore, the SLaM memory services in this study have access to tertiary level neuroradiologists 
with special expertise in dementia imaging. This level of expertise in assessing brain scans is not 
generally available to memory services, and may have reduced the added usefulness of morphometry. It 
may be that this sort of tool will have a more pronounced effect in memory clinics and primary care 
centres which do not have access to such a high level of expertise.  
6.4.1.2 Clinician Rating of Likelihood of Vascular Dementia or Alzheimer’s Disease.  
The clinicians were significantly more likely to conclude VaD may have contributed to a patient’s 
symptoms in the control group than the intervention group, and this difference remained in the AD 
patients when looking at each diagnostic group separately.  
While this report only contained volumetric information on very specific brain regions and no 
information on white matter, seeing a distinguished pattern of atrophy centralised in the medial 
temporal lobe may have helped rule out VaD for a number of patients. VaD does not have the same 
neuropathological pattern that centralises around the hippocampus and medial temporal lobe that is 
seen in AD (O’Brien & Thomas, 2015b). Hippocampal atrophy is not as prevalent or severe in VaD, and 
while patients with VaD have smaller hippocampi than healthy controls, they still have larger 
hippocampi than those diagnosed with AD (Kim et al., 2015). Additionally, cognition in VaD does not 
always correlate with hippocampal volume (Mungas et al., 2002). 
There was no difference in clinicians’ likelihood to conclude that AD was the cause of a patient’s 
symptoms between the two groups, when looking at the entire cohort. For AD patients specifically, 
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clinicians were significantly more likely to attribute a patient’s symptoms to AD in the intervention 
group. This may also be attributed to AD patients having the most pronounced hippocampal atrophy on 
the reports.  
While patients in the control group were more likely to have clinicians believe VaD was a cause of their 
symptoms, neither group was more like to receive a diagnosis of VaD or AD than other condition.  
6.4.1.3 Number of Specific Diagnoses 
Contrary to our original hypothesis, having the automated morphometry report did not result in 
clinicians giving a more specific diagnosis. Unexpectedly, none of the 91 participants received a 
diagnosis of unspecified dementia, which is not the case in the earlier described BRC memory clinic 
cohort (Chapter 2: The BRC Memory Clinic Cohort) and other memory clinics (Falahati et al., 2015). We 
believed that the control group would receive more of this type of diagnosis, however this finding 
suggests that this may not be as common as a diagnosis as previously thought. We are unsure if these 
patients are more likely to receive no diagnosis, or be categorised into a specific type of dementia that is 
suspected, or categorised as MCI as it is often used as a precursor to AD, MD, or even VaD.  
Qualitative evidence from the clinicians’ comments revealed that the automated morphometry report 
was helpful in ruling out dementia. While this may result in no diagnosis, it may also be instrumental in 
preventing a wrong diagnosis. Wrong diagnoses are just as harmful as missed and delayed diagnosis, 
and can not only result in lost opportunities for correct treatment and therapies, but can also drain 
resources when they may not be needed or useful (Bradford et al., 2009).  Moving forward, it would be 
interesting to follow this cohort and look at any changes made in diagnoses, and see whether those 
receiving the morphometry report were more likely to keep their original diagnosis. Because 
misdiagnosis is such a big concern in making diagnoses timelier, this tool can be useful in achieving 
earlier diagnoses in dementia (Dubois, Padovani, et al., 2016; Gaugler et al., 2013).  
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A secondary analysis on the subset of patients who received a dementia diagnosis examined whether 
patients in one group or the other were more likely to receive a diagnosis of MCI or some other form of 
dementia (AD, VaD, MD, or FTD). While MCI may be considered a substantial diagnosis on its own, it 
could also be categorised as a non-specific diagnosis. Amnesic MCI is often considered a precursor to 
AD, however there are different forms of the disorder (such as MCI due to vascular impairment) that 
were not distinguished in these diagnoses. Additionally, patients diagnosed with MCI may not go on to 
develop AD, and either remain with MCI or revert to normal cognition. A majority (60-70%) of cases of 
amnestic MCI can be attributed to AD pathology mixed with another type of dementia pathophysiology 
such as white matter changes and cerebrovascular disease, or Lewy body disease (Jicha et al., 2006; 
Ronald C. Petersen et al., 2006).  This reinforces that while MCI may often be a precursor to AD, it is a 
very heterogeneous condition and may be a precursor to another type of dementia or a stand-alone 
condition (Gordon & Martin, 2013; Janoutová, Šerý, Hosák, & Janout, 2015).  
6.4.2 Limitations 
As with any study, there was numerous limitations that may have contributed to some of our findings. 
Firstly, this was a pilot study and not a fully powered efficacy study. It is very possible that our sample 
sizes were simply not large enough, and more data is needed to truly see the useful effects of this tool in 
a memory clinic. There is evidence that significance thresholds may need to be reconsidered for pilot 
type studies, and this may need to be considered when interpreting results (Lee, Whitehead, Jacques, & 
Julious, 2014). Most of the group sizes once broken down by diagnosis were extremely small, and 
therefore were not sufficient to detect differences. Additionally, extremely small sample sizes may not 
actually be representative of a disease population. Because these extremely small sample sizes, used 
solely for exploratory analysis, no corrections were made for multiple comparisons, and significance 
between disorders may not be present if a corrected p-value was used.  
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For the analyses of clinical confidence, and likelihood of AD or VaD, unpaired t-tests were used to 
measure mean differences between the two groups. While this statistical test was used previously in 
measuring increase in clinician confidence, it may not be the most appropriate for the given dataset 
(Grundman et al., 2013). There was no assessment of the normality of the distribution of the data, and 
therefore non-parametric tests may be more appropriate. Non-parametric tests use ranked order of 
observations, instead of the measurements themselves, to distinguish group differences. In addition to 
skewed data, it can also be useful for tests that have a small range of possible values, such as the 1-5 
scale used in the survey. These tests have almost as much statistical power as t-tests when the samples 
are large, however they do not provide estimates of means or confidence intervals (Douglas G. Altman & 
Bland, 2009). It should be noted that different statistical analyses can reveal different results, and this 
should be remembered when interpreting the results. 
With any new tool, there comes complications with implementation. While clinicians are most likely 
very familiar with the concept of hippocampal atrophy in AD and dementia, a volumetry report that 
clinicians are unfamiliar with may take time before its full potential is realised. Clinicians are very busy, 
and often working with limited resources, which may cause a delay in filling out final clinician surveys. 
While the surveys are intended to be filled out jointly with the entire MDT team, some may have been 
filled out after the diagnosis was made. Clinicians are always able to look at case notes, but it is unclear 
what kind of impact a delay in survey completion could have on the results. Lastly, because results are 
based solely on clinician self-reports, it is important to consider the possible interpretations of the 
question ‘How confident are you in this diagnosis?’. Because there were multiple clinicians filling out 
these surveys, there may be a difference in what each clinician considers confident. Some may be likely 
to say they are confident in no diagnosis, while some may believe they cannot be confident in no 
diagnosis. The qualitative evidence certainly helps discern clinicians’ feelings, but more work could be 
done to more closely dissect their scores.  
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When making diagnoses, clinicians may take into consideration inherent differences in ethnic 
populations. It is well documented that various populations are affected differently by various types of 
dementia (Anderson, Bulatao, Cohen, & National Research Council (US) Panel on Race, 2004). It may be 
that, unintentionally, clinicians are more likely to diagnose based on a patient’s ethnicity based on 
previous literature. Additionally, comorbidities are taken into consideration when assessing patients. 
These two types of information were not looked at in the present study, and may have had interesting 
effects on clinician confidence and type of diagnosis.  
6.4.3 Future Work 
While the qualitative evidence from the clinicians’ comments is encouraging, more studies need to be 
done to measure the efficacy of this as a diagnostic tool in memory clinics. It can be especially hard to 
test the diagnostic accuracy of a new test when the reference test, which is usually a clinical diagnosis, is 
an imperfect test itself (Coart et al., 2015). Officially, the gold standard of dementia diagnosis is a 
postmortem examination revealing relevant AD pathology, however there are many issues with using 
this as a reference test (Philip Scheltens & Rockwood, 2011). Firstly, lab results can differ with their 
postmortem examination results, especially given the heterogeneity of neuropathology of AD and lack 
of standardisation. It can also be problematic in early stages of the disease, when the diagnosis is not 
clear, such as mild AD or MCI. Ultimately, there lacks a definitive relationship between the 
neuropathology and clinical stages of AD, especially in the oldest where the disease is most common, 
which makes postmortem an insufficient reference point (Savva et al., 2009; Philip Scheltens & 
Rockwood, 2011). While biomarkers are a popular option for replacement, they can also be fallible and 
lack lab measurement standardization (Coart et al., 2015; Philip Scheltens & Rockwood, 2011). 
It may be necessary to move toward integrating multiple sources of information, from a variety of 
biomarkers and clinical assessments, for reference tests given the complexity of the disease and lack of 
gold standard (Coart et al., 2015; Philip Scheltens & Rockwood, 2011). The heterogeneity of AD, and 
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variety of neuropathological presentations must be taken into consideration when examining a tool’s 
validity, as there must be an extension of what includes a ‘normal’ presentation of AD (Philip Scheltens 
& Rockwood, 2011). One groups use of a bayesian model to integrate various sources of diagnostic 
information, including clinician diagnosis and CSF biomarkers, four it can account for the imperfection in 
tests by combining more data sources (Coart et al., 2015). These studies show the importance of 
considering multiple biomarkers when judging diagnostic accuracy of a new tool, and should be looked 
at in the future when assessing this automated morphometry report.  
6.4.3.1 Future work within this pilot 
There are several secondary hypotheses that may be examined in the future. The ultimate aim of using 
this tool is two-fold, to increase clinician’s confidence in their diagnosis, and in turn to allow clinicians to 
make a more confident diagnosis earlier on. As discussed earlier, a more timely diagnosis allows people 
better access to care, a more positive experience, and can even potentially have economically impact on 
health care systems (Dubois, Padovani, et al., 2016). One potential analysis could examine time from 
referral to diagnosis, and whether those with the additional volumetry report were diagnosed more 
quickly. Using the electronic health records available through SLaM, we could access both date of 
referral and date of diagnosis, and measure group differences in average time to diagnosis using 
independent sample t-tests. Some of the other differences we believe would be directly impacted by 
this earlier diagnosis would be less utilisation of extra resources like additional visits, retesting, and use 
of other scanning modalities such as positron emission tomography (PET). Additionally, we would expect 
those in the intervention condition who are diagnosed with AD would then receive an earlier 
prescription of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine, due to their 
earlier diagnosis. It would also be interesting to look at any changes in diagnoses made in follow-up 
appointments, to see if the volumetry reports may have lead clinicians to a correct diagnosis earlier. 
Finally, we would expect that overall patient and carer experience would be more positive, a common 
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finding with earlier diagnoses (Boise et al., 1999; de Vugt & Verhey, 2013). This would be measured with 
follow-up surveys sent to patients one year from their MRI scan.   
Lastly, within this study it would be interesting to measure differences in diagnoses based on ethnicities 
and comorbidities. As previously mentioned, it is well documented that dementia type proportions vary 
within different populations, and it would be interesting to see if this trend also held true in the current 
study. It would also be interesting to see if different diagnoses were more or less likely based on various 
comorbidities, to test whether or not clinicians are more likely to diagnose patients with vascular risk 
factors, such as high-blood pressure and type II diabetes, with VaD. Ethnic information and medical 
history are also available on the hospitals electronic patient record system, and would be easily 
accessible.  
6.4.3.2 Potential Uses for an Automated Morphometry Reporting System 
Even though more work needs to be done to validate this as a tool to be used in clinical practice, there 
are is a large variety of applications that could follow.  
6.4.3.2.1 Potential Uses in Memory Clinics and Primary Care 
While the current diagnostic standards are based on clinical symptoms alone, it is a logical next step to 
begin including brain imaging (G. M. McKhann et al., 2011). The ASSESSA® automated morphometry 
report also supports a longitudinal feature, and can create an MTAI using longitudinal information from 
multiple scans and cognitive exams. There is evidence that rate of atrophy can predict clinical status 
better than a single volumetric measurement alone (C. R. Jack et al., 2005). Following our cohort of 
patients, and giving them subsequent volumetry reports at each follow up visit may have an even 
greater impact. Using more scanning information, such as white matter lesion load, may also give 
greater insight into dementia type. While this tool may be useful, it would only be useful if implemented 
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correctly. As previously mentioned, more clinics would need to provide MRI scans for all memory clinic 
patients. 
It has been found that from initial symptom presentation, a dementia diagnosis usually takes between 
18-30 months, but can take up to four years in primary care services (Bamford, Eccles, Steen, & 
Robinson, 2007). Primary care services are often already inundated, and since they are not specialist 
memory services dementia diagnoses are often missed. Previous efforts with educational interventions, 
such as practice based workshops and decision support systems, were not effective in increasing 
detection rates or speeding up time to diagnoses (Wilcock et al., 2013). An easy to use tool, such as 
ASSESSA®, with easily interpreted data and normalised scores may assist general practioners in 
identifying potential dementia cases. As previously discussed, clinician confidence may not have 
increased with the additional use of such a tool because of the high expertise of the neuroradiologists 
and consultants at the SLaM’s memory services, and it may prove to be more effective at increasing 
diagnostic confidence in a primary care setting.  
6.4.3.2.2 Potential Uses in Clinical Trials  
In addition to the clinic, this too may prove to be useful in clinical trials and other forms of research. The 
volumetric measurements could provide quantitative data about rate of atrophy in drug trials, for more 
comprehensive interpretation of the efficacy of a given drug. It could also be used as a screening tool, to 
make sure those recruited into clinical trials actually do have AD or dementia, as a large percentage of 
drug trials fail because they may be targeting the wrong disease population (Mangialasche, Solomon, 
Winblad, Mecocci, & Kivipelto, 2010). Additionally, it is found hippocampal volumes can be useful in 




Use of automated morphometry reports that included hippocampal, amgydalar, and ventricular volume 
in a memory clinic was examined. While the use of automated morphometry reports did not increase 
clinician confidence in diagnosis overall, exploratory post-hoc tests suggest it did improve confidence in 
patients that were ultimately diagnosed with AD. Qualitative evidence from the surveys show the 
clinicians find this tool useful in a subset of cases, and it may be beneficial for clinicians to have when 
making a diagnosis.  While the automated morphometry reports did not result in more specific 
diagnoses, further investigation is needed to examine patient outcomes with and without the 











7 GENERAL DISCUSSION 
7.1 PURPOSE AND RATIONALE 
The purpose of this PhD thesis is to explore the application of common used research techniques in 
Alzheimer’s Disease (AD) and dementia studies in a clinical cohort. While recommended, imaging 
biomarkers are still not in the core diagnostic criteria of AD or Mild Cognitive Impairment (MCI) (Albert 
et al., 2011; G. M. McKhann et al., 2011). More validation of these biomarkers is needed, especially in 
clinical cohorts. While research cohorts like the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (R C. 
Petersen et al., 2010) and AddNeuroMed (Simmons et al., 2009) have been invaluable to AD research in 
the past decade, they are still research based cohorts and are therefore not always representative of the 
general population. A key factor in developing new biomarkers is ensuring their ability to apply to a 










7.2 REVIEW OF FINDINGS 
This thesis focused on the use of research techniques in a clinical cohort, using EHRs. Table 1 shows a 
summary of findings in this thesis.  
Table 7-1 – Summary of findings from each study included in this thesis. 
Study Title  Summary of Findings  
Correlation of 
MMSE score and 
Hippocampal 
Volume in a 
Memory Clinic 
Cohort 
A large cohort of memory clinic patients’ MRI scans were linked with their 
EHRs. This is the one of the first instances of MRI automated volumetric data 
and EHR linkages, and paves the way for future research.  
As expected, MMSE score was positively correlated with hippocampal volume, 
and this correlation was strongest in those with AD. 
OPLS in a Memory 
Clinic Cohort 
OPLS multivariate analysis has been examined in research cohorts numerous 
times, and have found to classify AD and healthy controls with relatively high 
accuracy. While the models did not perform as well in clinical cohorts, they still 
performed relatively well. This may be a useful clinical tool in the future, 
especially with the addition of other modalities such as CSF measures or 





Mixed Dementia in 
a Memory Clinic 
Cohort 
Using automated white matter hyperintensity and volumetric measures, 
groups were created to identify the distribution of AD, VaD, and MD pathology 
in memory clinic patients. Hard defined cut-off points may not be useful 
currently, but with further research and identification of other sub-group cut-
offs (such as MCI) they could be useful. Additionally, there is substantial 





Use of automated morphometry reports (including hippocampal, amygdalar, 
and ventricular volumes) was examined in a clinical trial. The use of automated 
morphometry reports did not increase clinician confidence in diagnosis overall, 
however exploratory post-hoc analyses suggest it may improve confidence in 
those ultimately diagnosed with AD. Qualitative evidence from surveys show 
clinicians find the tool useful, especially for a subset of unclear cases. Further 
investigation is needed to examine the use of this tool in a clinical setting.  
7.3 IMPLEMENTATION OF RESEARCH TECHNIQUES IN CLINICAL COHORTS 
While ADNI and AddNeuroMed have made a tremendous impact on a variety of research areas, such as 
basic research, clinical trials, and data sharing, these cohorts still have their limitations. Within a decade, 
well over 600 publications have been generated with the ADNI dataset (Weiner et al., 2015). The ADNI 
cohort is mostly made of an amnestic clinical population, and is not selected based on the actual 
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population. These subjects have limited comorbidities, and many with pre-existing conditions are 
excluded from study participation. Because of this, the findings from these studies cannot always be 
directly extrapolated to the general population. One of the advantages of a clinical cohort is it mitigates 
this confound, and it is important to continue this with other research tools to ensure their usefulness in 
a clinical setting.  
7.3.1 The Importance of Clinical Cohorts 
Clinical cohorts are extremely useful in examining the efficacy of diagnostic tools in a clinical setting, 
where they would ultimately be used. While clinical cohorts are not a population based cohort, they are 
still are more heterogeneous than the previously mentioned research cohorts. The patients in these 
cohorts usually come from a wider range of socioeconomic backgrounds, with more varying levels of 
education. Most importantly, clinical cohorts have more lenient inclusion criteria and do not omit 
participants based on comorbidities. As manly people with dementia do indeed have other disorders in 
addition, it is important to test diagnostic tools in this setting to ensure any tool is robust enough to not 
be influenced by other conditions.  
Additionally, if diagnostic tools are to be used in memory clinics, they must be proficient at 
distinguishing different types of dementia. The memory clinic cohort offers the opportunity to observe 
diagnostic tools on a wide range of symptoms and dementia subtypes. Research cohorts such as ADNI 
and AddNeuroMed, only include healthy controls, MCI, and AD patients in any analyses, and do not 
provide the opportunity to examine different types of dementia.  
While not all clinical cohorts will have connection with EHRs, this integration provides an opportunity to 
gather patient data beyond what would normally be collected in a research study. There may be 
information about lifestyle choices, or records from other clinics that may aid in research studies.  
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In addition to testing the accuracy of diagnostic tools, clinical cohorts provide the opportunity to test 
practicality, and the ease of implementation. Ensuring full and efficient integration of diagnostic tools is 
possible is just as important as accuracy testing.   
7.4 ELECTRONIC HEALTH RECORD USAGE FOR RESEARCH PURPOSES  
Both medical professionals and researchers have concluded that there is a very strong opportunity for 
studies with clinical cohorts and even population-wide research that may aid in bridging the 
translational gap between research and clinical practice through the use of sharing electronic health 
records (Jensen et al., 2012). Using EHR records allows investigation of clinical disorders without 
potential cohort biases such as those with the ‘volunteer-gene’. This ‘volunteer-gene’ refers to people 
with inherent differences that make them more likely to volunteer for a research study (Sperling et al., 
2011). Additionally, using EHRs may eliminate biases brought on by samples of convenience.  
Integration of EHRs for research purposes may also aid in the implementation of longitudinal studies. As 
EHRs follow standard clinical care, there are no extra appointment requirements, and may result in less 
participant attenuation. Many patients may move hospitals, and therefore effectively ‘drop-out’, the 
wider catchment means that even with these subjects leaving, there will still be a substantial number of 
patients with follow-up data.  
Finally, the application of EHR for research purposes extends far past the research completed in this 
thesis. In the case of MRI imaging, a myriad of mental health disorders, such as depression or psychosis, 
could benefit from EHR integration to monitor brain imaging, pharmacological treatments, and other 
cognitive therapies. Furthermore, EHRs can be integrated with various modalities, such as blood testing, 
which could further fuel research into blood based biomarkers.  
210 
 
7.5 LIMITATIONS  
While this PhD discusses promising potentials for the future of dementia research, there are several 
limitations that must be addressed.  
7.5.1 Clinical Cohort Samples  
There are significant benefits for using a clinical cohort instead of a research based cohort, however 
clinical cohorts are still not full population samples. Clinical cohorts are subjected to bias as they may 
contain people who have better access to health care, or have more severe symptoms (Brodaty et al., 
2014). Consistent with this, clinically referred MCI participants are more likely to be married and living 
independently than wider population of MCI patients (Barnhart et al., 1995; Farias, Mungas, Reed, 
Harvey, & DeCarli, 2009).   
7.5.2 Lack of Consistency in Electronic Health Records and Memory Clinic Centres 
As seen in this study, there are many challenges with EHR linkages. Many subjects in the BRC Memory 
Clinic Cohort, roughly 40%, were missing MMSE score in their electronic health records, and a number of 
them did not have a final diagnosis listed. This was not a challenge in these analyses, as the large 
number of participants to begin with meant there was still a decent sized cohort even despite of these 
missing records.   
Additionally, while patients received their diagnoses in a generally close proximity to any diagnostic 
tests used in the analyses, not all patients received their diagnosis the same specified time (for example, 
3 months after MRI scan). In the future, it would be beneficial to factor in how long to final diagnosis 
into analyses.  
The South London and Maudsley Hospital (SLaM) has developed a standardised procedure for their 
memory clinics, however, this is not the case for the majority of the UK. There is often a lack of 
standardisation for diagnostic procedures, which may hinder EHR integration across various clinics. 
211 
 
7.5.3 Volumetric Studies in Alzheimer’s Disease and Dementia 
As previously mentioned, AD is a heterogenous disorder and can have several neuropathological 
presentations (Daniel Ferreira, Verhagen, et al., 2017). It has been found that potentially 17% of patients 
with AD do not exhibit hippocampal atrophy, and greater than 10% of those with AD do not experience 
atrophy at all. The diagnostic tests examined in this thesis may not apply to a portion of patients with 
AD, and therefore my hinder clinical applicability.  
Additionally, hippocampal is not exclusive to AD, and can be found in other disorders such as depression 
(Taylor et al., 2014). This must be taken into consideration when testing and analysing diagnostic tools in 
dementia.  
7.6 CONCLUSION 
Automated measures, such as white matter hyperintensity measurements and automated volumetry 
reports, have the potential to increase efficiency in clinics and aid in the diagnostic process. The results 
of this thesis show these measures may be promising, and are still accurate in a clinical setting. More 
research needs to be done on effective transition to using these tools.  
Additionally, this thesis has shown the promise of integrating EHRs for research purposes. There are a 
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Chapter 3: Group differences (male versus female) in age, average MMSE, and total normalised 
hippocampal volume in the portion of the BRC memory clinic cohort used in chapter 3 study, as measured 









Square F Sig. 
norm total HC Between Groups .000 1 .000 7.311 .007 
Within Groups .000 534 .000   
Total .000 535    
age at MMSE Between Groups 54.927 1 54.927 .524 .469 
Within Groups 55946.458 534 104.769   
Total 56001.385 535    
MMSE Between Groups 25.059 1 25.059 .950 .330 
Within Groups 14087.001 534 26.380   







Chapter 4: Group differences (between diagnostic categories) in age and average MMSE in the portion of 
BRC memory clinic cohort used in the chapter 4 study, as measured by ANOVA and Bonferroni’s post-hoc 









Square F Sig. 
MMSE score Between Groups 2036.155 8 254.519 12.361 .000 
Within Groups 9759.725 474 20.590   
Total 11795.880 482    
age Between Groups 15087.518 8 1885.940 20.995 .000 
Within Groups 59196.762 659 89.828   






Bonferroni   
Dependent 
Variable 
(I) primary dx 
category 












MMSE score diagnosis not 
listed 
no diagnosis -.365 1.292 1.000 -4.52 3.79 
AD 3.491* .572 .000 1.65 5.33 
MCI -1.055 .744 1.000 -3.45 1.34 
Mixed Dementia 3.658* .823 .000 1.01 6.30 
VaD 4.680* 1.065 .000 1.26 8.10 
unspecified 
dementia 
5.200* 1.046 .000 1.84 8.56 
other dementia 5.635* 1.502 .007 .80 10.47 
other psychiatric 
disorder 
1.675 .786 1.000 -.85 4.20 
280 
 
no diagnosis diagnosis not 
listed 
.365 1.292 1.000 -3.79 4.52 
AD 3.856 1.265 .087 -.21 7.92 
MCI -.690 1.351 1.000 -5.04 3.66 
Mixed Dementia 4.023 1.396 .149 -.47 8.51 
VaD 5.045* 1.551 .044 .06 10.03 
unspecified 
dementia 
5.565* 1.538 .012 .62 10.51 
other dementia 6.000 1.879 .054 -.04 12.04 
other psychiatric 
disorder 
2.041 1.375 1.000 -2.38 6.46 
AD diagnosis not 
listed 
-3.491* .572 .000 -5.33 -1.65 
no diagnosis -3.856 1.265 .087 -7.92 .21 
MCI -4.546* .695 .000 -6.78 -2.31 
Mixed Dementia .167 .779 1.000 -2.34 2.67 
VaD 1.189 1.032 1.000 -2.13 4.51 
unspecified 
dementia 
1.709 1.012 1.000 -1.55 4.96 
other dementia 2.144 1.479 1.000 -2.61 6.90 
other psychiatric 
disorder 
-1.815 .741 .527 -4.20 .57 
MCI diagnosis not 
listed 
1.055 .744 1.000 -1.34 3.45 
no diagnosis .690 1.351 1.000 -3.66 5.04 
AD 4.546* .695 .000 2.31 6.78 
Mixed Dementia 4.713* .913 .000 1.78 7.65 
VaD 5.735* 1.136 .000 2.08 9.39 
unspecified 
dementia 
6.255* 1.118 .000 2.66 9.85 
other dementia 6.690* 1.554 .001 1.69 11.69 
other psychiatric 
disorder 
2.730 .880 .074 -.10 5.56 
Mixed Dementia diagnosis not 
listed 
-3.658* .823 .000 -6.30 -1.01 
no diagnosis -4.023 1.396 .149 -8.51 .47 
AD -.167 .779 1.000 -2.67 2.34 
281 
 
MCI -4.713* .913 .000 -7.65 -1.78 
VaD 1.022 1.189 1.000 -2.80 4.85 
unspecified 
dementia 
1.542 1.172 1.000 -2.23 5.31 
other dementia 1.977 1.593 1.000 -3.15 7.10 
other psychiatric 
disorder 
-1.982 .948 1.000 -5.03 1.07 
VaD diagnosis not 
listed 
-4.680* 1.065 .000 -8.10 -1.26 
no diagnosis -5.045* 1.551 .044 -10.03 -.06 
AD -1.189 1.032 1.000 -4.51 2.13 
MCI -5.735* 1.136 .000 -9.39 -2.08 
Mixed Dementia -1.022 1.189 1.000 -4.85 2.80 
unspecified 
dementia 
.520 1.353 1.000 -3.83 4.87 
other dementia .955 1.731 1.000 -4.61 6.52 
other psychiatric 
disorder 





-5.200* 1.046 .000 -8.56 -1.84 
no diagnosis -5.565* 1.538 .012 -10.51 -.62 
AD -1.709 1.012 1.000 -4.96 1.55 
MCI -6.255* 1.118 .000 -9.85 -2.66 
Mixed Dementia -1.542 1.172 1.000 -5.31 2.23 
VaD -.520 1.353 1.000 -4.87 3.83 
other dementia .435 1.719 1.000 -5.09 5.96 
other psychiatric 
disorder 
-3.524 1.147 .081 -7.21 .16 
other dementia diagnosis not 
listed 
-5.635* 1.502 .007 -10.47 -.80 
no diagnosis -6.000 1.879 .054 -12.04 .04 
AD -2.144 1.479 1.000 -6.90 2.61 
MCI -6.690* 1.554 .001 -11.69 -1.69 
Mixed Dementia -1.977 1.593 1.000 -7.10 3.15 





-.435 1.719 1.000 -5.96 5.09 
other psychiatric 
disorder 





-1.675 .786 1.000 -4.20 .85 
no diagnosis -2.041 1.375 1.000 -6.46 2.38 
AD 1.815 .741 .527 -.57 4.20 
MCI -2.730 .880 .074 -5.56 .10 
Mixed Dementia 1.982 .948 1.000 -1.07 5.03 
VaD 3.005 1.165 .366 -.74 6.75 
unspecified 
dementia 
3.524 1.147 .081 -.16 7.21 
other dementia 3.959 1.575 .441 -1.10 9.02 
age diagnosis not 
listed 
no diagnosis -6.944* 2.064 .029 -13.57 -.32 
AD -10.403* 1.044 .000 -13.75 -7.05 
MCI -8.259* 1.290 .000 -12.40 -4.12 
Mixed Dementia -12.367* 1.446 .000 -17.01 -7.72 
VaD -11.875* 1.968 .000 -18.19 -5.56 
unspecified 
dementia 
-5.970* 1.841 .045 -11.88 -.06 
other dementia -2.204 3.106 1.000 -12.18 7.77 
other psychiatric 
disorder 
-.345 1.383 1.000 -4.79 4.10 
no diagnosis diagnosis not 
listed 
6.944* 2.064 .029 .32 13.57 
AD -3.459 2.004 1.000 -9.89 2.98 
MCI -1.316 2.143 1.000 -8.19 5.56 
Mixed Dementia -5.423 2.240 .567 -12.62 1.77 
VaD -4.931 2.608 1.000 -13.30 3.44 
unspecified 
dementia 
.973 2.513 1.000 -7.09 9.04 
other dementia 4.740 3.546 1.000 -6.65 16.13 
other psychiatric 
disorder 
6.598 2.200 .101 -.47 13.66 
AD diagnosis not 
listed 
10.403* 1.044 .000 7.05 13.75 
283 
 
no diagnosis 3.459 2.004 1.000 -2.98 9.89 
MCI 2.144 1.192 1.000 -1.68 5.97 
Mixed Dementia -1.964 1.360 1.000 -6.33 2.40 
VaD -1.472 1.906 1.000 -7.59 4.65 
unspecified 
dementia 
4.432 1.774 .457 -1.26 10.13 
other dementia 8.199 3.067 .277 -1.65 18.05 
other psychiatric 
disorder 
10.057* 1.293 .000 5.91 14.21 
MCI diagnosis not 
listed 
8.259* 1.290 .000 4.12 12.40 
no diagnosis 1.316 2.143 1.000 -5.56 8.19 
AD -2.144 1.192 1.000 -5.97 1.68 
Mixed Dementia -4.108 1.557 .307 -9.11 .89 
VaD -3.616 2.051 1.000 -10.20 2.97 
unspecified 
dementia 
2.289 1.929 1.000 -3.90 8.48 
other dementia 6.056 3.159 1.000 -4.09 16.20 
other psychiatric 
disorder 
7.914* 1.499 .000 3.10 12.73 
Mixed Dementia diagnosis not 
listed 
12.367* 1.446 .000 7.72 17.01 
no diagnosis 5.423 2.240 .567 -1.77 12.62 
AD 1.964 1.360 1.000 -2.40 6.33 
MCI 4.108 1.557 .307 -.89 9.11 
VaD .492 2.153 1.000 -6.42 7.40 
unspecified 
dementia 
6.397 2.037 .063 -.14 12.94 
other dementia 10.163 3.226 .061 -.19 20.52 
other psychiatric 
disorder 
12.022* 1.635 .000 6.77 17.27 
VaD diagnosis not 
listed 
11.875* 1.968 .000 5.56 18.19 
no diagnosis 4.931 2.608 1.000 -3.44 13.30 
AD 1.472 1.906 1.000 -4.65 7.59 
MCI 3.616 2.051 1.000 -2.97 10.20 





5.905 2.435 .561 -1.91 13.72 
other dementia 9.671 3.492 .208 -1.54 20.88 
other psychiatric 
disorder 





5.970* 1.841 .045 .06 11.88 
no diagnosis -.973 2.513 1.000 -9.04 7.09 
AD -4.432 1.774 .457 -10.13 1.26 
MCI -2.289 1.929 1.000 -8.48 3.90 
Mixed Dementia -6.397 2.037 .063 -12.94 .14 
VaD -5.905 2.435 .561 -13.72 1.91 
other dementia 3.767 3.421 1.000 -7.22 14.75 
other psychiatric 
disorder 
5.625 1.992 .176 -.77 12.02 
other dementia diagnosis not 
listed 
2.204 3.106 1.000 -7.77 12.18 
no diagnosis -4.740 3.546 1.000 -16.13 6.65 
AD -8.199 3.067 .277 -18.05 1.65 
MCI -6.056 3.159 1.000 -16.20 4.09 
Mixed Dementia -10.163 3.226 .061 -20.52 .19 
VaD -9.671 3.492 .208 -20.88 1.54 
unspecified 
dementia 
-3.767 3.421 1.000 -14.75 7.22 
other psychiatric 
disorder 





.345 1.383 1.000 -4.10 4.79 
no diagnosis -6.598 2.200 .101 -13.66 .47 
AD -10.057* 1.293 .000 -14.21 -5.91 
MCI -7.914* 1.499 .000 -12.73 -3.10 
Mixed Dementia -12.022* 1.635 .000 -17.27 -6.77 
VaD -11.530* 2.111 .000 -18.31 -4.75 
unspecified 
dementia 
-5.625 1.992 .176 -12.02 .77 





Chapter 5: Group differences (between diagnostic categories) in age, average MMSE, WMH load, 
normalised hippocampal volume and ypred score in the portion of the BRC memory clinic cohort used in 









Square F Sig. 
age Between Groups 4315.356 8 539.420 5.779 .000 
Within Groups 54136.471 580 93.339   
Total 58451.827 588    
MMSE Between Groups 1979.175 8 247.397 12.189 .000 
Within Groups 8504.087 419 20.296   
Total 10483.262 427    
ypred - uncorrected Between Groups 10.891 8 1.361 11.075 .000 
Within Groups 71.297 580 .123   
Total 82.188 588    
normalise HC volume Between Groups .000 8 .000 7.393 .000 
Within Groups .000 580 .000   
Total .000 588    
WMH load (mL) Between Groups 5102.861 8 637.858 4.082 .000 
Within Groups 90626.646 580 156.253   





























(I-J) Std. Error Sig. 
95% Confidence Interval 






























































































































































































































































































































































































AD -8.035* 1.694 .000 -13.48 -2.59 
MCI -6.363 2.013 .060 -12.83 .10 
Mixed 
Dementia 
-9.632* 2.163 .000 -16.58 -2.68 






























3.857* .866 .000 1.07 6.64 




5.216* 1.087 .000 1.72 8.72 
other 
dementia 
























4.435 1.448 .084 -.22 9.09 






5.795* 1.590 .011 .68 10.91 
other 
dementia 










-3.814* .597 .000 -5.74 -1.89 
no 
diagnosis 
-4.392* 1.305 .030 -8.59 -.19 









































AD 4.519* .734 .000 2.16 6.88 
Mixed 
Dementia 
4.562* .965 .000 1.45 7.67 




5.922* 1.168 .000 2.16 9.68 
other 
dementia 











-3.857* .866 .000 -6.64 -1.07 
no 
diagnosis 


































-5.118* 1.187 .001 -8.94 -1.30 
no 
diagnosis 





























-3.307 1.295 .397 -7.47 .86 
diagnosis 
not listed 








































-6.883* 1.659 .001 -12.22 -1.54 
no 
diagnosis 












































AD 2.002 .790 .419 -.54 4.54 













3.405 1.204 .177 -.47 7.28 
other 
dementia 












































































































































AD -.32675041800* .05713114790 .000 -.5102831130 -.1432177230 
Mixed 
Dementia 












































MCI .32750615100* .07513462030 .001 .0861376537 .5688746490 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































-7.3172240* 2.1736313 .029 -14.299972 -.334476 























































































-5.9152637 2.2796943 .349 -13.238737 1.408209 










































-6.9814896 2.6787493 .338 -15.586919 1.623940 
































AD 5.9152637 2.2796943 .349 -1.408209 13.238737 






















7.3438700 2.7986108 .321 -1.646612 16.334352 
VaD diagnosis 
not listed 
14.7275539* 3.1311499 .000 4.668796 24.786312 
no 
diagnosis 
10.6048404 4.6055176 .779 -4.190295 25.399976 
AD 13.3255936* 3.2056875 .001 3.027385 23.623802 












13.2016340* 4.0782294 .046 .100402 26.302866 
other 
dementia 




























































































































-7.3438700 2.7986108 .321 -16.334352 1.646612 
























Chapter 5: Group differences (between categories created using the median value of normalised 
hippocampal volume and WHM load) in age, average MMSE, WMH load, normalised hippocampal volume 
and ypred score in the portion of the BRC memory clinic cohort used in the chapter 5 study, as measured by 







Square F Sig. 
age Between Groups 20076.619 3 6692.206 102.017 .000 
Within Groups 38375.208 585 65.599   
Total 58451.827 588    
MMSE Between Groups 693.163 3 231.054 10.007 .000 
Within Groups 9790.098 424 23.090   
Total 10483.262 427    
ypred - uncorrected Between Groups 35.387 3 11.796 147.442 .000 
Within Groups 46.801 585 .080   
Total 82.188 588    
normalise HC volume Between Groups .000 3 .000 420.227 .000 
Within Groups .000 585 .000   
Total .000 588    
WMH load (mL) Between Groups 43418.097 3 14472.699 161.849 .000 
Within Groups 52311.409 585 89.421   
































(I-J) Std. Error Sig. 
95% Confidence Interval 





-9.045* .996 .000 -11.68 -6.41 
MD-
like 
-13.585* .820 .000 -15.76 -11.41 
VaD-
like 





9.045* .996 .000 6.41 11.68 
MD-
like 
-4.540* .996 .000 -7.18 -1.90 
VaD-
like 





13.585* .820 .000 11.41 15.76 
AD-
like 
4.540* .996 .000 1.90 7.18 
VaD-
like 





11.768* 1.000 .000 9.12 14.41 
AD-
like 
2.724 1.148 .108 -.32 5.76 
MD-
like 





1.639 .694 .111 -.20 3.48 
MD-
like 
3.104* .569 .000 1.60 4.61 
VaD-
like 





















-3.104* .569 .000 -4.61 -1.60 
AD-
like 
-1.465 .696 .215 -3.31 .38 
VaD-
like 






















-.51522883500* .03478925470 .000 -.6073250720 -.4231325970 
MD-
like 
-.55349771700* .02864501900 .000 -.6293285590 -.4776668750 
VaD-
like 

































.21576150000* .03490520430 .000 .1233583140 .3081646870 
AD-
like 


















































































































































































-17.5413608* .9576746 .000 -20.076575 -15.006146 
VaD-
like 













-16.3424929* 1.1630918 .000 -19.421500 -13.263485 
VaD-
like 





17.5413608* .9576746 .000 15.006146 20.076575 
AD-
like 











17.5939451* 1.1669682 .000 14.504676 20.683215 
AD-
like 













Chapter 5: Group differences (between categories created using the median value of ypred score and WHM 
load) in age, average MMSE, WMH load, normalised hippocampal volume and ypred score in the portion of 
the BRC memory clinic cohort used in the chapter 5 study, as measured by ANOVA and Bonferroni’s post-








Square F Sig. 
age Between Groups 24963.333 3 8321.111 145.359 .000 
Within Groups 33488.494 585 57.245   
Total 58451.827 588    
MMSE Between Groups 1333.952 3 444.651 20.606 .000 
Within Groups 9149.310 424 21.579   
Total 10483.262 427    
ypred - uncorrected Between Groups 47.234 3 15.745 263.498 .000 
Within Groups 34.955 585 .060   
Total 82.188 588    
normalise HC volume Between Groups .000 3 .000 145.198 .000 
Within Groups .000 585 .000   
Total .000 588    
WMH load (mL) Between Groups 43556.671 3 14518.890 162.796 .000 
Within Groups 52172.835 585 89.184   

































J) Std. Error Sig. 
95% Confidence Interval 





-11.973* .911 .000 -14.38 -9.56 
MD 
like 
-17.887* .858 .000 -20.16 -15.62 
VaD 
like 





11.973* .911 .000 9.56 14.38 
MD 
like 











17.887* .858 .000 15.62 20.16 
AD 
like 
5.914* .724 .000 4.00 7.83 
VaD 
like 



















2.943* .656 .000 1.20 4.68 
MD 
like 













-2.943* .656 .000 -4.68 -1.20 
MD 
like 
1.405* .522 .044 .02 2.79 
VaD 
like 





-4.349* .623 .000 -6.00 -2.70 
AD 
like 
-1.405* .522 .044 -2.79 -.02 
VaD 
like 











3.442* 1.028 .005 .72 6.17 
MD 
like 








-.62708830100* .02943099350 .000 -.7049998220 -.5491767790 
MD 
like 
-.71747974900* .02770976760 .000 -.7908347360 -.6441247610 
VaD 
like 





.62708830100* .02943099350 .000 .5491767790 .7049998220 
MD 
like 
-.09039144790* .02340117750 .001 -.1523404730 -.0284424232 
VaD 
like 





.71747974900* .02770976760 .000 .6441247610 .7908347360 
AD 
like 
.09039144790* .02340117750 .001 .0284424232 .1523404730 
VaD 
like 










-.53020696600* .04956795980 .000 -.6614262940 -.3989876390 
MD 
like 







































































































































































-1.8361528 1.1370330 .641 -4.846176 1.173870 
MD 
like 










1.8361528 1.1370330 .641 -1.173870 4.846176 
MD 
like 
-16.4473705* .9040779 .000 -18.840701 -14.054040 
VaD 
like 





18.2835233* 1.0705354 .000 15.449537 21.117510 
AD 
like 











18.5001821* 1.9989801 .000 13.208360 23.792004 
AD 
like 













Chapter 5: Group differences (between categories created using the 33rd percentile values of normalised 
hippocampal volume and WHM load) in age, average MMSE, WMH load, normalised hippocampal volume 
and ypred score in the portion of the BRC memory clinic cohort used in the chapter 5 study, as measured by 







Square F Sig. 
age Between Groups 12637.284 3 4212.428 53.788 .000 
Within Groups 45814.542 585 78.315   
Total 58451.827 588    
MMSE Between Groups 741.782 3 247.261 10.762 .000 
Within Groups 9741.480 424 22.975   
Total 10483.262 427    
ypred - uncorrected Between Groups 30.550 3 10.183 115.367 .000 
Within Groups 51.638 585 .088   
Total 82.188 588    
normalise HC volume Between Groups .000 3 .000 307.223 .000 
Within Groups .000 585 .000   
Total .000 588    
WMH load (mL) Between Groups 57678.221 3 19226.074 295.581 .000 
Within Groups 38051.286 585 65.045   




























(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
age Control
-like 
AD-like -7.579* 1.035 .000 -10.32 -4.84 
MD-
like 
-10.404* 1.027 .000 -13.12 -7.68 
VaD-
like 
-9.342* 1.035 .000 -12.08 -6.60 
AD-like Control
-like 
7.579* 1.035 .000 4.84 10.32 
MD-
like 
-2.825 1.264 .155 -6.17 .52 
VaD-
like 





10.404* 1.027 .000 7.68 13.12 











9.342* 1.035 .000 6.60 12.08 









AD-like 1.853* .661 .032 .10 3.61 
MD-
like 
3.213* .650 .000 1.49 4.94 
VaD-
like 
2.446* .672 .002 .66 4.23 
AD-like Control
-like 
-1.853* .661 .032 -3.61 -.10 
MD-
like 













-3.213* .650 .000 -4.94 -1.49 




























AD-like -.49538380700* .03475933480 .000 -.5874008390 -.4033667750 
MD-
like 
-.52108651100* .03449387610 .000 -.6124008050 -.4297722180 
VaD-
like 
-.17933970500* .03475933480 .000 -.2713567370 -.0873226730 
AD-like Control
-like 



























.17933970500* .03475933480 .000 .0873226730 .2713567370 
AD-like -.31604410200* .04266149150 .000 -.4289802050 -.2031079990 
MD-
like 

































































































































































AD-like -1.7023836 .9435638 .430 -4.200243 .795476 
MD-
like 
-21.4678453* .9363578 .000 -23.946629 -18.989062 
VaD-
like 
-21.2949869* .9435638 .000 -23.792847 -18.797127 
AD-like Control
-like 
1.7023836 .9435638 .430 -.795476 4.200243 
MD-
like 
-19.7654617* 1.1522091 .000 -22.815660 -16.715263 
VaD-
like 





21.4678453* .9363578 .000 18.989062 23.946629 
322 
 











21.2949869* .9435638 .000 18.797127 23.792847 



































Chapter 5: Group differences (between categories created using the 33rd percentile values of ypred score 
and WHM load) in age, average MMSE, WMH load, normalised hippocampal volume and ypred score in the 
portion of the BRC memory clinic cohort used in the chapter 5 study, as measured by ANOVA and 







Square F Sig. 
age Between Groups 13645.235 3 4548.412 59.385 .000 
Within Groups 44806.592 585 76.592   
Total 58451.827 588    
MMSE Between Groups 1560.379 3 520.126 24.716 .000 
Within Groups 8922.883 424 21.045   
Total 10483.262 427    
ypred - uncorrected Between Groups 51.619 3 17.206 329.266 .000 
Within Groups 30.570 585 .052   
Total 82.188 588    
normalise HC volume Between Groups .000 3 .000 130.016 .000 
Within Groups .000 585 .000   
Total .000 588    
WMH load (mL) Between Groups 57854.731 3 19284.910 297.868 .000 
Within Groups 37874.775 585 64.743   
































(I-J) Std. Error Sig. 
95% Confidence Interval 





-8.101* .981 .000 -10.70 -5.51 
MD-
like 
-10.762* 1.083 .000 -13.63 -7.89 
VaD-
like 





8.101* .981 .000 5.51 10.70 
MD-
like 
-2.661 1.261 .212 -6.00 .68 
VaD-
like 





10.762* 1.083 .000 7.89 13.63 
AD-
like 











9.939* .981 .000 7.34 12.53 
AD-
like 











3.017* .594 .000 1.44 4.59 
MD-
like 
5.429* .677 .000 3.63 7.22 
VaD-
like 







-3.017* .594 .000 -4.59 -1.44 
MD-
like 
2.413* .779 .013 .35 4.48 
VaD-
like 





-5.429* .677 .000 -7.22 -3.63 
AD-
like 
-2.413* .779 .013 -4.48 -.35 
VaD-
like 





-1.673* .607 .037 -3.28 -.06 
AD-
like 
1.343 .719 .374 -.56 3.25 
MD-
like 








-.65504561900* .02561409540 .000 -.7228528150 -.5872384230 
MD-
like 
-.67973798000* .02828575700 .000 -.7546177620 -.6048581980 
VaD-
like 






































-.44330387500* .03068472950 .000 -.5245343630 -.3620733870 
MD-
like 







































































































































































-1.7444843 .9015864 .321 -4.131219 .642250 
MD-
like 










1.7444843 .9015864 .321 -.642250 4.131219 
MD-
like 
-18.7196311* 1.1597228 .000 -21.789720 -15.649542 
VaD-
like 





20.4641154* .9956257 .000 17.828434 23.099797 
AD-
like 
18.7196311* 1.1597228 .000 15.649542 21.789720 
VaD-
like 





22.2134920* .9015864 .000 19.826758 24.600226 
AD-
like 
20.4690077* 1.0800668 .000 17.609789 23.328226 
MD-
like 






Chapter 5: Calculation of mean (and standard deviation) normalised hippocampal volume of normal 
controls from the ADNI and AddNeuroMed Cohorts. 
To compare normalised hippocampal volume values used for cut-offs, a set of 340 healthy controls from 
both the ADNI and AddNeuroMed datasets were analysed. Mean normalised hippocampal volume (right 
and left normalised hippocampi were averaged for each subject) and standard deviation were 
calculated. Statistics for normalised hippocampal volume and a histogram volumes with a normalised 










Std. Deviation 0.000330 
Percentiles 25 0.002125  








Chapter 6: Ethical approval and approval of minor amendments for the Clinical Trial: BrainMeasure: 

























Chapter 6: Average clinicians’ rating of ‘How likely are these patient’s symptoms caused by AD?’ and ‘How 
likely are these patient’s symptoms caused by VaD?’ for each diagnostic category. Differences measured by 
one-way ANOVA and Bonferroni’s post-hoc tests. One participant was excluded from this analysis 
(diagnosed with FTD) as they were the only person in that diagnostic category, and if included post-hoc 
analyses could not be conducted. P < 0.05 is considered statistically significant.  
 
ANOVA 
 Sum of Squares df Mean Square F Sig. 
How likely AD Between Groups 90.173 5 18.035 22.703 .000 
Within Groups 66.727 84 .794   
Total 156.900 89    
How likely VaD Between Groups 42.735 5 8.547 9.239 .000 
Within Groups 77.712 84 .925   




Bonferroni   
Dependent 












How likely AD No Diagnosis Alzheimer's 
Disease 
-2.0266* .2690 .000 -2.839 -1.214 
Mild Cognitive 
Impairment 
-.0588 .3104 1.000 -.997 .879 
Mixed Dementia -1.8713* .3104 .000 -2.809 -.933 
Vascular Dementia -.3922 .5581 1.000 -2.079 1.294 
Other .3697 .4003 1.000 -.840 1.579 
Alzheimer's 
Disease 
No Diagnosis 2.0266* .2690 .000 1.214 2.839 
Mild Cognitive 
Impairment 
1.9677* .2744 .000 1.139 2.797 
Mixed Dementia .1552 .2744 1.000 -.674 .984 
Vascular Dementia 1.6344* .5389 .048 .006 3.263 
Other 2.3963* .3730 .000 1.269 3.523 







-1.9677* .2744 .000 -2.797 -1.139 
Mixed Dementia -1.8125* .3151 .000 -2.765 -.860 
Vascular Dementia -.3333 .5607 1.000 -2.028 1.361 
Other .4286 .4039 1.000 -.792 1.649 
Mixed Dementia No Diagnosis 1.8713* .3104 .000 .933 2.809 
Alzheimer's 
Disease 
-.1552 .2744 1.000 -.984 .674 
Mild Cognitive 
Impairment 
1.8125* .3151 .000 .860 2.765 
Vascular Dementia 1.4792 .5607 .149 -.215 3.173 
Other 2.2411* .4039 .000 1.021 3.461 
Vascular Dementia No Diagnosis .3922 .5581 1.000 -1.294 2.079 
Alzheimer's 
Disease 
-1.6344* .5389 .048 -3.263 -.006 
Mild Cognitive 
Impairment 
.3333 .5607 1.000 -1.361 2.028 
Mixed Dementia -1.4792 .5607 .149 -3.173 .215 
Other .7619 .6150 1.000 -1.096 2.620 
Other No Diagnosis -.3697 .4003 1.000 -1.579 .840 
Alzheimer's 
Disease 
-2.3963* .3730 .000 -3.523 -1.269 
Mild Cognitive 
Impairment 
-.4286 .4039 1.000 -1.649 .792 
Mixed Dementia -2.2411* .4039 .000 -3.461 -1.021 
Vascular Dementia -.7619 .6150 1.000 -2.620 1.096 
How likely VaD No Diagnosis Alzheimer's 
Disease 
.2372 .2903 1.000 -.640 1.114 
Mild Cognitive 
Impairment 
-.1801 .3350 1.000 -1.192 .832 
Mixed Dementia -1.3364* .3350 .002 -2.349 -.324 
Vascular Dementia -2.1176* .6023 .011 -3.938 -.298 
Other .5966 .4320 1.000 -.708 1.902 
Alzheimer's 
Disease 
No Diagnosis -.2372 .2903 1.000 -1.114 .640 
Mild Cognitive 
Impairment 
-.4173 .2961 1.000 -1.312 .477 
Mixed Dementia -1.5736* .2961 .000 -2.468 -.679 
Vascular Dementia -2.3548* .5816 .002 -4.112 -.598 
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Other .3594 .4025 1.000 -.857 1.576 
Mild Cognitive 
Impairment 
No Diagnosis .1801 .3350 1.000 -.832 1.192 
Alzheimer's 
Disease 
.4173 .2961 1.000 -.477 1.312 
Mixed Dementia -1.1563* .3401 .015 -2.184 -.129 
Vascular Dementia -1.9375* .6051 .029 -3.766 -.109 
Other .7768 .4359 1.000 -.540 2.094 
Mixed Dementia No Diagnosis 1.3364* .3350 .002 .324 2.349 
Alzheimer's 
Disease 
1.5736* .2961 .000 .679 2.468 
Mild Cognitive 
Impairment 
1.1563* .3401 .015 .129 2.184 
Vascular Dementia -.7813 .6051 1.000 -2.610 1.047 
Other 1.9330* .4359 .000 .616 3.250 
Vascular Dementia No Diagnosis 2.1176* .6023 .011 .298 3.938 
Alzheimer's 
Disease 
2.3548* .5816 .002 .598 4.112 
Mild Cognitive 
Impairment 
1.9375* .6051 .029 .109 3.766 
Mixed Dementia .7813 .6051 1.000 -1.047 2.610 
Other 2.7143* .6637 .001 .709 4.720 
Other No Diagnosis -.5966 .4320 1.000 -1.902 .708 
Alzheimer's 
Disease 
-.3594 .4025 1.000 -1.576 .857 
Mild Cognitive 
Impairment 
-.7768 .4359 1.000 -2.094 .540 
Mixed Dementia -1.9330* .4359 .000 -3.250 -.616 
Vascular Dementia -2.7143* .6637 .001 -4.720 -.709 
 
 
 
